Nuevos modelos preclínicos en insuficiencia cardiaca: caracterización con técnicas de imagen avanzada y aplicación en nuevas terapias by Agüero Ramón-Llin, Jaume
  
Universidad Autónoma de Madrid 
Programa de Doctorado en Biociencias Moleculares 
 
TESIS DOCTORAL 
 
Nuevos modelos preclínicos en insuficiencia 
cardiaca: caracterización con técnicas de imagen 
avanzada y aplicación de nuevas terapias 
 
 
Autor: Jaume Agüero Ramón-Llin 
Director: Borja Ibáñez Cabeza 
Madrid, 2017 
 
1 
 
Departamento de Bioquímica. 
Programa de Doctorado en Biociencias Moleculares  
Universidad Autónoma de Madrid. 
 
Título de la Tesis: “Nuevos modelos preclínicos en insuficiencia cardiaca: 
caracterización con técnicas de imagen avanzada y aplicación de nuevas terapias”. 
 
 
Doctorando: Jaume Agüero Ramón-Llin. Licenciado en Medicina por la Universidad 
de Valencia. 
Director: Borja Ibáñez Cabeza. 
Lugar de realización. Centro Nacional de Investigaciones Cardiovasculares Carlos III 
(CNIC), Madrid. 
 
  
2 
 
 
BORJA IBÁÑEZ CABEZA, DOCTOR EN MEDICINA Y DIRECTOR DEL 
DEPARTAMENTO DE INVESTIGACIÓN CLÍNICA DEL CENTRO NACIONAL DE 
INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC), Y LEANDRO SASTRE 
GASCÓN, PROFESOR TITULAR DEL DEPARTAMENTO DE BIOQUÍMICA DE LA 
UNIVERSIDAD AUTÓNOMA DE MADRID, 
 
INFORMAN: Que D. Jaume Agüero Ramón-Llin ha realizado durante los últimos tres 
años bajo nuestra dirección la Tesis Doctoral “Nuevos modelos preclínicos en insuficiencia 
cardiaca: caracterización con técnicas de imagen avanzada y aplicación de nuevas 
terapias”. Estimamos que este trabajo contribuye de forma original y significativamente al 
campo de la investigación traslacional en enfermedades cardiovasculares. 
 
 
 
              BORJA IBAÑEZ CABEZA                                       LEANDRO SASTRE GASCÓN 
 
 
 
 
 
 
 
3 
 
 Dedicatoria. 
 
 Para Iratxe, Josu y Manel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 You can’t connect the dots looking forward;  
you can only connect them looking backward.  
So you have to trust that the dots will somehow connect in your future. 
Steve Jobs 
4 
 
Agradecimientos. 
 A Borja Ibañez, Roger J Hajjar y Valentin Fuster, por haberme dado la oportunidad 
de dedicarme a la investigación durante estos años, y haberme dado la motivación 
necesaria en los momentos difíciles. 
 A mis compañeros y amigos de Mount Sinai en Nueva York, en especial Kiyotake 
Ishikawa y Carlos Santos-Gallego por su inestimable ayuda en éste otros trabajos, y su gran 
amistad. 
 A toda la gente de mi grupo en CNIC, muy en especial  a Carlos Galán, Rodrigo 
Fernández, Javier Sánchez, Gonzalo López, Austin Bruce, David Sanz-Rosa, Andrés Pun y 
Jaime García-Prieto con quienes he tenido la suerte de compartir tantas horas de trabajo, 
por su inagotable entusiasmo y dedicación, y el apoyo que me han dado dentro y fuera del 
trabajo en estos años.    
 A mis colegas y amigos de los hospitales La Fe de Valencia, Francesc de Borja de 
Gandía, y General de Castellón, por haberme dado la visión clínica con la que he intentado 
dirigir mi trabajo como investigador. 
 
Muy especialmente, a mis padres Celia y Antonio, y a mis hermanos Cristina, Elena, 
Antonio, Celia y Alberto, por darme siempre su cariño y apoyo, y enseñarme a no rendirme 
nunca. 
5 
 
Índice. 
1. Resumen ………………………………………………………………………………..  6 
2. Abreviaturas …………………………………………………………………………….  8 
3. Introducción general ……………………………………………………………………  9 
4. Objetivos ……………………………………………………………………………….. 17 
5. Materiales y Métodos y Resultados ………………………………………………… 18 
     5.1. Parte 1: Modelos de hipertensión pulmonar crónica. Introducción  
a los artículos 1 y 2 ………………………………………………………………………. 20 
 Artículo 1 …………………………………………………………………………. 22 
 Artículo 2 …………………………………………………………………………. 35 
     5.2. Parte 2: Modelos de disfunción ventricular izquierda. Introducción 
 a los artículos 3 y 4, y manuscrito 1 …………………………………………………... 52 
 Artículo 3 …………………………………………………………………………. 54 
 Artículo 4 …………………………………………………………………………. 64 
 Manuscrito 1 ……………………………………………………………………... 78 
     5.3. Parte 3: Desarrollo de nuevas terapias experimentales en  
hipertensión pulmonar. Introducción a los artículos 5 y 6 ………………………… 111 
  Artículo 5 ……………………………………………………………….. 113 
  Artículo 6 ……………………………………………………………….. 129 
6. Discusión ……………………………………………………………………………... 141 
7. Conclusiones…………………………………………………………………………. 146 
8. Bibliografía general…………………………………………………………………… 147
6 
 
1. Resumen. 
La insuficiencia cardíaca crónica (IC) se caracteriza por una alta prevalencia en los 
países occidentales, un impacto dramático en la calidad de vida del paciente y su capacidad 
funcional, y una enorme carga económica para los sistemas de salud. En la IC crónica, la 
transformación de los nuevos descubrimientos en investigación básica en mejoras en el 
cuidado de los pacientes es una prioridad, y se basa en una validación preclínica de nuevos 
conceptos diagnósticos y terapéuticos. Se han desarrollado modelos animales que 
recapitulan la IC en el laboratorio. Sin embargo, al igual que en otras enfermedades 
crónicas, el modelado de IC es un desafío debido a la heterogeneidad fisiopatológica. Los 
modelos de IC en animales grandes son costosos y técnicamente complejos, pero 
proporcionan una oportunidad única para evaluar nuevos conceptos y terapias de imagen 
utilizando herramientas clínicamente relevantes. Aunque los intentos de reproducir el cuadro 
clínico completo junto con anomalías hemodinámicas y estructurales graves de la IC crónica 
no han tenido éxito, la recapitulación de fenotipos específicos puede ser factible y 
clínicamente relevante. Este documento incluye un trabajo de Tesis doctoral centrado en la 
creación y caracterización de modelos animales grandes sobre características clave de la 
IC: 1) hipertensión pulmonar crónica y remodelado ventricular derecha; 2) remodelado 
ventricular izquierdo de causa isquémica y por sobrecarga de presión. Finalmente, se 
evalúan nuevas estrategias de terapia génica en la IC ventricular derecha asociada a 
hipertensión pulmonar crónica en el contexto preclínico. En general, este trabajo contribuye 
con nuevos hallazgos en investigación preclínica sobre terapias innovadoras para una mejor 
atención al paciente. 
Summary 
Chronic heart failure (HF) is characterized by a high prevalence in the aging western 
countries, dramatic impact in the patient quality of life and functional performance, and 
overwhelming economic burden for health systems. In chronic HF, translation of basic 
research knowledge into innovative patient care is a priority, and relies on the preclinical 
testing and validation of new diagnostic and therapeutic concepts. Animal models have been 
developed that recapitulate HF in the laboratory setting. However, as in other chronic 
diseases, modeling of HF is challenging due to the heterogeneous and complex 
pathophysiology. Models of HF in large animals are costly and technically complex, but 
provide a unique opportunity to evaluate novel imaging concepts and therapies using 
clinically relevant tools, and therefore accelerate the potential translation. While attempts to 
reproduce the full clinical picture along with severe hemodynamic and structural 
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abnormalities of chronic HF have been unsuccessful, recapitulation of specific phenotypes 
may be feasible and clinically relevant. This document summarizes a PhD Thesis 
compendium focused on the creation and characterization of large animal models of key HF 
features: 1) chronic pulmonary hypertension and right ventricular remodeling, 2) ischemic 
and pressure overload left ventricular remodeling. Finally, novel strategies of gene therapy in  
chronic PH-associated right ventricular heart failure are evaluated in the preclinical setting. 
Overall, this work contributes with novel findings in a challenging field of preclinical research 
in the search of innovative therapies for better patient care. 
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2. Abreviaturas. 
HTP: hipertensión pulmonar. 
IC: insuficiencia cardíaca. 
VD: ventrículo derecho. 
VI: ventrículo izquierdo. 
HF: heart failure. 
  
9 
 
3. Introducción general 
3.1. La insuficiencia cardiaca crónica como problema cardiovascular de primera 
magnitud y necesidad de investigación preclínica. 
La insuficiencia cardíaca (IC) es un síndrome clínico caracterizado por disnea, 
intolerancia al esfuerzo, y congestión a nivel sistémico y pulmonar. Estas manifestaciones 
se deben a la incapacidad del corazón para proporcionar un gasto cardíaco suficiente que 
permita el normal funcionamiento de los tejidos. La IC es una de las primeras de causas de 
morbimortalidad en los países desarrollados, con una prevalencia y gasto sanitario en 
progresivo aumento debido, entre otros factores, al envejecimiento de la población1. 
Pese a los avances que se han producido en el manejo integral de la IC en la última 
década, se considera un área prioritaria de investigación para mejorar el pronóstico vital y la 
calidad de vida de estos pacientes. Un aspecto clave de esta investigación es la 
identificación de nuevos tratamientos que sean más eficaces para prevenir, enlentecer o 
revertir la progresión de la enfermedad. En este sentido, un limitación importante ha sido la 
falta de modelos animales clínicamente relevantes en los que poder evaluar la eficacia y 
seguridad de nuevos tratamientos. 
3.2. Modelos preclínicos en insuficiencia cardíaca como herramienta en investigación 
traslacional.  
Los modelos animales son un eslabón clave para trasladar los nuevos 
descubrimientos en investigación básica al ámbito clínico. La validación de tratamientos en 
distintos modelos animales se considera un requerimiento para la aprobación de los mismos 
para su ensayo en humanos (Figura 1). Esto pone de manifiesto la importancia de 
desarrollar modelos clínicamente relevantes2. El modelo animal preclínico suele hacer 
referencia a modelos de animal grande (cerdo, oveja, etc), por su mayor semejanza 
fisiológica al ser humano, en particular en el sistema cardiovascular2. Esto hace que, 
aunque muchos estudios en investigación cardiovascular se desarrollan inicialmente en 
modelos de roedor, posteriormente sea necesario una validación en un modelo de mayor 
complejidad biológica3-4. 
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Figura 1. Descubrimiento, validación y fase clínica en el desarrollo de nuevas 
terapias, empleando modelos in vitro e in vivo de diferente complejidad. 
Además de la relevancia respecto a las características clínicas que se busca 
recapitular en el modelo, otro aspecto clave a tener en cuenta en estudios preclínicos de 
intervención es el potencial traslacional de la misma. Este término hace referencia a la 
similitud de la metodología de la intervención (modo de administración de un fármaco, 
regeneración celular o terapia génica, por ejemplo), así como los métodos para evaluar el 
éxito de la misma. En este aspecto, la caracterización de los modelos preclínicos 
cardiovasculares en animal grande, que permite el uso de técnicas de imagen y estrategias 
terapéuticas (administración intracoronaria de tratamientos, implante de dispositivos 
percutáneos, nuevas técnicas quirúrgicas) similares a las que se utilizan en pacientes con la 
patología de interés es de vital importancia para garantizar la validez de los resultados. 
3.3. Heterogeneidad clínica y  fenotipos específicos en IC como principal problema 
en la creación de modelos. 
La IC es un síndrome muy heterogéneo en cuanto a las causas subyacentes 
(cardiopatía isquémica, hipertensión arterial, enfermedad valvular cardíaca, miocardiopatías, 
miocarditis, etc), así como en cuanto a la forma de manifestación clínica. En los últimos 
años la percepción de que esta heterogeneidad clínica es de gran importancia ha dado 
lugar a la definición de distintos “fenotipos clínicos” en pacientes con IC, haciendo referencia 
Investigación Básica:
Descubrimiento de nuevos 
mecanismos
Estudios in vitro
Modelos en roedor
Validación en 
modelos preclínicos 
(animal grande):
Eficacia
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nueva terapia
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a las alteraciones estructurales y funcionales predominantes. Desde esta nueva 
perspectiva, las técnicas diagnósticas deben ser orientadas a describir adecuadamente los 
distintos perfiles clínicos, y estos a su vez deben guiar el tratamiento5. 
Tradicionalmente, las alteraciones en la estructura y función del ventrículo izquierdo 
(VI) se han considerado el aspecto clave en el tratamiento de la IC. Esto se debe a que a 
menudo es la alteración primaria de la cardiopatía, como ocurre tras un infarto agudo de 
miocardio, o en respuesta a la sobrecarga de presión crónica en la hipertensión arterial. Sin 
embargo, y gracias a los avances en técnicas de imagen, se ha comprobado que a menudo 
son alteraciones a otros niveles las que determinan el pronóstico y las respuesta al 
tratamiento. Los fenotipos clínicos en IC tienen en cuenta no sólo alteraciones estructurales 
o funcionales específicas (como la presencia o ausencia de disfunción sistólica, fibrilación 
auricular crónica, insuficiencia mitral funcional, hipertensión pulmonar (HTP) y fallo 
ventricular derecho [VD]), sino también características clínicas relacionadas con 
comorbilidades, como la edad avanzada, diabetes mellitus, obesidad, enfermedad renal 
crónica, anemia y fragilidad5. 
3.4. Modelos preclínicos actuales en IC: características y principales limitaciones. 
A continuación se resumen brevemente las características y limitaciones de los 
principales modelos preclínicos que se han desarrollado en investigación sobre IC2, 6: 
a. Modelos de cardiopatía isquémica crónica. Se han empleado modelos 
basados en infarto agudo de miocardio mediante isquemia coronaria transitoria 
seguida de reperfusión, oclusión coronaria sin reperfusión, isquemia crónica 
mediante estenosis progresiva (dispositivos de constricción coronaria progresiva, 
conocidos como ameroides), y menos frecuentemente microembolizaciones 
coronarias repetidas. Estos modelos simulan diferentes escenarios clínicos en 
cardiopatía isquémica aguda como daño inicial, cuya consecuencia a largo plazo es 
el remodelado ventricular progresivo. Se considera un modelo altamente traslacional 
porque recapitula aspectos esenciales de la IC de etiología isquémica. Se han 
empleado ampliamente en estudios de regeneración miocárdica mediante terapia 
celular. Como modelo de IC, las principales limitaciones son: 1) falta de 
caracterización de las diferencias entre infartos en diferentes territorios coronarios, 2) 
incertidumbre respecto a los cambios estructurales y funcionales en el miocardio no 
infartado (“remoto” al infarto, y en gran parte responsable del remodelado global), 3) 
fenotipo de HTP y disfunción del VD no reproducible.   
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b. Modelos de sobrecarga de presión crónica emulando cardiopatía 
hipertensiva. El modelo más empleado ha sido la estenosis o constricción aórtica 
supravalvular. Este modelo simula determinadas características de la respuesta 
ventricular ante una estenosis aórtica, y en menor medida una situación de 
hipertensión arterial crónica. Este modelo induce un aumento de la masa ventricular 
relacionada con la gravedad de la sobrecarga de presión (es decir, el grado de 
estenosis inducida) y la duración del seguimiento. Las principales limitaciones son: 
1) no recapitular un escenario clínico concreto (las estenosis aórticas son patologías 
lentamente progresivas de años de evolución, mientras que el tipo de sobrecarga de 
presión no es equiparable a la cardiopatía hipertensiva), 2) no está caracterizada en 
modelos preclínicos una transición desde hipertrofia compensadora a una situación 
de IC por criterios clínicos o hemodinámicos.   
c. Modelos de sobrecarga de volumen para recapitular lesiones valvulares. El 
modelo de insuficiencia mitral orgánica mediante rotura quirúrgica de las cuerdas 
tendinosas ha sido descrito como un modelo relevante de IC aguda o subaguda, 
asociado a HTP y grados variables de disfunción del ventrículo izquierdo. Este 
modelo se asocia a una elevada mortalidad lo que ha limitado mucho su utilización 
en el ámbito preclínico, y es complejo llevar a cabo un seguimiento a largo plazo por 
la gravedad del mismo. 
d. Modelos de estimulación ventricular rápida emulando 
“taquimiocardiopatias”. Consisten en una estimulación ventricular rápida durante 
varias semanas mediante el implante de un marcapasos. Se recapitulan 
características esenciales de la IC, como la activación neurohormonal, la dilatación 
de cavidades y los signos congestivos. La principal limitación es la reversibilidad en 
gran parte, y en ocasiones impredecible, de las alteraciones fenotípicas una vez 
interrumpida la estimulación, lo cual suele ser necesario para caracterizar los 
cambios estructurales y funcionales mediante técnicas de imagen. 
e. Otros modelos. La inducción de toxicidad cardiaca por antraciclinas se ha 
descrito en algunos modelos, si bien la consistencia del fenotipo en relación a las 
dosis administradas no está bien caracterizada en la literatura, así como las dosis 
mínimas y duración del seguimiento necesarios, y el daño inducido por el tóxico en 
tejidos extracardíacos ha limitado su aplicación en el ámbito preclínico. 
3.5. Nuevos enfoques en modelos preclínicos de IC:  caracterización de fenotipos 
específicos y su aplicación para desarrollo de nuevas terapias. 
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El trabajo de la presente Tesis Doctoral se ha centrado en aspectos concretos de los 
modelos animales de IC que consideramos muy relevantes desde el punto de vista clínico. 
Según se ha indicado, los siguientes aspectos no se habían caracterizado en descripciones 
previas y que son fundamentales para llevar a cabo un estudio traslacional en IC. En 
relación a cada uno de estos aspectos, se indican los trabajos publicados como parte de la 
presente Tesis Doctoral. 
3.5.1. Modelos preclínicos de hipertensión pulmonar crónica.  
Los pacientes con IC desarrollan con frecuencia HTP en su evolución, lo cual 
determina un elemento adicional de sobrecarga hemodinámica, en este caso en el VD. 
Multitud de estudios han demostrado que la aparición de HTP y sobretodo disfunción del VD 
determina una mayor morbimortalidad en estos pacientes. En los últimos años ha surgido 
un gran interés por las implicaciones de la HTP en la IC. Así pues, la presencia de HTP 
junto al remodelado y la disfunción del VD constituyen un fenotipo específico por sus 
principales características: 1) se asocian a un mal pronóstico independientemente de las 
lesiones estructurales asociadas (disfunción del VI sistólica o diastólica, valvulopatías mitral 
o aórtica, miocardiopatías de cualquier etiología), 2) el diagnóstico y caracterización son 
más compleja, por las dificultades de las técnicas no invasivas para estimar el estado de la 
hemodinámica pulmonar y la complejidad anatómica del VD, y 3) la falta de tratamientos 
efectivos dirigidos a tratar este aspecto de la enfermedad en pacientes con IC. A esto se 
añade una heterogeneidad fisiopatológica en las causas de HTP en la IC: 1) congestión 
venosa pulmonar (HTP pasiva), 2) vasoconstricción (HTP precapilar reactiva), 3) 
remodelado vascular distal y reducción del lecho vascular (HTP precapilar fija), 4) HTP de 
mecanismo mixto. En todos los casos, el aumento de la poscarga del VD da lugar a un 
fenómeno de remodelado que deteriora la función cardíaca más allá de la cardiopatía 
subyacente a todo el proceso. 
Como parte de esta Tesis Doctoral, hemos contribuido en este campo con dos 
artículos originales de los que como doctorando soy el primer autor: 
Artículo 1: “Characterization of right ventricular remodeling and failure in a chronic 
pulmonary hypertension model” 7. En este trabajo hemos demostrado que un modelo de 
HTP pasiva (constricción venosa pulmonar) es capaz de inducir un fenotipo de HTP mixto 
(es decir, pre y postcapilar) que progresa tanto en la gravedad de los parámetros 
hemodinámicos como en el remodelado del VD. Este trabajo contribuyó de forma original 
con los siguientes hallazgos: 1) demostramos que el remodelado adaptativo evoluciona a 
una fase de fallo del VD y aparición de síntomas cuando se produce un desacoplamiento de 
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la unidad ventrículo-arterial. Este fenómeno sólo fue posible demostrarlo mediante el patrón 
oro para definir el desacoplamiento basado en análisis de curvas de presión-volumen en el 
VD. A nivel de histología y molecular, observamos un aumento progresivo de fibrosis 
intersticial y alteración de la homeostasis del calcio en el tejido miocárdico; 2) demostramos 
a través de histología de la vasculatura pulmonar el efecto del incremento crónico de las 
presiones venosas pulmonares, siendo este remodelado vascular en vasos pulmonares 
distales un factor responsable de aumento de resistencias vasculares, y relacionado con el 
fallo ventricular derecho; 3) en este modelo de HTP crónica se demostró una activación de 
la vía de la aldosterona, apoyando estudios clínicos que sugieren un potencial beneficio del 
bloqueo de este mecanismo en pacientes con HTP. 
Artículo 2: “Combination Proximal Pulmonary Artery Coiling and Distal Embolization 
Induces Chronic Pulmonary Hypertension in Swine” 8. En este estudio evaluamos el efecto 
de la oclusion progresiva del lecho vascular pulmonar, para determinar el efecto aislado del 
componente precapilar de la HTP en la hemodinámica pulmonar y su impacto en el VD. Si 
bien este modelo ha sido evaluado previamente, la persistencia del efecto a largo plazo de 
embolizaciones repetidas y la repercusión en el VD no han sido abordados en estudios 
previos. Las principales contribuciones de este estudio son: 1) se requiere un elevado 
número de embolizaciones para inducir HTP a largo plazo, lo que sugiere que, en respuesta 
a daño precapilar o reducción del lecho vascular pulmonar, el incremento de presiones 
pulmonares es un marcador de una fase avanzada de la enfermedad; 2) el remodelado 
ventricular derecho en este contexto es tardío y por tanto poco sensible en fases iniciales 
del proceso; 3) en presencia de una obstrucción proximal en el árbol pulmonar (como suele 
ocurrir en pacientes con tromboembolismo pulmonar), se produce una mayor sobrecarga 
del VD y un mayor remodelado; 4) con todo ello, se trata de un modelo adecuado para 
estudiar fases iniciales de HTP precapilar, pero el fenotipo observado no permite llevar a 
cabo estudios sobre fallo del VD.          
3.5.2. Modelos de remodelado ventricular izquierdo post-infarto agudo de miocardio, 
y secundarios a sobrecarga de presión crónica. Este apartado se compone de tres trabajos 
(dos artículos ya publicados, y un manuscrito pendiente de publicación). 
Artículo 3.“Characterizing Preclinical Model of Ischemic Heart Failure: Difference 
Between LAD and LCx Infarctions” 9. En este estudio comparamos los dos modelos más 
utilizados en cardiopatía isquémica. Los principales hallazgos y contribuciones al campo 
son: 1) la idoneidad del modelo de oclusión de la arteria descendente anterior proximal 
como modelo de IC, debido a su mayor remodelado ventricular, y su mayor repercusión en 
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la función longitudinal, y 2) la moderada disfunción del miocardio remoto detectada 
mediante ecocardiografía avanzada (técnica de strain miocárdico) como potencial diana 
terapéutica en estudios preclínicos. 
Manuscrito 1. Left atrial remodeling after acute myocardial infarction: insight into the 
role of atrial infarction. El remodelado ventricular extenso, en particular en determinadas 
localizaciones, se ha asociado a la aparición de insuficiencia mitral funcional. Se trata de 
una alteración morfológica de la válvula mitral secundaria al remodelado ventricular, y que 
es a su vez un marcador de mal pronóstico, y que aumenta el riesgo de HTP por sobrecarga 
de volumen en la aurícula izquierda. En este estudio, que profundiza en la caracterización 
de los principales modelos de IC de etiología isquémica del artículo 3, hemos demostrado 
que tras un infarto agudo de miocardio, la insuficiencia mitral funcional y la isquemia 
auricular contribuyen de forma decisiva a la progresión de la IC post-infarto. En 
comparación con otros modelos de cardiopatía isquémica crónica (como los evaluados en el 
artículo 3), se trata de un modelo con características únicas y potencialmente muy 
relevantes para estudios relacionados con: 1) estudios diagnósticos y terapéuticos 
asociados a remodelado auricular izquierdo y fibrosis, 2) diagnóstico y tratamiento 
quirúrgico o percutáneo de la insuficiencia mitral isquémica. 
Artículo 4. “Increased Stiffness is the Major Early Abnormality in a Pig Model of 
Severe Aortic Stenosis and Predisposes to Congestive Heart Failure in the Absence of 
Systolic Dysfunction” 10. En este trabajo evaluamos un modelo de sobrecarga de presión del 
VI a largo plazo mediante constricción aórtica supravalvular. Como principales hallazgos, 
observamos que en este modelo la principal alteración fisiopatológica se encuentra en el 
aumento de elastancia ventricular diastólica, mientras que la relajación rápida al inicio de la 
diástole, y la función sistólica permanecen normales. La principal contribución de este 
trabajo es demostrar las limitaciones como modelo de IC avanzada, y el potencial como 
herramienta para estudio de alteraciones funcionales precoces en la hipertrofia cardiaca en 
el ámbito preclínico. 
3.5.3. Aplicación de modelos preclínicos en hipertensión pulmonar crónica: 
Desarrollo de nuevas terapias experimentales. Este apartado se compone de dos 
publicaciones (un artículo original, y un artículo metodológico basado en el anterior): 
Artículo 5. “Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-
Capillary Pulmonary Hypertension in a Large Animal Preclinical Model” 11. En este estudio 
desarrollamos una metodología para administración de terapia génica en modelo de animal 
grande por vía aérea mediante un dispositivo específico. Los vectores virales basados en 
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virus adeno-asociados tenían como objetivo la sobreexpresión vascular de la ATPasa 2a del 
retículo sarcoplásmico (SERCA2a) en células musculares lisas. Esta terapia se había 
validado previamente en un modelo de roedor (HTP por monocrotalina en ratas)12, y en 
humanos en el ensayo clínico CUPID (Calcium Up-regulation by Percutaneous 
administration of Gene Therapy in Cardiac Disease Phase 2b13) desarrollado en la última 
década. Para probar el beneficio de esta terapia empleamos el modelo animal caracterizado 
en el artículo 1 por reunir los aspectos idóneos de la enfermedad potencialmente tratable 
mediante sobreexpresión vascular de SERCA2a (remodelado de la capa media muscular, 
deterioro progresivo de la hemodinámica pulmonar y disfunción ventricular derecha). Los 
resultados han demostrado el potencial de esta estrategia terapéutica y ha sido el primer 
trabajo sobre esta metodología en un modelo preclínico. Por otra parte, se trata de una 
contribución relevante al demostrar las limitaciones y necesidad de mejoras en la tecnología 
de vectores y administración de los mismos para aumentar las posibilidades de éxito en 
pacientes. 
Artículo 6. “Inhaled Gene Transfer for Pulmonary Circulation” 14. Se trata deuna 
revisión detallada sobre la metodología empleada en la creación de modelos, 
caracterización de los mismo, y administración de terapia génica, basada en los artículos 1 
y 5.  
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4. Objetivos. 
Objetivo 1. Desarrollo de nuevos modelos experimentales que permitan una 
caracterización integral de fenotipos específicos de enfermedades cardiovascular crónica: 1) 
hipertensión pulmonar crónica y disfunción ventricular derecha, 2) disfunción y remodelado 
ventricular izquierdo (cardiopatía isquémica y por sobrecarga de presión) e insuficiencia 
mitral funcional. 
Objetivo 2. Caracterización de modelos preclínicos mediante técnicas de imagen y a 
nivel de las principales alteraciones histológicas y moleculares, que permita evaluar su valor 
traslacional. 
Objetivo 3. Desarrollo de nuevas opciones de intervención sobre dichos modelos 
con especial atención a nuevas dianas y vectores en terapia génica. 
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5. Materiales, Métodos y Resultados. 
Los aspectos metodológicos de esta Tesis Doctoral pueden resumirse según los tres 
grandes Objetivos: 
1. Capacitación para diseño y ejecución de procedimientos experimentales en 
modelos de animal grande. Se han desarrollado modelos animales que han requerido 
entrenamiento en técnicas quirúrgicas, de cateterización percutánea y procedimientos de 
intervencionismo intracoronarios, así como instrumentación invasiva para estudio de la 
circulación pulmonar, y de las relaciones de presión-volumen en ambos ventrículos. El 
doctorando ha adquirido amplia experiencia en experimentación preclínica tras pasar 5 años 
con dedicación exclusiva a esta metodología en distintos laboratorios (Cardiovascular 
Research Center, Icahn School of Medicine, Nueva York, y CNIC, Madrid). Esta 
capacitación ha permitido la creación y caracterización de los modelos animales descritos 
en el siguiente apartado.  
2. Caracterización de los modelos experimentales mediante técnicas de imagen, 
histología y biología molecular. Se han desarrollado protocolos de adquisición y análisis en 
el ámbito preclínico basados en ecocardiografía avanzada y resonancia magnética nuclear. 
Además se ha llevado a cabo una caracterización histológica y molecular del remodelado 
miocárdico y vascular pulmonar en los modelos descritos, contribuyendo a incrementar el 
conocimiento sobre dichos escenarios preclínicos, así como para establecer una correlación 
clínico-patológica entre los cambios estructurales y la información estructural y funcional 
procedente de las técnicas de imagen.  
3. Descripción de tipos de vectores y métodos de transferencia génica en modelos 
de insuficiencia cardiaca. Desarrollo de métodos traslacionales de transferencia génica 
sobre el modelo preclínico.  Tras una estancia de 2 años en un grupo de investigación 
centrado en la terapia génica cardiovascular, el doctorando ha llevado a cabo protocolos 
para administrar terapia génica en modelos de animal grande. Esta metodología incluye el 
manejo in vivo de vectores virales basados en  virus adeno-asociados recombinantes así 
como la puesta a punto de métodos para evaluar los mecanismos inmunes ante estos 
vectores, tanto existentes previamente al tratamiento, como inducidos por el mismo. 
Además se han desarrollado protocolos para detección de expresión génica en muestras de 
tejido miocárdico. Finalmente, los experimentos basados en una intervención basada en 
terapia génica han sido evaluados en modelos animales descritos en trabajos anteriores del 
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mismo doctorando y grupo de investigación, empleando técnicas de diagnóstico descritas 
en los puntos anteriores. 
En base a la temática de las publicaciones, estas se han agrupado en tres partes: 
Parte 1. Modelos de hipertensión pulmonar crónica (artículos 1 y 2). 
Parte 2. Modelos de disfunción ventricular izquierda. 
Parte 3. Desarrollo de nuevas terapias experimentales en hipertensión 
pulmonar. 
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Parte 1. Modelos de hipertensión pulmonar crónica.  
Introducción a los artículos 1 y 2. 
Como parte de esta Tesis Doctoral, hemos contribuido en este campo con dos 
artículos originales de los que como doctorando soy el primer autor. En ambos trabajos fui 
responsable de llevar a cabo gran parte de los procedimientos experimentales, incluida la 
creación de los modelos animales mediante técnica quirúrgica o percutánea, de la 
adquisición de parámetros estructurales y funcionales mediante técnicas invasivas y de 
imagen (cateterismos cardiacos, ecocardiografía), análisis de los datos brutos (curvas de 
presión volumen, hemodinámica pulmonar, postprocesado de imagen avanzada 
tridimensional y análisis de la mecánica cardiaca mediante strain miocárdico), análisis 
estadístico de los datos, y redacción de los manuscritos. En ambos trabajos se planteó una 
metodología de trabajo similar, con la diferencia de los tiempos de seguimiento que se 
adaptaron a las características de la cada modelo. La Figura 2 resume los principales 
hallazgos y compara ambos modelos en las dos vertientes más importantes: el remodelado 
vascular pulmonar, y el remodelado del VD. 
 
 
Figura 2 (Resumen Parte 1, Modelos de hipertensión pulmonar). Según el modelo, 
los efectos a nivel de remodelado vascular pulmonar y del VD difieren. Esto permite 
seleccionar la opción más adecuada en función del los objetivos del estudio preclínico. 
Modelo post-capilarModelo pre-capilar
Tiempo Tiempo
PA
P
PA
P
Remodelado vascular pulmonar
Remodelado ventricular derecho
Aumento presiones
pulmonares (PAP, mmHg)
Lesiones obliterantes
Engrosamiento capa media
Fibrosis miocardio VD
Desacoplamiento
ventriculo arterial
Cambios estructurales
(masa VD )
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Aguero J, Ishikawa K, Hadri L, Santos-Gallego C, Fish K,
Hammoudi N, Chaanine A, Torquato S, Naim C, Ibanez B,
Pereda D, García-Alvarez A, Fuster V, Sengupta PP, Leopold JA,
Hajjar RJ. Characterization of right ventricular remodeling and
failure in a chronic pulmonary hypertension model. Am J Physiol
Heart Circ Physiol 307: H1204–H1215, 2014. First published August
22, 2014; doi:10.1152/ajpheart.00246.2014.—In pulmonary hyperten-
sion (PH), right ventricular (RV) dysfunction and failure is the main
determinant of a poor prognosis. We aimed to characterize RV
structural and functional differences during adaptive RV remodeling
and progression to RV failure in a large animal model of chronic PH.
Postcapillary PH was created surgically in swine (n 21). After an 8-
to 14-wk follow-up, two groups were identified based on the devel-
opment of overt heart failure (HF): PH-NF (nonfailing, n  12) and
PH-HF (n  8). In both groups, invasive hemodynamics, pressure-
volume relationships, and echocardiography confirmed a significant
increase in pulmonary pressures and vascular resistance consistent
with PH. Histological analysis also demonstrated distal pulmonary
arterial (PA) remodeling in both groups. Diastolic dysfunction, de-
fined by a steeper RV end-diastolic pressure-volume relationship and
longitudinal strain, was found in the absence of HF as an early marker
of RV remodeling. RV contractility was increased in both groups, and
RV-PA coupling was preserved in PH-NF animals but impaired in the
PH-HF group. RV hypertrophy was present in PH-HF, although there
was evidence of increased RV fibrosis in both PH groups. In the
PH-HF group, RV sarcoplasmic reticulum Ca2-ATPase2a expres-
sion was decreased, and endoplasmic reticulum stress was increased.
Aldosterone levels were also elevated in PH-HF. Thus, in the swine
pulmonary vein banding model of chronic postcapillary PH, RV
remodeling occurs at the structural, histological, and molecular level.
Diastolic dysfunction and fibrosis are present in adaptive RV remod-
eling, whereas the onset of RV failure is associated with RV-PA
uncoupling, defective calcium handling, and hyperaldosteronism.
right ventricular remodeling; pulmonary hypertension model; pres-
sure-volume relationships; echocardiography; SERCA2a; aldosterone
PULMONARY HYPERTENSION (PH) is a complex clinical condition
that may be associated with cardiac, pulmonary, or other
systemic diseases. At present, PH is categorized into five
distinct groups on the basis of pathological, pathophysiologi-
cal, and therapeutic commonalities shared by patients with
different forms of the disease (14). Right ventricular (RV)
failure is a common consequence of chronic PH of any etiology
and is currently considered the strongest indicator of prognosis
in these patients (44). RV failure occurs when contractility of
the hypertrophied RV is insufficient to compensate for the
increase in pulmonary vascular resistance, or RV afterload, and
RV-pulmonary artery (PA) uncoupling occurs. Although distal
pulmonary vascular disease severity is a major determinant of
RV hypertrophy and subsequent failure in Group 1 PH (pul-
monary arterial hypertension), less is known about the mech-
anisms leading to maladaptive RV remodeling in Group 2
patients (left heart disease). In heart failure (HF) patients,
concomitant PH is a frequent diagnosis, but the relevance of
distal pulmonary vascular remodeling and the passive increase
in venous pulmonary pressure for RV function and RV-PA
coupling has not been well characterized (43).
In PH, understanding the RV remodeling process and
RV-PA uncoupling remains challenging as the anatomical and
pathophysiological responses to chronically increased after-
load differ significantly from that of the left ventricle (LV)
(44). RV-PA uncoupling in chronic PH has been quantified
directly in experimental models (19, 20, 34) and estimated in
clinical studies (26, 38). Although RV-PA uncoupling is now
recognized as a critical event leading to RV failure, the tem-
poral relationship between RV-PA uncoupling and the onset of
RV failure remains less clear (45). Some studies have sug-
gested that uncoupling is a late complication of severe long-
standing PH (34), which is preceded by RV adaptive remod-
eling (35), whereas others have suggested that RV-PA uncou-
pling is an early phenomenon in chronic PH (19, 20). Exposure
of the RV to chronic pressure overload also promotes cellular
and molecular remodeling, which may underlie the early
changes in RV cardiomyocyte function that occur prior to RV
failure (3, 45). Pathologic cardiomyocyte growth, abnormal
calcium handling (21, 31), and increased apoptosis (3, 10) as
well as RV ischemia and neurohormonal activation (5) have all
been identified as mechanisms that promote RV remodeling
and transition to failure.
Given the importance of RV function for prognosis in PH,
few studies have provided a comprehensive RV hemodynamic,
cellular, and molecular profile that differentiates compensatory
RV hypertrophy from RV failure associated with RV-PA
uncoupling (9). This knowledge deficit has resulted, in part,
from both the aforementioned complexity in RV functional
characterization as well as the lack of availability of relevant
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large animal models that recapitulate different stages of RV
remodeling. Experimental models of PH in large animals offer
a unique opportunity to analyze RV structure and function with
clinical relevance for human disease; however, large animal
models of PH have been difficult to create and have not
mimicked completely the pulmonary vascular and RV patho-
physiology observed in human PH. We hypothesized that there
are physiological, cellular, and phenotypic differences in the
RV that differentiate between adaptive and maladaptive re-
modeling in a large animal model of pulmonary hypertension.
To examine this hypothesis, we chose to study the porcine
pulmonary vein banding model of postcapillary PH as a rep-
resentative large animal model of PH that would allow us to
identify unique hemodynamic parameters using invasive pres-
sure-volume loops and noninvasive echocardiographic imag-
ing, in association with key molecular abnormalities in the
myocardium, that differentiate adaptive from maladaptive RV
remodeling.
METHODS
The study was performed in accordance with the Guidelines for the
Care and Use of Laboratory Animals and was approved by the Icahn
School of Medicine at Mount Sinai Institutional Animal Care and Use
Committee.
EXPERIMENTAL PROCEDURES
Experimental design. Twenty-five Yorkshire pigs were included in
this study. The postcapillary PH model was created by surgical
banding of the inferior pulmonary venous drainage (PH Group, n 
21). The pigs were housed in the animal facility for up to 16 wk and
developed PH gradually during this period. A sham-operated group
(n  4) undergoing a left lateral thoracotomy without pulmonary vein
banding was included as a control. The pigs were considered to have
signs of RV HF when they showed progressively increased respiratory
rate at rest, loss of appetite and water intake, and weight loss or slower
weight gain as compared with controls. Accordingly, at the onset of
RV HF, the PH group was divided into two groups based on the RV
response to pulmonary venous banding: adaptive (PH-NF, pulmonary
hypertension with nonfailing RV) and maladaptive (PH-HF, pulmo-
nary hypertension with RV HF). At the end of the study, animals were
euthanized with pentobarbital sodium and the heart and lungs were
removed for analysis.
Surgical and periprocedural anesthesia. Animals were premedi-
cated using 6.0 mg/kg Telazol (tiletamine/zolazepam), intubated, and
ventilated using the following parameters: 40% oxygen, 10 ml/kg tidal
volume at 15 respirations per minute to maintain an end-tidal CO2
between 35 and 45 mmHg. General anesthesia was maintained with
5–8 mg·kg1·h1 propofol except during the surgical procedures that
required a thoracotomy that were performed under isoflurane (1.5–
3%) anesthesia. Before a thoracotomy procedure, animals were given
25 mg/kg im cefazolin and 2 mg/kg iv gentamicin; 25 mg/kg im
cefazolin twice daily was given for 10 days after the thoracotomy.
Animals postoperatively received a 25–50 mcg/h fentanyl patch.
Postcapillary PH model. The procedure was adapted from the a
previous description by Silove et al. (39) and Pereda et al. (33) and
performed in 9–13 kg pigs with minor modifications. Briefly, through
a left lateral thoracotomy at the fifth intercostal space, the superior left
pulmonary vein and the common inferior pulmonary vein (drains both
right and left diaphragmatic veins) were dissected in the extrapericar-
dial space close to the left atrium. To provide consistency in the
degree of venous stenosis created between animals, each vein was
constricted initially with a 3.5-mm diameter plastic cylinder; after the
fabric tape is placed around the vein and secured with a 2-0 silk
suture, the cylinder is removed. The optimal degree of constriction
was determined from the experience of three pilot experiments that
varied the degree of the constriction. In this case, a band with
restriction 3.5 mm created no hemodynamic effects at follow-up,
whereas a more severe restriction (3.5 mm) led to refractory
pulmonary edema in the first 24 h. All animals received a single dose
of furosemide (4 mg/kg) immediately after the surgery.
Pulmonary hemodynamic evaluation. At the final follow-up, a
7.5-Fr Swan-Ganz (Edwards Lifesciences) catheter was advanced
through a femoral vein to the right heart. Right atrial (RA) pressure
and systolic, diastolic, and mean pressures were recorded in the
pulmonary artery (PA) and PA wedge position (PAWP) positions.
PAWP is reported as the average of measurements obtained from both
right and left lung. Cardiac output (CO) was measured using the
thermodilution method. Pulmonary vascular resistance (PVR) was
calculated as (mean PA  PAWP)/CO and PA capacitance as SV/PP,
where SV is stroke volume and PP is pulse pressure. CO, SV, PVR,
and PA capacitance were indexed to the body surface area as reported
previously (24). All parameters were recorded during brief periods of
end-expiratory breath-hold in anesthetized ventilated animals.
Pressure-volume relationships. RV pressure-volume loops were
obtained with a 7-Fr conductance micromanometer catheter (Millar
Instruments, Houston, TX) connected to a MPVS Ultra Control
Interface (Millar Instruments, Houston, TX). The position of the
conductance catheter inside the RV chamber was coordinated using a
customized 7-Fr XB3.5 guide catheter (Cordis, Johnson & Johnson)
that was advanced into the center of the RV cavity via femoral vein
access. A small dose of iodinated contrast agent was injected through
the catheter to delineate the RV shape. Under fluoroscopic guidance,
the tip of the catheter was placed in the RV apex and, typically, 5–7
electrodes, depending on the chamber size, were included to compute
the total RV volume. Simultaneous pressure-volume data were ac-
quired under steady-state conditions and during transient inferior vena
cava occlusion using a Fogarty Occlusion catheter (Edwards Life-
sciences). All measurements were performed during brief periods of
breath-hold in anesthetized and ventilated animals.
Pressure-volume data were analyzed using Iox2 Software (EMKA
Technologies). For calibration, the  gain factor was calculated using
the simultaneously determined SV (obtained from thermodilution
cardiac output) as a reference method and volumes were corrected
using the values obtained by three-dimensional (3D) echocardiogra-
phy. The following parameters were subsequently obtained from
steady-state or occlusion series loops: peak RV pressure rate of rise
(dP/dt) maximum and decline (dP/dt) minimum,  value (time
constant of isovolumic relaxation), RV stroke work (SW) index,
preload recruitable stroke work [as the slope of SW and end-diastolic
volume (6)], RV end-systolic elastance slope [end-systolic pressure-
volume relationship (ESPVR)] and volume intercept (Vo), pulmonary
artery elastance (Ea), and the ratio ESPVR/Ea as an estimate of
RV-PA coupling, as described previously (6). The RV diastolic
properties were quantified further by the end-diastolic pressure-vol-
ume relationship (EDPVR) defined as its linear slope. The assumption
of linearity for both ESPVR and EDPVR was confirmed by a Pearson
correlation coefficient 0.9 within the physiological range of pres-
sures and volumes within the occlusion series for all studies.
Echocardiography
Echocardiographic data were collected at baseline and final fol-
low-up in all animals by using a Philips iE33 ultrasound system
(Philips Medical Systems, Andover, MA). According to current rec-
ommendations of the American Society of Echocardiography for RV
assessment (35), cardiac performance was analyzed by measuring the
following parameters: 1) anatomical M-mode tricuspid annulus plane
systolic excursion (TAPSE), 2) tissue Doppler-derived tricuspid an-
nular systolic velocity, 3) myocardial performance index (MPI), 4)
RV volumes and ejection fraction (RVEF) obtained from 3D datasets
that were analyzed offline with QLAB software (Philips Medical
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Systems, Andover, MA) and a disk summation method validated
previously using magnetic resonance imaging (MRI) as a reference
method (32), and 5) RV free wall mechanics. Modified four-chamber
views were used to measure the RV free wall peak longitudinal strain
and strain rate. Two-dimensional (2D) speckle tracking-derived strain
and strain rate were measured offline in three consecutive beats using
Cardiac Performance Analysis (TomTec, Munich, Germany). The 2D
clip acquisition protocol focused on the endocardial border definition
while ensuring frame rates between 50 and 70 frames/s for an
appropriate performance of the tracking algorithm (15).
LV volumes and ejection fraction were also assessed using 3D
datasets, and LV diastolic function was quantified by the E/A ratio of
the mitral inflow. All measurements were averaged from three con-
secutive beats obtained during brief periods of breath-hold.
The severity of pulmonary vein banding was estimated by the mean
gradient of the common inferior pulmonary vein flow using the
velocity-time integral from the pulsed wave echo-Doppler signal.
Heart and Lung Morphology
After the animals were euthanized, the RV and LV were sec-
tioned and weighed, and RV hypertrophy was assessed by the ratio
RV/(LV  septum). Heart and lung tissue samples were placed in
10% formaldehyde solution and subsequently fixed, processed,
embedded in paraffin, and sectioned into 5-	m-thick sections for
analysis. From randomly selected segments of upper and lower
lobes from both lungs, the relative medial thickness (MT) was
measured as: MT  (WT 
 2) 
 100/ED, where WT is wall
thickness and ED is external diameter). MT for each PH group was
compared with the sham at different sizes of ED (in 	m): 50,
50 –100, 100 –150, and 150. In the upper and lower lobes of both
lungs, we measured MT in 30 – 40 randomly identified arteries/pig
with an external diameter 300 	m. PA vessel characterization
and morphometric quantification were performed after staining
with Elastica Van Gieson. Cardiomyocyte cross-sectional area was
measured in cardiac sections stained with wheat germ agglutinin
(conjugated to Oregon Green 488, 10 	g/ml; Invitrogen) and
costained with phalloidin (conjugated to Alexa fluor 546, 165 nM;
Invitrogen). Images of RV cardiomyocyte cell membranes were
captured digitally and analyzed by image analysis using ImageJ
software (National Institutes of Health). RV myocardial fibrosis
was assessed with Masson’s Trichrome staining, quantified, and
reported as percent area.
Myocardial Tissue and Serum Sample Analysis
Protein lysates were obtained from RV tissue that was homoge-
nized in radioimmunoprecipitation assay buffer containing protease
and phosphatase inhibitors (Pierce, Rockford, IL). Twenty micro-
grams of total protein extracts were mixed with Laemmli sample
buffer containing 5% -mercaptoethanol (Bio-Rad, Hercules, CA).
Samples were heated at 95°C for 5 min, with the exception of those
used for phospholamban (PLN) analysis, which were incubated at
37°C for 30 min. Samples then were loaded onto 4–20% SDS-PAGE
gels. After electrophoresis proteins were transferred onto polyvi-
nylidene difluoride membrane (Millipore, Billerica, MA). Membranes
were blocked with 5% fat-free milk in Tris-buffered saline (TBS) for
1 h at room temperature and incubated with the primary antibodies
diluted in blocking buffer overnight at 4°C. The following primary
antibodies were used: GAPDH (Sigma, St. Louis, MO; 1:10,000
dilution), sarco(endo)plasmic reticulum Ca2-ATPase 2a (SERCA2a;
21st Century Biochemicals, Marlboro, MA; 1:3,000 dilution), PLN
(Badrilla Leeds innovation center, Leeds, United Kingdom; 1:5,000
dilution), and CCAAT/enhancer binding protein homology protein
(CHOP; Cell Signaling, Danvers, MA; 1:1,000 dilution). The second
day, after three washing steps with TBS-0.05% Tween-20, the mem-
brane was incubated with secondary horseradish peroxidase conju-
gated antibody (Thermo Scientific, Barrington, IL; 1:10,000 dilution)
for 45 min. The blot was washed three times with TBS-0.05%
Tween-20, and then a SuperSignal West Pico chemiluminescent
substrate (Thermo Scientific, Barrington, IL) was used for the detec-
tion of protein bands. Band density was quantified using Photoshop.
Values were normalized to GAPDH to correct for variation in protein
loading.
Aldosterone levels were measured using the Aldosterone EIA
kit-Monoclonal (Cayman Chemical) as reported previously (30)
Briefly, serum samples were subjected to methylene chloride extrac-
tion to remove corticosteroids that may interfere with the assay. After
extraction, samples were dissolved in 0.5 ml of assay buffer and
aldosterone levels were determined according to the manufacturer’s
instructions and read on a Spectramax 190 plate reader (Molecular
Devices).
Statistical Analysis
Continuous variables are expressed as median [percentiles 25th-
75th] unless indicated otherwise. The distribution of each contin-
uous variable was graphically assessed using histograms, and
normality was analyzed using Q-Q plots. Continuous variables
were compared at the final follow-up time point using the inde-
pendent samples t-test, Mann-Whitney test, one-way ANOVA, or
the nonparametric Kruskal-Wallis test as appropriate. Post hoc
analysis (Hochberg method) was used to correct for multiple
pairwise comparisons. The association between two continuous
variables was analyzed using the Pearson correlation coefficient.
The differences in pulmonary arteriole MT between groups were
analyzed using a mixed model regression for arterial media thick-
ness to account for repeated measurements on the same animals at
different vessel diameters. All statistical analyses were performed
using R software version 2.15.3 (http://cran.r-project.org/) and
OriginPro 9.1 package (Northampton, MA).
RESULTS
Survival and Heart Failure Occurrence in the Chronic
Postcapillary PH Model
Of the 21 animals that underwent pulmonary venous band-
ing to create postcapillary PH, only one animal died postoper-
atively due to acute pulmonary edema. Of the remaining group
of 20 postcapillary PH pigs, 8 animals developed overt signs of
HF characterized by increased respiratory rate, decreased food
intake, and impaired weight gain as determined by daily
examination by the veterinary team. Based on this assessment,
the final follow-up examination for these animals was expe-
dited (median follow-up: 8[7–9] wk). The final follow-up of
the remaining 12 pigs was performed at wk 14[13–16]. Be-
cause 40% of the animals in the PH group exhibited early signs
of RV failure, we sought to compare RV functional, cellular,
and molecular parameters to differentiate a compensatory from
a failing RV phenotype in our model of chronic postcapillary
PH. Accordingly, we divided animals into two groups: PH-NF
(n  8) and PH-HF (n  12).
Cardiopulmonary Hemodynamics and PA Remodeling
The hemodynamic measurements obtained from the sham-
operated controls, PH-NF, and PH-HF groups are summarized
in Table 1. Although both PH groups developed elevated
pulmonary pressures and hemodynamic profiles consistent
with PH, the mean pulmonary arterial pressure (42[39–47] vs.
28[25–33] mmHg; P  0.03) and PVR index (8.8[6.8–12.3]
vs. 3.0[2.1–3.9] WU*m2; P  0.02) were higher in PH-HF
compared with PH-NF animals, indicating the presence of
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more severe disease in PH-HF animals (Fig. 1, A and B).
Furthermore, the finding that the transpulmonary gradient and
the PVR index were increased in both PH groups identifies a
precapillary factor as a contributor to elevated pulmonary
pressures in this model of chronic postcapillary PH. The
inverse curvilinear relationship between the PA capacitance
(pulsatile) and PVR index (resistive) components that deter-
mine RV afterload identified a transition from adaptive to
maladaptive RV remodeling that was determined by the rise in
PVR index: an early decrease in PA capacitance without a rise
in PVR was associated with adaptive RV remodeling, whereas
maladaptive RV remodeling occurred in the setting of a
marked increase in PVR index (Fig. 1C). As expected, a
decrease in the cardiac index (3.0[2.8–4.2] vs. 4.4[4.1–4.7] vs.
Table 1. Invasive hemodynamics in PH with adaptive or maladaptive RV remodeling
Pairwise Comparisons*
Sham PH-NF PH-HF P, ANOVA
Sham vs.
PH-NF
Sham vs.
PH-HF
PH-NF vs.
PH-HF
n 4 12 8
Body weight, kg 30.5 (29.5–31.3) 29.0 (26.8–32.2) 20.0 (17.5–22.5) 0.0000007 0.67 0.00013 0.000013
Hemodynamics
Heart rate, beats/min 65 (53–76) 73 (61–79) 75 (72–86) 0.17
Mean aorta, mmHg 96 (84–108) 106 (83–126) 75 (68–80) 0.03 0.43 0.36 0.027
Pressure, mmHg
Pulmonary artery wedge 5 (4–6) 12 (11–15) 12 (11–14) 0.005 0.007 0.007 0.94
Mean pulmonary artery 15 (13–15) 28 (25–33) 42 (29–47) 0.0009 0.019 0.0007 0.03
Right atrial 2 (1–2) 3 (3–4) 3 (1–4) 0.2
Transpulmonary gradient, mmHg 9 (8–10) 14 (11–22) 29 (27–33) 0.014 0.12 0.015 0.09
Cardiac index, l/min*m2 4.4 (4.1–4.7) 4.7 (3.8–5.0) 3.0 (2.8–4.2) 0.056 0.056
Stroke volume index, ml/m2 69 (62–77) 64 (58–76) 41 (39–46) 0.007 0.58 0.019 0.016
PVR index, wood units*m2 2.0 (1.7–2.3) 3.0 (2.1–3.9) 8.8 (6.8–12.3) 0.004 0.21 0.008 0.02
PVR-to-systematic vascular resistance ratio 0.12 (0.11–0.13) 0.18 (0.13–0.33) 0.58 (0.43–0.59) 0.001 0.18 0.003 0.006
Pulmonary artery capacitance index,
ml/mmHg*m2 5.7 (5.2–5.9) 3.3 (2.6–3.8) 1.7 (1.5–1.9) 0.00001 0.0017 0.000012 0.0017
PH-NF, pulmonary hypertension, adaptive right ventricular (RV) remodeling, and no failure; PH-HF, pulmonary hypertension, maladaptive RV remodeling,
and heart failure; PVR, pulmonary vascular resistance. *Presented if ANOVA P  0.05.
Fig. 1. Pulmonary pressures and vascular remodeling in pigs with pulmonary hypertension (PH) and adaptive versus maladaptive right ventricular (RV)
remodeling. In comparison with pigs that had PH, adaptive RV remodeling, and no failure (PH-NF), pigs with PH, maladaptive RV remodeling, and failure
(PH-HF) had a higher mean pulmonary arterial (PA) pressure (mPAP; A) and pulmonary vascular resistance (PVR) index (B). C: inverse curvilinear relationship
between PA capacitance (pulsatile component) and PVR index (steady component) of RV afterload shows the transition from RV adaptive to maladaptive
remodeling in PH-NF (light gray triangles) and PH-HF (dark gray triangles) as compared with shams (light gray circles). Representative lung vascular
morphometry (
20) showing pulmonary arteriole remodeling stained with Elastica Van Gieson staining for a sham-operated (D) and PH (E) pig. F: quantification
of pulmonary arteriole medial thickness comparing sham (white), PH-NF (gray), and PH-HF (black) stratified by vessel diameter, P  0.05 for sham vs. PH
(*P  0.05 vs. PH-NF). WU, wood units.
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4.7[3.8–5.0] l/min*m2; P  0.056 by ANOVA) and stroke
volume index were found only in PH-HF animals as compared
with sham-operated controls or PH-NF pigs.
To examine the precapillary contribution to elevated pulmo-
nary pressures and resistance, histopathological analysis of
lung sections was performed, which revealed that significant
pulmonary arteriole remodeling occurred in this model of
chronic postcapillary PH. In distal pulmonary arterioles 300
	m from both PH-NF and PH-HF animals, there was evidence
of medial hypertrophy, severe narrowing and regression of the
vessel lumen, and disruption of the internal elastic lamina (Fig.
1, D–F). Although there were no quantitative differences found
in the number of remodeled vessels between the PH-NF and
PH-HF groups, the presence of pulmonary arteriole hypertro-
phic remodeling identifies structural precapillary vascular
changes as a consequence of chronically increased pulmonary
venous pressures in this model.
Functional and Structural Parameters in the Chronically
Overloaded RV Assessed by Invasive Pressure-Volume Loops
and Echocardiography
As differences in pulmonary vascular remodeling alone
could not explain the adaptive versus maladaptive RV re-
sponses observed in the chronic postcapillary PH model, de-
tailed RV functional and structural analyses were performed.
Summary data for pressure-volume relationships are shown in
Table 2, and representative examples are displayed in Fig. 2A.
With the use of steady state high-fidelity micromanometry, the
adjusted (dP/dt) maximum revealed that there was a decrease
in RV function in the PH-NF and PH-HF groups compared
with shams (19.7 [17.4–22.4] vs. 14.5 [13.3–20.3] vs. 14.6
[12.3–15.7] (s  1); P  0.052). SW index was also increased
in both PH group despite the lower stroke volume. From the
inferior vena cava occlusion study, we observed that RV
elastance (as the ESPVR linear slope) was increased in both
groups, as was the arterial elastance. This resulted in com-
pensated RV-PA coupling (ESPVR/Ea) in the PH-NF adap-
tive group, which markedly impaired in the maladaptive
PH-HF animals, consistent with RV-PA uncoupling (Fig.
2B). Among invasive parameters of RV diastolic function, a
significantly longer  constant was observed in both PH
groups compared with shams indicative of diastolic dys-
function; however, there were no differences found between
the PH groups. Regardless, other indexes of RV relaxation,
including a less negative absolute value of (dP/dt) minimum
and EDPVR slope, revealed RV relaxation was impaired to
Table 2. Pressure-volume loop and echocardiographic assessment of RV function
Pairwise Comparisons*
Sham PH-NF PH-HF P, ANOVA
Sham vs.
PH-NF
Sham vs.
PH-HF
PH-NF vs.
PH-HF
n 4 12 8
Pressure-volume analysis
Systolic function
dP/dtmax, mmHg/s 551 (511–618) 690 (592–746) 783 (702–896) 0.1
Adjusted dP/dtmax, s1 19.7 (17.4–22.4) 14.5 (13.3–20.3) 14.6 (12.3–15.7) 0.052 0.22 0.05 0.23
RV stroke work index,
(mmHg*ml)/m2 1,060 (1,041–1,079) 1,817 (1,619–2,070) 1,931 (1,495–2,157) 0.19
Arterial elastance index,
(mmHg/ml)*m2 0.81 (0.73–0.91) 1.27 (1.18–1.33) 5.10 (2.50–5.70) 0.0004 0.57 0.002 0.0009
ESPVR slope, mmHg/ml 0.48 (0.48–0.53) 0.7 (0.59–0.81) 1.7 (1.25–1.58) 0.0002 0.45 0.0009 0.0006
ESPVR volume intercept, ml 10 ([21]–2) 5 ([23]–4) 24 ([7.5]–30) 0.22
ESPVR/Ea 0.59 (0.54–0.66) 0.58 (0.46–0.69) 0.30 (0.26–0.50) 0.041 0.75 0.08 0.07
Preload recruitable stroke work
slope 12 (11–13) 18 (17–19) 25 (22–28) 0.002 0.037 0.002 0.037
Diastolic function
dP/dtmin, mmHg/s 301 ([331]–[293]) 532 ([646]–[443]) 844 ([1019]–[605]) 0.0006 0.08 0.0009 0.0005
, ms 22 (16–25) 31 (30–40) 29 (24–37) 0.041 0.04 0.19 0.28
End-diastolic pressure-volume
relationship slope, mmHg/ml 0.13 (0.10–0.16) 0.19 (0.18–0.23) 0.43 (0.36–0.47) 0.005 0.12 0.006 0.03
Echocardiography
RV
RV EDV, ml/m2 103 (101–104) 125 (115–134) 130 (118–138) 0.087
RV ESV, ml/m2 30 (28–32) 41 (36–47) 58 (54–65) 0.002 0.09 0.002 0.0016
RV ejection fraction, % 70 (69–72) 67 (63–70) 54 (41–61) 0.001 0.32 0.0037 0.0037
Myocardial performance index 0.377 (0.369–0.411) 0.406 (0.390–0.480) 0.590 (0.460–0.650) 0.06 0.52 0.014 0.014
S=, Doppler tissue imaging,
cm/s 9.7 (9.5–10.3) 8.8 (7.9–8.2) 8.4 (8.1–8.7) 0.024 0.024 0.024 0.85
Tricuspid annular plane
systolic excursion, mm 25 (23–26) 20 (19–22) 15 (14–18) 0.0003 0.028 0.0003 0.012
Longitudinal strain, % 31 ([32]–[29]) 25 ([25]–[22]) 20 ([21]–[18]) 0.00006 0.006 0.00005 0.006
Longitudinal strain rate, s1 3.0 ([3.2]–[2.8]) 2.0 ([2.2]–[1.9]) 1.5 ([1.6]–[1.4]) 0.00002 0.0024 0.00019 0.0024
LV
LV EDV, ml/m2 88 (76–95) 96 (84–100) 75 (60–83) 0.12
LV ESV, ml/m2 17 (15–19) 19 (16–19) 14 (11–19) 0.36
LV ejection fraction, % 80 (79–81) 80 (76–82) 80 (78–83) 0.97
Mitral E/A 1.0 (0.9–1.1) 1.2 (1.1–1.3) 1.4 (1.1–1.5) 0.24
dP/dt, rate of pressure change in the ventricle; Ea, arterial elastance; ESPVR, end-systolic pressure volume relationship; LV, left ventricle; EDV, end-diastolic
volume; ESV, end-systolic volume. *Presented if ANOVA P  0.05.
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a significantly greater degree in PH-HF as compared with
PH-NF animals (Fig. 2C).
An echocardiographic assessment of cardiac function was
also performed and data are summarized in Table 2. RV
remodeling quantified using 3D-echocardiography revealed
increases in indexed RV end-diastolic and end-systolic vol-
umes in both PH groups compared with sham-operated con-
trols. RV remodeling was associated with RV dysfunction with
decreased RVEF, TAPSE, and an increase in the MPI in the PH
groups compared with shams. Moreover, the RVEF was sig-
nificantly lower in the PH-HF compared with the PH-NF
animals (54 [41–61] vs. 67 [63–70] %; P  0.004), as was
TAPSE (15 [14–18] vs. 20 [19–22] mm; P  0.012), and MPI
was significantly higher (0.059 [0.46–65] vs. 0.41 [0.39–
0.48]; P  0.014). Longitudinal strain was also reduced in
PH-HF compared with PH-NF animals (20 [21 18] vs.
25 [25-22] %; P  0.006; Fig. 3, A and B).
At the final follow-up, the inferior pulmonary vein was also
interrogated using pulsed-wave Doppler echocardiography to
determine if there was increased severity of the pulmonary vein
luminal restriction over time as a cause of RV maladaptive
remodeling. This demonstrated that the mean gradient at the
common inferior vein was 1 mmHg in the sham-operated
group and increased significantly in both PH groups. Interest-
ingly, the mean gradient was significantly higher in the PH-HF
group compared with the PH-NF (17[16–18] vs. 12 [11–13]
mmHg, respectively; adjusted P  0.047) despite a similar
degree of venous banding at the index procedure to create the
model.
Chronic Postcapillary PH is Associated With RV
Cardiomyocyte Hypertrophy and Fibrosis
Additional evidence of RV remodeling in the chronic post-
capillary PH model was obtained from the explanted heart by
measurement of the weight of the RV free wall relative to that
of the LV  septum indexed to the animal body weight. When
compared with sham-operated controls, the PH groups had a
marked increase in RV weight consistent with RV hypertrophy
(Fulton index: 0.40 [0.38–0.43] vs. 0.62 [0.54–0.77]; P 
0.05; RV weight/body weight: 1.13 [1.11–1.16] vs 1.56 [1.38–
1.98] g/kg; P  0.05; Fig. 3, C and D).
On histopathological analysis of the RV myocardium, there
was evidence of RV cardiomyocyte hypertrophy with in-
creased cardiomyocyte cross-sectional area in both PH-NF and
PH-HF animals compared with sham-operated controls and no
difference identified between the PH groups (Fig. 4, A–C).
There was also an increase in fibrosis detected in the RV of
animals with PH compared with sham-operated controls with a
predilection for the perivascular space and no observed differ-
ences between the PH groups (Fig. 4, D–F).
Myocardial SERCA2a and Endoplasmic Reticulum
Stress-Related Protein Expression
To determine whether there were appreciable differences in
the RV of PH-NF versus PH-HF animals at the molecular
level, we analyzed the expression of calcium handling proteins
since studies performed in a canine model of severe RV
pressure overload found a decrease in SERCA and PLN phos-
Fig. 2. Pressure-volume relationships in adaptive versus
maladaptive RV remodeling. A: representative RV pres-
sure-volume loops during inferior vena cava occlusion
showing end-systolic pressure-volume relationships
(ESPVR) and end-diastolic pressure-volume relation-
ships (EDPVR) in a sham-operate pig (green), a pig
with adaptive RV remodeling with increased EDPVR
(0.24) and preserved RV-PA coupling/pulmonary arte-
rial elastance (ESPVR/Ea) (0.84; blue), and a pig with
maladaptive RV remodeling, high EDPVR slope (0.31),
and impaired ESPVR/Ea (0.26; red). Solid lines: end-
systolic pressure-volume (Ees) slope; dashed lines: ED-
PVR. B: ESPVR/Ea was determined as a measure of
RV-PA coupling. C: EDPVR was assessed as measure
of diastolic function. *P  0.05 vs. PH-NF.
H1209RV REMODELING IN EXPERIMENTAL PULMONARY HYPERTENSION
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00246.2014 • www.ajpheart.org
 by 10.220.33.4 on February 14, 2017
http://ajpheart.physiology.org/
D
ow
nloaded from
 
28
phorylation (31). In the RV myocardium, SERCA2a protein
expression was decreased significantly in the PH-HF animals
compared with PH-NF animals and sham-operated controls
(Fig. 5A). Interestingly, RV SERCA2a levels correlated lin-
early with indexes of RV remodeling, including RV hypertro-
phy determined by the RV/LV septum weight ratio (Pearson
r  0.71, P  0.040), RV-PA coupling determined by
ESPVR/Ea (R  0.68, P  0.061), and EDPVR slope (r 
0.70, P  0.052) reflecting an association of SERCA2a
downregulation with more severe RV functional impairment.
We also examined the expression and phosphorylation status of
PLN, which is the main regulator of SERCA2a activity. In the
RV myocardium from PH-HF animals, phosphorylation of
PLN at Ser16 was decreased (inhibition of SERCA2a activity)
compared with PH-NF and sham-operated control animals
(Fig. 5B). As SERCA2a activity has been inversely related to
endoplasmic reticulum (ER) stress, we also examined the
expression of the pro-apoptotic ER stress-related protein
CCAAT/enhancer binding protein homology protein (CHOP).
Increased expression of CHOP was detected in the PH-HF
group as compared with the PH-NF and sham-operated con-
trols (Fig. 5C). Taken together, these findings indicate that at a
molecular level, the RV in PH-HF animals is characterized by
a decrease in SERCA2a expression and activation with a
concomitant increase in ER stress.
Hyperaldosteronism Occurs in Chronic Postcapillary PH
Aldosterone levels were also examined in PH animals since
aldosterone has been shown to mediate pulmonary arteriole
remodeling and fibrosis in PA hypertension (28–30) and aldo-
sterone is a recognized indicator of HF status. Aldosterone
levels were elevated in chronic postcapillary PH pigs compared
with sham-operated controls with the highest levels detected in
PH-HF animals (28.12  4.56 vs. 60.69  6.47 vs. 190.90 
61.44 mg/dL; P  0.02 by ANOVA; Fig. 6).
DISCUSSION
RV dysfunction and progression to RV failure is a major
determinant of adverse prognosis that underlies the unaccept-
ably high mortality rate associated with PH (2). It is increas-
ingly recognized that the spectrum of RV remodeling that
occurs in PH ranges from adaptive remodeling, characterized
by RV hypertrophy with overall preserved ventricular function
and RV-PA coupling, to maladaptive remodeling associated
with RV hypertrophy, diastolic, and systolic dysfunction, and
RV-PA uncoupling (45). To date, much of the mechanistic
insight to understand RV remodeling and dysfunction has been
provided by studies performed in rodent models of experimen-
tal PH; however, detailed RV mechanical studies using inva-
sive hemodynamic monitoring are difficult to perform in these
models and highlight the need for clinically relevant large
animal models (18). In the present study, we analyzed the RV
remodeling response in a swine pulmonary vein banding model
to define hemodynamic, structural, and functional characteris-
tics that differ between compensated or adaptive RV remodel-
ing and decompensated or maladaptive RV remodeling. We
found that elevated pulmonary artery pressures, pulmonary
vascular resistance index, and distal pulmonary arterial remod-
Fig. 3. RV function and hypertrophy. In
sham-operated and PH pigs, myocardial per-
formance index (MPI) was measured as an
index of RV contractile reserve (A) and RV
longitudinal strain was assessed (B). C: RV
hypertrophy was evaluated by RV weight
relative to left ventricle (LV)  septum
(Fulton index) and indexed for body weight.
D: RV weight. *P  0.05 vs. PH-NF or vs.
sham.
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eling, all measures of increased afterload, all occur consistently
with pulmonary vein banding model. Using invasive pressure-
volume relationships and multi-parameter noninvasive imag-
ing, we confirmed that RV diastolic dysfunction and chamber
dilatation are present in early adaptive RV remodeling,
whereas RV-PA uncoupling is related to the onset of RV
failure. At a cellular level, we found that RV cardiomyocyte
hypertrophy and RV fibrosis are present in both adaptive and
maladaptive RV remodeling; however, only RV failure is
associated with abnormalities in calcium handling protein
expression and the ER stress-related protein CHOP. We also
observed that RV adaptive and maladaptive remodeling is
associated with hyperaldosteronism with higher levels present
in the setting of RV failure. Based on these observations, we
are now able to define RV maladaptive remodeling on the basis
of indexes of RV systolic and diastolic dysfunction, increased
RV contractility and decreased arterial elastance, RV-PA un-
coupling, and abnormal SERCA2a-related calcium handling.
Despite the growing interest in understanding adaptive and
maladaptive RV remodeling in PH, a major hurdle to defining
these pathophenotypes has been the lack of clinically relevant
large animal models that allow for a comprehensive analysis of
RV structure and function (41). One other porcine model of
chronic pressure overload that is created by left pulmonary
artery banding and weekly right pulmonary artery infusion of
cyanoacrylate beads is amenable to subsequent unloading of
the RV through the creation of a PA-PA conduit. This model
develops PH with RV dysfunction over time, similar to pul-
monary vein banding model, but requires several surgical
interventions and alters pulmonary artery flow patterns (19,
20). The advantage of the pulmonary vein swine banding
model is that, ultimately, the degree of inferior pulmonary vein
constriction is determined by animal somatic growth leading to
gradual onset but sustained elevations in RV afterload, consis-
tent with the clinical course in humans. Moreover, owing to
differences in the imposed RV afterload, the remodeling pat-
tern in the RV may differ between animals, leading some to
develop PH with maladaptive RV remodeling and failure while
others undergo adaptive RV remodeling as we observed. Al-
though a swine pulmonary vein banding model has been
described previously (33, 39), this is the first study that focuses
specifically on characterizing RV structure and function in PH
during the remodeling process in this model.
RV pressure-volume relationships, which have been used
widely to evaluate LV performance under different loading
conditions (6), were performed and shown to provide detailed
information pertaining to RV systolic and diastolic function in
adaptive and maladaptive RV remodeling the porcine pulmo-
nary vein banding model of PH. Interestingly, we found that
RV remodeling considered to be adaptive was associated with
systolic dysfunction as well as early diastolic dysfunction
assessed by a longer  constant, less negative (dP/dt) minimum,
and EDPVR slope, but RV-arterial coupling was preserved.
Although these abnormalities were also observed in RV mal-
adaptive remodeling, the difference between adaptive and
maladaptive remodeling and failure was the association with
RV-arterial uncoupling. This occurred when the increase in
ventricular elastance was insufficient to match pulmonary ar-
terial elastance concomitant with a further increase in the
EDPVR. Although this finding is in contradistinction with
Fig. 4. Cardiomyocyte hypertrophy and RV fibrosis. RV cardiomyocyte cross-sectional area (CSA) was examined by staining with wheat germ agglutinin to
evaluate RV sections for cardiomyocyte hypertrophy. Representative sections are shown for sham-operated (A) and PH (B) pigs, with quantification of pooled
data (C). RV sections were stained with Masson’s trichrome to examine fibrosis. Representative sections are shown for sham-operated (D) and PH (E) pigs with
quantification of pooled quantification (F). *P  0.05.
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prior studies that reported early abnormalities in RV-PA cou-
pling (19, 20), our observations are supported by other works
in large animal models showing that RV-PA uncoupling oc-
curred with RV failure; however, in this model, RV-PA un-
coupling was related to RV hypertrophy and systolic dysfunc-
tion (19, 20). The difference between our observations and the
aforementioned study is likely related to how the large animal
models were created. In our study, we also observed an
increase in RVSWI in the setting of maladaptive remodeling in
failure. Although an increase in this measure of RV workload
and contractility is counterintuitive, this finding has been
reported previously in other large animal models of pulmonary
hypertension and in patients with Group 2 pulmonary hyper-
tension (20, 25).
The concept of using pressure-volume relationships to define
RV-PA coupling as a measure of RV remodeling in PH has
merit (4, 8, 9, 26, 36). Studies analyzing RV pressure-volume
relationships in experimental or clinical PH have reported
increased RV contractility as determined by the ESPVR slope
as well as some degree of RV-PA uncoupling (19, 20, 26, 34,
38). Although invasive measures of RV-PA coupling are not
always feasible clinically, there is preclinical evidence demon-
strating a direct relationship between RV-PA coupling and
noninvasive indexes of RV function (19, 20). In patients with
PH, noninvasive estimations of RV-PA coupling have been
reported using the single beat method and maximal time
varying elastance (Emax) has been estimated as the ratio mean
pulmonary arterial pressure/ESV, thus neglecting the volume
axis intercept of ESPVR (26, 38). In this study, noninvasive
imaging using 3D volumetry and 2D speckle-tracking strain
was used to evaluate RV remodeling. With the use of these
tools, adaptive RV remodeling was characterized noninva-
sively by increased RV volumes and mildly abnormal param-
eters of longitudinal function, such as TAPSE or strain,
whereas RVEF or MPI was preserved. Further impairment of
longitudinal function along with decreased RVEF and high
MPI defined the maladaptive RV remodeling and failure con-
dition. The present study uses 2D strain techniques within the
context of the pressure-volume framework and shows that
2D-derived longitudinal strain is afterload dependent, consis-
tent with other studies evaluating RV strain using speckle-
tracking algorithms, and correlates with RV-PA coupling (13,
22). These observations also confirm other reports that support
Fig. 5. Molecular remodeling occurs in RV maladaptive remodeling. Myocardial protein quantification and representative blots for SERCA2a (A), relative
phosphorylation of phospholamban (PLN) at serine 16 (p-PLNS16/PLN; B), and CCAAT/enhancer binding protein homology protein (CHOP; C) as markers of
molecular remodeling in PH-HF. *P  0.05 vs. sham (for SERCA2a, CHOP); *P  0.05 vs. sham and PH-NF for p-PLNS16/PLN.
Fig. 6. Hyperaldosteronism is present in PH with RV maladaptive remodeling.
Serum aldosterone levels were measured at the end of the study in sham-
operated and PH pigs. *P  0.02 by ANOVA.
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the clinical feasibility and validity of longitudinal strain as a
prognostic marker in chronic PH (10, 12, 22, 37).
In this study, RV dysfunction and failure in the PH-HF
subset of animals is likely related to differences in the severity
of PH (indicated by the hemodynamic profile) that occurred as
a result of the surgical banding resulting in greater constriction
of the pulmonary vein. Although the degree of constriction was
similar between all animals at baseline, differences in somatic
growth may have influenced the ultimate degree of afterload
imposed on the RV. Hemodynamically, RV failure was asso-
ciated with reactive PH (higher PVR) and severe impairment of
PA capacitance as indicators of the steady and pulsatile com-
ponents of afterload. Stiffness parameters, including capaci-
tance, are independent markers of prognosis and RV failure in
chronic PH (27, 40).
RV cardiomyocyte hypertrophy and fibrosis were identified
as histolopathological markers of both adaptive and maladap-
tive RV remodeling in PH. These abnormalities may underlie
the early diastolic dysfunction observed in the functional stud-
ies in animals without heart failure. We also found that
SERCA2a expression was downregulated in the failing RV but
maintained in the adaptive stage of RV remodeling. This is
similar to what has been described in chronic pressure overload
by PA banding (31) and in the rat monocrotaline-PH model
(21). In addition to defects in calcium handling, other molec-
ular mechanisms have been associated to RV failure in re-
sponse to chronic pressure overload, such as abnormal cardi-
omyocyte growth (/ MHC switch) (3) and increased oxida-
tive stress and apoptosis (34). We explored ER stress, which
has been reported to mediate pulmonary vascular remodeling
(42), in the RV in our model and found evidence of ER stress
in animals developing RV failure. Interestingly, increased ER
stress in the myocardium has been recently described in re-
sponse to ischemia (16) possibly as a result of capillary
rarefaction and decreased blood supply to the hypertrophied
RV, which has been suggested to contribute to RV failure in
PH (1, 10, 17). Neurohormonal activation has also been iden-
tified as potential contributor to RV failure (3). In support of
this, we measured elevated levels of aldosterone in animals
with maladaptive RV remodeling and failure. Hyperaldoste-
ronism has been described in patients with PH (28) and is a
clinically relevant biomarker of disease severity (28, 29).
Limitations of the Study
There are several limitations to the findings from the present
study. An established definition of maladaptive RV remodeling
that incorporates functional and structural parameters down to
the cellular level is not currently available. We, therefore,
chose an arbitrary definition of maladaptive RV remodeling
based on the onset of RV failure, as assessed by clinical signs,
that was corroborated by structural, functional, and molecular
changes consistent with maladaptive remodeling. Although it
is possible that the differences between adaptive to maladap-
tive remodeling to RV failure may have been identified more
precisely for each animal by repeated hemodynamic assess-
ments over time, we did not perform these studies owing to the
morbidity associated with repeat instrumentation as well as the
fact that the time course of disease has been established (33).
In our model, the mean RA pressure in PH-HF subjects was not
increased compared with PH-NF or controls. Although it is
expected that the mean RA pressure would be increased under
these circumstances, similar findings have been reported in
other studies (33). Our study used 2D and 3D echocardiogra-
phy as opposed to magnetic resonance imaging to assess the
RV. This technique is subject to interoperator variability and
can underestimate RV volumes when RV dilation is present (7,
12). MRI might also have provided additional insight into the
role of RV myocardial ischemia in RV dysfunction by allowing
for an assessment of coronary flow reserve (23).
In conclusion, we provide evidence that the porcine pulmo-
nary vein banding model of PH is an excellent clinically
relevant model to characterize adaptive and maladaptive re-
modeling in PH using invasive and noninvasive structural and
functional quantification tools, as well as histological and
molecular analysis. Cardiomyocyte hypertrophy and fibrosis
underlie early RV adaptive remodeling and diastolic dysfunc-
tion, whereas abnormal calcium cycling protein expression,
increased ER stress, and hyperaldosteronism are associated
with RV-PA uncoupling and the onset of RV failure.
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Abstract
Pulmonary hypertension (PH) is associated with aberrant vascular remodeling and right
ventricular (RV) dysfunction that contribute to early mortality. Large animal models that re-
capitulate human PH are essential for mechanistic studies and evaluating novel therapies;
however, these models are not readily accessible to the field owing to the need for ad-
vanced surgical techniques or hypoxia. In this study, we present a novel swine model that
develops cardiopulmonary hemodynamics and structural changes characteristic of chronic
PH. This percutaneous model was created in swine (n=6) by combining distal embolization
of dextran beads with selective coiling of the lobar pulmonary arteries (2 procedures per
lung over 4 weeks). As controls, findings from this model were compared with those from a
standard weekly distal embolization model (n=6) and sham animals (n=4). Survival with the
combined embolization model was 100%. At 8 weeks after the index procedure, combined
embolization procedure animals had increased mean pulmonary artery pressure (mPA)
and pulmonary vascular resistance (PVR) compared to the controls with no effect on left
heart or systemic pressures. RV remodeling and RV dysfunction were also present with a
decrease in the RV ejection fraction, increase in the myocardial performance index, im-
paired longitudinal function, as well as cardiomyocyte hypertrophy, and interstitial fibrosis,
which were not present in the controls. Pulmonary vascular remodeling occurred in both
embolization models, although only the combination embolization model had a decrease in
pulmonary capacitance. Taken together, these cardiopulmonary hemodynamic and struc-
tural findings identify the novel combination embolization swine model as a valuable tool for
future studies of chronic PH.
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Introduction
Pulmonary hypertension is associated with pathological pulmonary vascular remodeling as
well as maladaptive RV remodeling and, ultimately, RV failure that leads to poor clinical out-
comes and early death [1]. Vascular remodeling occurs predominantly, but not exclusively, in
the pulmonary arterioles and manifests as intimal and medial hypertrophy, inflammation,
thrombosis, and fibrosis that disrupts the normal vessel architecture and leads to subtotal lumi-
nal obliteration. The RV also undergoes structural and functional remodeling with evidence of
hypertrophy and impaired indices of ventricular contraction and relaxation 1. The finding of
pathologically remodeled vessels and RV dysfunction is shared among WHO pulmonary hy-
pertension (PH) Groups, although the pathogenesis of Group 1 PH originates within the vascu-
lature in contradistinction to other forms of PH (Groups 2–5) where pulmonary arteriole
remodeling occurs as a consequence of sustained hemodynamic disturbances [2].
Large animal models that are representative of human PH are necessary to bridge the gap be-
tween studies in the well-accepted rodent models of experimental PH and clinical testing [3].
Large animal models also offer a unique opportunity to study PH using typical clinical diagnostic
methodologies, such as right heart catheterization and advanced imaging techniques, together
with a comprehensive characterization of the disease at a cellular and molecular level. This has
led to attempts to develop accessible large animal models that recapitulate the pathological and
clinical features of human PH. Several models of PH have been created in large animals using ad-
vanced surgical procedures such as the subclavian-pulmonary artery shunt overcirculation and
pulmonary vein stenosis models [4,5,6]. To overcome the complexity associated with these surgi-
cal models, recurrent pulmonary vascular embolization to obstruct the distal pulmonary arteri-
oles has been utilized as a methodology to create a model of PH (Group 4) [7,8,9,10,11,12,13];
however, studies of this model have reported mixed results with some protocols failing to achieve
PH cardiopulmonary hemodynamics. There is also no consensus pertaining to the choice of em-
bolic material, timing of administration, and the number of embolization procedures required to
create the model. In addition, many of the studies did not evaluate RV function and only exam-
ined hemodynamic changes at a time-point<1 month after the final embolization procedure
thereby calling into the question the long-term durability of those models.
Owing to the lack of information about longer-term pulmonary hemodynamics and RV
function in a large animal pulmonary embolization model, the aim of the present study was to
determine if this model could develop chronic PH with characteristics of human disease or if
the model required modification to achieve chronic PH. We, therefore, hypothesized that only
a pulmonary embolization protocol that was sufficient to produce pulmonary vascular (sub)
total occlusion would create a model of chronic PH with RV dysfunction. To test this hypothe-
sis, we utilized a novel embolization protocol that combined repeated distal embolization with
microspheres, similar to prior studies, with proximal pulmonary coil embolization using silk
suture fragments and examined cardiopulmonary hemodynamics and structural changes at
8 weeks.
Methods
Experimental design
Sixteen female Yorkshire pigs were included in the study. The pigs were housed in the animal
facility until the final follow-up assessment. At the end of the study, animals were euthanized
with sodium pentobarbital and the heart and lungs were resected for analysis. The study was
performed in accordance with the Guidelines for the Care and Use of Laboratory Animals and
Novel Model of Chronic Embolic Pulmonary Hypertension in Swine
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was approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and
Use Committee.
Peri-procedural anesthesia
For procedures related to creating the model and at final follow-up, animals were pre-medicat-
ed using Telazol (tiletamine/zolazepam) 6.0 mg/kg, intubated, and ventilated with 40% oxygen
at 10 ml/kg tidal volume and 15 respirations per minute to maintain an end-tidal CO2 between
35–45 mmHg. General anesthesia was maintained throughout the procedures with propofol
5–8 mg/kg/hr.
Recurrent embolization model of chronic PH
Two different recurrent pulmonary embolization protocols were utilized to compare the stan-
dard distal embolization model (D-Embo) with the combination proximal coiling and distal
embolization model (P+D-Embo). The final follow-up assessment was planned for week 8,
which was at least 2 weeks after the last embolization procedure. A sham group (n = 4) that did
not undergo embolization served as a control and was used as a benchmark of changes over
time related to somatic growth. The experimental protocol is shown in Fig 1.
Distal embolization model (D-Embo)(n = 6). First, pulmonary angiography was per-
formed using a 5F pigtail catheter to identify branches of the right and left main pulmonary ar-
teries. A 7.5 Fr Swan-Ganz catheter (Edwards Lifesciences) was advanced to the right or left
Fig 1. Study design and experimental protocol.
doi:10.1371/journal.pone.0124526.g001
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pulmonary artery via femoral vein access and dextran microspheres (100–300 μm diameter,
coarse Sephadex G-50, Sigma-Aldrich) at a dose of 20 mg/kg were infused through the lumen
of the Swan-Ganz catheter on a weekly basis. The dextran microspheres were mixed with 30 ml
of sterile 0.9% sodium chloride at least 6 hours prior to the injection. Using this approach, all
animals recovered with 100% survival. This dosing regimen was based on the results of a pilot
study that demonstrated that infusion of concentrated microspheres (i.e., without dilution in
saline) at doses as low as 10 mg/kg led to severe respiratory distress and high early mortality.
Once the microspheres were diluted in saline prior to infusion doses as high as 15–20 mg/kg
were tolerated without acute morbidity or mortality.
Proximal + distal embolization model (P+D-Embo) (n = 6). This model combined distal
microsphere embolization with coiling of multiple pulmonary artery branches. To avoid acute
severe PH and RV failure as a result of acute bilateral obstruction of the pulmonary arteries, the
distal embolization procedure was modified. Using a 7.5 Fr Swan-Ganz (Edwards, Lifesciences)
catheter, 20 mg/kg of dextran microspheres were injected through the distal port while the bal-
loon was inflated in the right pulmonary artery. The Swan-Ganz catheter was exchanged for a
5F JR 3.5 coronary guide catheter (Cordis) followed by selective coiling of the main branches of
the right pulmonary artery. The coiling procedure was performed by cutting sterile silk sutures
into 3 cm long sections and selectively deploying these segments into each branch. The follow-
ing week, the same procedures were performed on the contralateral lung. Over a period of 4
weeks, the embolization procedures were performed 2 times for each lung per animal.
Hemodynamic assessment
Cardiopulmonary hemodynamics were recorded using a 7.5 Fr Swan-Ganz catheter (Edwards
Lifesciences) that was advanced to the heart via femoral vein access to measure mean right atri-
al (RA) pressure, mean pulmonary artery pressure (mPA), pulmonary artery occlusion pres-
sure (PAOP), and cardiac output (CO) was measured using the thermodilution method.
Pulmonary vascular resistance (PVR) was calculated as (mPAP-PAOP)/CO, and pulmonary
artery capacitance as SV/PP, where SV is stroke volume and PP is pulse pressure. CO, SV, PVR
and pulmonary artery capacitance were indexed to the body surface area as previously reported
[14]. All parameters were recorded during brief periods of end-expiratory breath-hold in anes-
thetized and ventilated animals.
Echocardiography
Echocardiographic data were collected at baseline and final follow-up in all animals using a Phil-
ips iE33 ultrasound system (Philips Medical Systems, Andover, MA, USA). Cardiac perfor-
mance was analyzed by measuring the following parameters: 1) anatomical M-mode tricuspid
annulus plane systolic excursion (TAPSE); 2) tissue Doppler-derived tricuspid annular systolic
velocity; 3) myocardial performance index (MPI); and 4) RV end-systolic and end-diastolic vol-
umes and RV ejection fraction (RVEF) that were obtained from 3D datasets that were analyzed
offline with QLAB software (Philips Medical Systems, Andover, MA, USA). All parameters
were averaged from three consecutive measurements. For RV volumetric data, interobserver
variability was assessed in a subset of 10 animals and estimated using the intraclass correlation
coefficient. This parameter was 0.81, 0.96 and 0.93 for end-diastolic volume, end-systolic vol-
ume and RVEF, respectively.
Heart and lung morphology
To assess relative RV hypertrophy, the heart was sectioned into RV and left ventricle (LV),
weighed, and RV hypertrophy was assessed using the Fulton index (RV/LV + septum). After
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harvests, the heart and lung tissue samples were placed in 10% formaldehyde solution, fixed,
processed and tissue blocks were embedded in paraffin. From randomly selected segments har-
vested from the upper and lower lobes from both lungs, the presence and type of vascular le-
sions were assessed from 5 μm thick sections stained with Masson's trichrome or hematoxylin
and eosin. Distal pulmonary artery remodeling was assessed in 10–12 randomly identified ves-
sels and was quantified by the relative medial thickness (MT) measured as: MT = (WTx2)
x100/ED (WT = wall thickness and ED = external diameter) at different vessel diameters. Car-
diomyocyte cross-sectional area (CSA) was measured in cardiac sections stained with wheat
germ agglutinin (WGA) (conjugated to Oregon Green 488, 10 μg/mL, Invitrogen) and co-
stained with phalloidin (conjugated to Alexa fluor 546, 165 nM, Invitrogen). Images of RV car-
diomyocyte cell membranes were captured digitally and analyzed using ImageJ software (Na-
tional Institutes of Health). RV myocardial fibrosis was assessed with Masson’s Trichrome
staining, quantified, and reported as % area.
Statistical analysis
All continuous variables are expressed as the mean ± SD. The distribution of continuous vari-
ables was assessed graphically using histograms. Normality was determined using Q-Q plots
Continuous variables were compared between three groups using one-way analysis of variance
or the non-parametric Kruskal-Wallis test, followed by post hoc analysis (Tukey HSDmethod to
correct for multiple pairwise comparisons). As the main objective of the study was the develop-
ment of chronic PVD, hemodynamic changes were computed as the difference between the last
follow-up (8 weeks) and the baseline values. For quantitative analyses of histological samples, a
mixed model regression was used considering the Group as a fixed factor and the animals within
groups as random factors to account for nested measurements within each animal. All statistical
analyses were performed using R software version 3.1.0 (http://cran.r-project.org/).
Results
All animals included in the study completed the embolization procedures per protocol and sur-
vived to the 8 week follow-up assessment timepoint. Pulmonary angiograms from before and
immediately following the infusion of dextran microspheres (20 mg/kg) revealed that the pro-
cedure created acute subtotal luminal obstruction and diminished pulmonary vascular blood
flow patterns (S1 and S2 videos). This finding, however, improved over time as the pulmonary
angiograms from animals after repeated distal pulmonary embolization procedures demon-
strated less luminal obstruction and better recovery of pulmonary blood flow compared to the
initial post-embolization study (S3 video). Representative images from angiograms of the pul-
monary arterial tree at baseline and immediately after embolization demonstrating acute occlu-
sion of the arterioles are shown in Fig 2.
Chronic increase in pulmonary artery pressure occurs in proximal +
distal embolization model
Although pulmonary artery pressures were elevated acutely ~2-fold after administration of the
dextran beads in both models (Fig 3), pulmonary pressures returned to baseline between all of
the subsequent embolization procedures in D-Embo animals (shown by the mPA pressure
measured pre-embolization at each procedure). By contrast, there was a gradual increase in the
mPA over time in P+D-Embo pigs. At the 8-week follow-up examination, indices of pulmo-
nary arterial hypertension were present only in P+D-Embo animals (Table 1). Compared to
sham controls and D-Embo pigs, mPA pressures were increased significantly in P+D-Embo
pigs (14 ±1 vs. 16 ± 2 vs. 23 ± 4 mmHg, p<0.05) with normal PAOP observed in all groups. To
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examine the effect of the FiO2 on measured mPA pressures, the FiO2 was decreased to 21% for
10 min and mPA pressures were remeasured in sham and P+D-Embo animals. While there
was no significant difference in mPA pressures at 21% compared to 40% FiO2 in sham pigs,
there was an observed increase in mPA pressure at 21% in P+B-Embo animals (S1 Fig). The
PVR index was also increased in P+D-Embo animals (3.9 ±1.6 WUm2) compared to shams
(2.0 ± 0.4 WUm2) and D-Embo animals (2.5 ± 0.5 WUm2). The pulmonary artery capaci-
tance index, a measure of the pulsatility or compliance of the pulmonary artery, was decreased
significantly in P+D-Embo pigs compared to D-Embo pigs (3.9 ±0.5 vs. 2.9 ±0.5, p<0.05) and
inversely related to the PVR index. Thus, at 8 weeks, the combination embolization pigs all
Fig 2. Infusion of dextranmicrospheres (100–300 μm) acutely obstructs pulmonary arteries.Representative still images from pulmonary artery
angiographies obtained at (A) baseline or (B) immediately after embolization of microspheres.
doi:10.1371/journal.pone.0124526.g002
Fig 3. Acute changes in mPA pressure at the time of consecutive weekly embolization procedures.
Hemodynamic assessments were made by right heart catheterization immediately before and after each
weekly infusion of dextran microspheres. Animals in the D-Embo group (n = 6) underwent 6 embolization
procedures (top) while pigs in the P+D-Embo group (n = 6) underwent 4 procedures (bottom). Changes for
individual animals are plotted with the mean for the group shown as a blue line. mPA, mean pulmonary artery,
P+D-Embo, proximal and distal embolization group; D-Embo, distal embolization group.
doi:10.1371/journal.pone.0124526.g003
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have evidence of chronic PH with increased vascular resistance and decreased compliance,
which was not observed in animals that underwent distal embolization alone.
The time course of the rise in mPA pressure and PVR index was also examined in both
models (Fig 4). In D-Embo pigs, the peak mPA pressure measured was 21 ± 4 mmHg and was
recorded at week 5, one week before the last embolization procedure; however, this increase in
Table 1. Cardiopulmonary hemodynamics.
Sham (n = 4) D-Embo (n = 6) P+D-Embo (n = 6) P (ANOVA)
Baseline 8 weeks Baseline 8 weeks Baseline 8 weeks
BW (kg) c, d, e 16±3 30±2 15±5 22±3 19±1 26±3 aP<0.05
HR (bpm) d, e 69±10 65±14 85±10 72±13 62±4 71±15 bP<0.05
Mean AoP (mmHg) 88±15 96±27 75±9 74±7 78±12 82±19 NS
PAOP (mmHg) 5±1 5±2 5±3 6±2 3±1 9±3 NS
mPAP (mmHg) d, e 17±5 14±1 13±4 16±2 14±3 23±4 aP<0.05
TPG (mmHg) 12±6 9±2 9±5 10±1 11±3 14±4 NS
RA pressure (mmHg) 3±1 2±1 3±1 4±2 2±1 2±2 NS
Cardiac index 3.5±1.0 4.4±0.4 4.1±1.3 4.3±0.8 3.7±0.4 3.7±0.6 NS
SV index e 50±8 70±9 48±15 60±9 60±6 52±6 aP<0.05
PVR index (WU*m2) 3.4±1.1 2.0±0.4 1.9±0.7 2.5±0.5 3.0±0.9 3.9±1.6 NS
Capacitance indexc, d, e 4.2±0.9 5.3±1.0 3.8±12 3.9±0.5 4.2±0.5 2.9±0.5 aP<0.05
BW, body weight; HR, heart rate; AoP, aortic pressure; PAOP, pulmonary artery occlusion pressure; mPAP, mean pulmonary artery pressure; TPG,
transpulmonary gradient; RA, right atrium; SV, stroke volume; PVR, pulmonary vascular resistance; WU, Wood units.
ap<0.05: ANOVA for baseline comparisons.
bp<0.05: ANOVA for 8-week follow-up comparisons.
cp<0.05 post-hoc comparison: Sham vs. D-Embo.
d p<0.05 post-hoc comparison: Sham vs. P+D-Embo.
ep<0.05 post-hoc comparison: D-Embo vs. P+D-Embo.
doi:10.1371/journal.pone.0124526.t001
Fig 4. Temporal changes in mPA pressure and PVR index. The change over time in mPA pressure (top) and PVR index (bottom) measured at each
embolization procedure and at the 8 week follow-up examination was evaluated in the P+D-Embo group (n = 6), D-Embo group (n = 6) and sham controls
(n = 4). mPA, mean pulmonary artery; PVR, pulmonary vascular resistance; P+D-Embo, proximal and distal embolization group; D-Embo, distal embolization
group. Data are reported as mean ± SD, *p<0.05 vs. sham, D-Embo by ANOVA.
doi:10.1371/journal.pone.0124526.g004
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pressure was normalized at the 8 week follow-up examination and was similar to pressures re-
corded in sham controls. In contrast, in P+D-Embo pigs, mPA pressures increased by week 2,
reached a maximum of 29 ± 8 mmHg (2.1-fold increase over baseline) by week 3, with some ev-
idence of recovery to 23 ± 4 mmHg mmHg by week 8 (1.6-fold increase over baseline). The
PVR index followed a similar temporal course with no difference observed between D-Embo
animals and sham controls compared to their respective baseline measurements. In P+D-Embo
pigs, the PVR index increased to 5.1 ± 1.1 WUm2 at week 3 and by week 8 remained increased
82% over baseline, similar to the temporal trend observed for mPA pressures. These hemody-
namic changes occurred without any observed differences between the groups with respect to
the cardiac index or mean aortic pressure, both of which were preserved over time.
Right ventricular dysfunction occurs in the proximal + distal embolization
model
Consistent with the finding of PH in P+D-Embo pigs, echocardiographic examination revealed
that there was also evidence of RV dysfunction (Table 2). Compared to shams and D-Embo
pigs, there was a significant decrease in RVEF in P+D-Embo (70.0 ± 2.7 vs. 68.8 ± 7.0 vs.
58.8 ± 3.7, p<0.005) and a significant increase in the myocardial performance index (0.4 ± 0.1
vs. 0.4 ± 0.1 vs. 0.5 ± 0.1, p<0.006). Other indices of RV dysfunction were more pronounced in
P+D-Embo compared to D-Embo animals, including abnormal longitudinal function as quan-
tified by TAPSE and tissue Doppler imaging-derived peak myocardial velocity.
There was also evidence of RV structural remodeling in P+D-Embo pigs. Compared to
shams and D-Embo animals, the RV end-systolic volume index and end-diastolic index was in-
creased significantly in P+D-Embo pigs. There was an increase in RV weight in P+D-Embo
pigs (1.14 ± 0.07 vs. 1.18 ± 0.09 vs. 1.42 ± 0.26 gm/kg, p<0.05) and RV/LV + septum weight
(0.40 ± 0.03 vs. 0.41 ± 0.02 vs. 0.47 ± 0.6 gm/kg, p<0.05) indicating that RV hypertrophic re-
modeling had occurred. To further characterize RV remodeling, myocardial interstitial fibrosis
and cardiomyocyte hypertrophy were examined. Compared to sham and D-Embo animals,
there was a significant increase in RV interstitial fibrosis in the P+D-Embo pigs (Fig 5). At a
cellular level, there was evidence of RV cardiomyocyte remodeling with an increase in cardio-
myocyte cross-sectional area observed only in in the P+D-Embo animals (Fig 5).
Table 2. Echocardiographic RV function and structural remodeling.
Sham (n = 4) D-Embo (n = 6) P+D-Embo (n = 6) P (ANOVA)
EDV index 101.7 ± 4.5 76.2 ± 14.1 104.4 ± 21.0 0.048
ESV index 30.5 ± 2.9 23.3 ± 4.1 43.3 ± 10.7a,b 0.006
RVEF (%) 70.0 ± 2.7 68.8 ± 7.0 58.8 ± 3.7a,b 0.005
MPI 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1a,b 0.006
TDI peak S (cm/s) 10.0 ± 0.9 8.6 ± 1.1 8.0 ± 1.0a 0.034
TAPSE (mm) 24.5 ± 2.4 21.6 ± 2.9 18.8 ± 2.4a 0.015
RV weight (g/kg) 1.14 ± 0.07 1.18 ± 0.09 1.42 ± 0.26 0.046
RV/(LV+septum) 0.40 ± 0.03 0.41 ± 0.02 0.47 ± 0.06 0.055
D-Embo, distal embolization model; P+D-Embo, proximal + distal embolization model; EDV, end-diastolic volume; ESV, end-systolic volume; RVEF, right
ventricular ejection fraction; MPI, myocardial performance index; TDI peak S, tissue Doppler imaging peak systolic myocardial velocity; TAPSE, tricuspid
annular plane systolic excursion; RV, right ventricle; LV, left ventricle.
ap<0.05 post-hoc comparison: Sham vs. P+D-Embo.
bp<0.05 post-hoc comparison: P+D-Embo vs. D-Embo.
doi:10.1371/journal.pone.0124526.t002
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Pulmonary vascular remodeling is present in the proximal + distal
embolization model
Macroscopic examination of the lungs of P+D-Embo pigs showed clusters of silk and fibrin oc-
cluding the majority of branches of the pulmonary arteries (Fig 6). In both embolization models,
Fig 5. Right ventricular fibrosis and hypertrophy.Myocardial fibrosis was examined in RV sections from the P+D-Embo group (n = 6), D-Embo group
(n = 6) and sham controls (n = 4) stained with Masson’s trichrome and quantified as % area fibrosis (top). Cardiomyocyte hypertrophy was evaluated by
staining RV sections with wheat germ agglutinin and co-staining with phalloidin to assess cardiomyocyte cross-sectional area (bottom). Representative
images are shown for each group. P+D-Embo, proximal and distal embolization group; D-Embo, distal embolization group; RV, right ventricular. *p<0.05 vs.
sham, D-Embo by ANOVA.
doi:10.1371/journal.pone.0124526.g005
Fig 6. The combination proximal coiling and distal embolization protocol results in occlusion of pulmonary arteries. Explanted segments from the
right inferior pulmonary artery showing silk coil and fibrin clusters obstructing the vessel lumen with dilation of the vessel. (left) Whole vessel segment
explant; (right) cross-section through vessel showing silk suture and fibrin clusters occluding the lumen.
doi:10.1371/journal.pone.0124526.g006
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dextran beads were present in the pulmonary artery lumen, which was narrowed significantly as
a result of intimal and medial hypertrophic vascular remodeling. There was also evidence of ex-
tensive perivascular collagen deposition in the embolization models as compared with the sham
controls. To determine the effect of proximal and distal embolization on distal pulmonary artery
remodeling, we examined medial thickness in non-occluded distal pulmonary arteries in the
lung periphery. This revealed that there was a significant increase in pulmonary arteriole medial
thickening in theP+D-Embo animals as compared to the D-Embo and sham pigs (Fig 7).
Discussion
Translation of scientific and therapeutic findings from PH studies using small animal models
into the clinic has been limited, in part, by the lack of accessible large animal models that
Fig 7. Pulmonary vascular remodeling. At 8 weeks, lungs were harvested, processed, and stained with Masson’s trichrome to examine pulmonary
vascular remodeling. Representative images from A) sham and B-D) embolization models with similar patterns of remodeling, including luminal
encroachment and hypertrophic intimal and medial remodeling, were observed for the D-Embo (B, D) and P+D-Embo pigs (C). In selected images (D),
microspheres are present in the vessel lumen. There is also extensive perivascular collagen deposition. The distal pulmonary arteries were examined in the
periphery of the lung in vessels that were not occluded by beads in sections stained with hematoxylin and eosin. Representative vessels from E) sham, F)
D-Embo, and G) P+D-Embo animals are shown. H) Vessel media thickness as an indicator of pulmonary artery remodeling was assessed. P+D-Embo,
proximal and distal embolization group; D-Embo, distal embolization group. Scale bars for A, B, C, and D are 60 μm, 100 μm, 60 μm, and 60 μm, respectively.
*p<0.05 vs. D-Embo, **p<0.01 vs. sham by ANOVA.
doi:10.1371/journal.pone.0124526.g007
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recapitulate the essential features of human disease. Investigators have attempted to create
large animal models of PH utilizing recurrent intravascular embolization to simulate pulmo-
nary arteriole obstruction with variable results. In many cases, PH did not develop, it occurred
acutely but recovered, or studies were not carried out long-term to know if the model was du-
rable over time. In the present study, we describe a novel swine model of chronic pulmonary
vascular diseasecreated using a proximal coiling procedure combined with distal embolization
(P+D-Embo). The key findings of the present study are: 1) a swine model of chronically elevat-
ed pulmonary artery pressures, RV dysfunction, and pulmonary vascular remodeling can be
created by the combined embolization procedure; 2) the P+D-Embo protocol adds multiple
lobar and segmental artery coiling to the standard D-Embo procedure and requires fewer
intrapulmonary artery injections than the distal embolization alone protocol; 3) hemodynamic
comparison between P+D-Embo and D-Embo animals reveals that the addition of proximal
vessel coiling is an essential element to induce PH; 4) the P+D-Embo model also develops RV
structural remodeling and RV dysfunction; and, 5) the procedure is safe with 0% mortality ob-
served over the 8-week follow-up period.
There have been other studies that utilized recurrent embolization techniques to create a PH
model in large animals (Table 3) [7,8,9,10,11,12,13,15,16]. These studies have a number of nota-
ble differences between them, including the embolic material (e.g., dextran beads, ceramic beads,
air), number of procedures required to create the model (e.g., continuous/daily, weekly, biweek-
ly), and the experimental conditions (e.g., mechanical ventilation, pO2, anesthesia) under which
the cardiopulmonary hemodynamics were assessed. The importance of these variables is demon-
strated by comparing our findings to those from a previous study that performed embolization
in pigs using similar doses of microsphere. Our study reported a small, albeit more sustained, in-
crease in mPA pressures and pulmonary hypertension than the other study[16], although pul-
monary vascular resistance was similar. Differences between these studies could be explained by
a different vascular response to the embolic injury in Yorkshire versus Large-White pigs that
were used in each study as well as the different anesthesia protocols and oxygenation conditions
at the time of hemodynamic evaluation, as shown in Table 3. The importance of oxygenation
conditions is also underscored by our observation that the mPA pressure was lower in anesthe-
tized animals ventilated with 40% FiO2 as compared to 21% FiO2. Another important variable is
the time interval between the last embolization procedure and the final assessment (ranging
from 1 hour to 6 months). This wide variability in experimental methodology is consistent with
the fact that not all embolization protocols developed PH. It has been suggested that the models
may have failed owing to pulmonary artery flow redistribution or the progressive recruitment or
distension of existing capillaries [17]. It has also been estimated that increases in resting PA pres-
sure don’t occur until>50% of the pulmonary circulation is obstructed [17]. Regarding the re-
quired amount of beads needed to cause significant levels of PH, Shelub et al [7] estimated that
the number of microspheres injected greatly exceeded the number of vessels of similar or smaller
diameter than the beads (~300 μm). They further speculated that: 1) flow would still occur de-
spite the impacted beads due to vessel dilatation in response to the acute occlusion, and that 2)
maldistribution of beads would spare a significant percentage of vessels that would eventually di-
late and contribute to restoring pulmonary blood flow. With respect to the second explanation,
we observed an acute increase in pulmonary pressures even at low doses of bead injection, sug-
gesting that acute vasoconstriction may occur and affect the even distribution of beads across the
pulmonary vasculature. Accordingly, a much higher dose or modification of the embolization
material may be required to create at least moderate elevations in pulmonary pressures. In our
study, we solved this issue by increasing the dose of dextran beads delivered (20 mg/kg) and pre-
diluting the beads in saline to increase bead swelling and, thereby, bead diameter to facilitate ob-
struction. When considering the effect of recurrent pulmonary artery embolization on mPA
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pressure and PVR index, the greatest observed relative change (> 2-fold vs. baseline or controls)
in these variables was achieved only in studies where hemodynamic assessments were made fol-
lowing a short ( 7 days) recovery period after the last embolization procedure. This finding ap-
pears to be independent of animal species, embolization material, or ventilation [8,9,15]. In the
current study, we added a proximal embolization procedure together with repeat distal emboliza-
tion to create the chronic PHmodel. The use of silk sutures for this purpose is advantageous
owing to its ready availability and low cost as compared to commercial coils. The coiling or prox-
imal embolization procedure was performed using silk suture material, which has been used pre-
viously to coil cerebral aneurysms[18]. When applied to the pulmonary arterial vasculature,
repeated silk suture deployment using angiographic guidance results in progressive occlusion of
the pulmonary artery branches. This, in turn, contributed to our finding of increased mPA pres-
sures and PVR one month after the last embolization procedure.
Other non-surgical approaches such as the administration of monocrotaline or hypobaric
hypoxia to create PH have been trialed in large animal models. In one study, monocrotaline
(12 mg/kg) elevated mPA pressures (34.0 ± 1.7 mmHg) after 6 weeks and echocardiographic
evaluation revealed a decreased pulmonary artery acceleration time and pulmonary artery
valve ejection time indicating PH and RV dysfunction, respectively. The model was, however,
incompletely characterized as PVR, systemic pressures, and other measures of RV function
were not reported. These pigs also had an increase in RV weight consistent with RV hypertro-
phy and pathological examination of the lungs revealed hypertrophic vascular remodeling
[19]. Although this model appears promising, it is susceptible to the same criticisms elicited
by the monocrotaline rat model. In particular, this model doesn’t form obstructive pulmo-
nary vascular lesions and PH has been attributed to sustained vasoconstriction [20,21,22].
Other investigators used chronic hypobaric hypoxia as a mechanism to induce PH; however,
this methodology is species specific as it was found to induce PH in calves but not in sheep.
Moreover, the inflammatory pulmonary vascular remodeling that occurs is reversible upon
exposure to normoxia [3].
In the present study, we conducted a comprehensive analysis of RV structural and func-
tional remodeling using advanced echocardiographic techniques. Using 3D-echocardiogra-
phy, we found that the P+D-Embo model of PH developed significant RV remodeling with an
increased RV end-systolic volume. Global RV performance (increased MPI) and longitudinal
function (TAPSE) were also impaired significantly in the P+D Embo model. In prior studies
using recurrent embolization models, RV function was not analyzed and reported systemati-
cally[23] (Table 3) despite the fact that it is a key contributor to the cardiopulmonary hemo-
dynamics observed in PH and has prognostic implications. Among the studies that reported
changes in relative RV mass as an indicator of RV hypertrophy, RV weight increased 18–42%,
with greater increases in weight associated with higher mortality and likely indicative of worse
RV function [7]. We also examined PA compliance as a measure of RV afterload and found
lower PA compliance (increased RV afterload) in the P+D-Embo model [24,25]. This is con-
sistent with the observation that pulmonary artery stiffness is an independent predictor of RV
failure and has been shown to add prognostic information to hemodynamic markers of in-
creased afterload such as PVR [24,25]. Moreover, histolopathological analysis of the pulmo-
nary vasculature demonstrated hypertrophic vascular remodeling and increased collagen
deposition, which likely contributes to the decrease in PA compliance and has been described
previously [16]. Regarding the degree of RV dysfunction in relation to relatively mild hemo-
dynamic chronic severity, our results indicate that decreased capacitance is an important con-
tributor to early impairment of RV function and the development of myocardial hypertrophy
and associated interstitial fibrosis,
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Limitations
There are several limitations associated with the findings of our study. Based on our initial goal
of examining cardiopulmonary hemodynamics within a sub-acute and longer-term time
frame, we examined these parameters 4 weeks after the final embolization procedure in the P+-
D-Embo model. It, therefore, remains unknown if the hemodynamic profile changes over a
longer follow-up time period. It is also unknown if additional embolization procedures would
have resulted in higher mPA pressures after 8 weeks although this is not likely based on the ob-
served trend in pre- and post-embolization mPA pressures. Furthermore, we demonstrated
that mPA pressures were actually higher in animals when ventilated with 21% FiO2 than with
40% FiO2 indicating that PH was present in our model although we did not measure mPA
pressures in D-Embo animals under these conditions. Another limitation common to all em-
bolization protocols is that the foreign material elicits an inflammatory response and possibly
an immune response that may contribute to the observed pulmonary vascular histopathology.
We also examined RV structure and function using advanced echocardiographic techniques
but did not examine pressure-volume relationships using PV loops, which would have provid-
ed additional information about RV function and performance.
Conclusions
In conclusion, we demonstrate a clinically relevant swine model of pulmonary vascular disease
that is created by the combination of a percutaneous proximal coil embolization procedure
with distal pulmonary vascular embolization. This requires fewer procedures than previously
reported embolization protocols and results in elevated mPA pressure, PVR, pulmonary vascu-
lar remodeling, and RV dysfunction at one month after the final procedure. Taken together
these findings indicate that the swine P+D-Embo model does recapitulate the cardiopulmonary
hemodynamic profile of human PH with RV structural and functional remodeling. Owing to
the relative ease with which this model is created as compared to surgical models, it is likely
that the combination embolization swine model of PH will serve as a valuable model for future
preclinical studies of PH.
Supporting Information
S1 Fig. The effect of oxygen on mPA pressures. To examine the effect of oxygen on mPA
pressures, the FiO2 was decreased from 40% to 21% for 10 minutes and mPA pressures were
remeasured in sham (n = 4) and P+D-Embo pigs (n = 6). P+D-Embo, proximal and distal em-
bolization group p<0.05 vs. sham, p<0.001 vs. sham.
(TIF)
S1 Video. Normal pulmonary artery angiogram.
(MOV)
S2 Video. Pulmonary artery angiogram immediately after embolization.
(MOV)
S3 Video. Pulmonary artery angiogram at the 8 week timepoint.
(MOV)
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Parte 2. Modelos de disfunción ventricular izquierda. 
Introducción a los artículos 3 y 4, y manuscrito 1. 
La disfunción ventricular izquierda es un componente esencial en la IC. A menudo, 
es la primera alteración fisiopatológica que inicia la progresión de la enfermedad. Los dos 
ejemplos paradigmáticos de disfunción ventricular izquierda en el ámbito clínico son la 
cardiopatía isquémica y la cardiopatía hipertensiva. En el caso de la cardiopatía isquémica, 
suele ser un daño miocárdico agudo debido a enfermedad coronaria lo que induce una 
lesión inicial (infarto agudo de miocardio), tras lo cual se inicia el proceso de remodelado 
ventricular. En cardiopatía hipertensiva, es la exposición prolongada a una poscarga 
anormalmente elevada lo que induce un remodelado lentamente progresivo que altera la 
fisiología cardiaca. 
En este apartado, la presente Tesis Doctoral ha contribuido con tres trabajos (dos 
publicados, y otro en fase de revisión) centrados en la caracterización de aspectos 
concretos de la cardiopatía isquémica y secundaria a sobrecarga de presión como modelos 
preclínicos. La aportación personal como doctorando en estos estudios se ha centrado tanto 
en la creación de estos modelos animales, tanto en los procedimientos percutáneos como 
quirúrgicos, y esencialmente en la adquisición de imagen y análisis de las mismas. He 
participado en el diseño de los estudios, así como en el análisis estadístico de los 
resultados y la discusión de los manuscritos.  
Las características de estos modelos, según los resultados de estos trabajos, se 
resumen en la Figura 3. 
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Figura 3 (Resumen Parte 2, Modelos de disfunción ventricular izquierda). Los 
modelos de causa isquémica dan lugar a marcadas alteraciones estructurales y funcionales 
que son bien identificables por técnicas de imagen. En los modelos de sobrecarga de 
presión, las alteraciones estructurales se producen de forma más progresiva, y los cambios 
funcionales son más leves. 
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Ishikawa K, Aguero J, Tilemann L, Ladage D, Hammoudi N,
Kawase Y, Santos-Gallego CG, Fish K, Levine RA, Hajjar RJ.
Characterizing preclinical models of ischemic heart failure: differ-
ences between LAD and LCx infarctions. Am J Physiol Heart Circ
Physiol 307: H1478–H1486, 2014. First published September 12,
2014; doi:10.1152/ajpheart.00797.2013.—Large animal studies are an
important step toward clinical translation of novel therapeutic ap-
proaches. We aimed to establish an ischemic heart failure (HF) model
with a larger myocardial infarction (MI) relative to previous studies,
and characterize the functional and structural features of this model.
An MI was induced by occluding the proximal left anterior descend-
ing artery (LAD; n  15) or the proximal left circumflex artery (LCx;
n  6) in Yorkshire pigs. Three pigs with sham procedures were also
included. All pigs underwent hemodynamic and echocardiographic
assessments before MI, at 1 mo, and 3 mo after MI. Analyses of left
ventricular (LV) myocardial mechanics by means of strains and
torsion were performed using speckle-tracking echocardiography and
compared between the groups. The proximal LAD MI approach
induced larger infarct sizes (14.2 3.2% vs. 10.6 1.9%, P 0.03),
depressed systolic function (LV ejection fraction; 39.8  7.5% vs.
54.1  4.6%, P  0.001), and more LV remodeling (end-systolic
volume index; 82  25 ml/m2 vs. 51  18 ml/m2, P  0.02, LAD vs.
LCx, respectively) compared with the LCx MI approach without
compromising the survival rate. At the papillary muscle level,
echocardiographic strain analysis revealed no differences in radial
and circumferential strain between LAD and LCx MIs. However,
in contrast with the LCx MI, the LAD MI resulted in significantly
decreased longitudinal strain. The proximal LAD MI model in-
duces more LV remodeling and depressed LV function relative to
the LCx MI model. Location of MI significantly impacts the
severity of HF, thus careful consideration is required when choos-
ing an MI model for preclinical HF studies.
anterior; posterior; remodeling; torsion; sphericity
THE STATISTICAL REPORT FROM the American Heart Association
revealed a decline in mortality attributable to cardiovascular
diseases by 30.6% in the last decade. However, one out of three
patients still die from cardiovascular diseases in the US and the
mortality in heart failure (HF) patients remains high (31).
Significant progresses in treatment devices as well as modern
pharmacotherapy have improved prognoses, while efforts on
greater improvements continue. Several novel treatments for
HF including gene therapy and cell therapy, and novel phar-
maceuticals show promising results in small animal experi-
mental studies. However, structural and physiological differ-
ences between human and small animals (27) continue to limit
their clinically relevant predictive value for translating to
humans. Hence, the need for large animal studies is still
required to validate the efficacy and safety of these novel
treatments in more clinically relevant models of HF.
There are several large animal models of HF using diverse
species. Pigs, dogs, and sheep are frequently used animals in
translational experimental studies of cardiovascular diseases
(18). Among them, the pig is most common due to similar
coronary anatomies to humans, lack of inherent coronary
collaterals, and ease of handling (14). HF can be induced by
ischemia (23, 34), rapid pacing (1), mitral valve regurgitation
(20), etc. Although all the models result in different phenotypes
representing different etiology, ischemic HF due to myocardial
infarction (MI) is the most widely accepted HF model (13, 18).
Not only does this approach recapitulate the most prevalent
etiology in human HF, but it also includes left ventricular
remodeling and neurohormonal activation, which are important
components of HF (6). Several studies have used the porcine
ischemic HF model to test various treatments with successful
results (8, 24, 29, 35, 37). However, most studies induce MI at
the mid-left anterior descending artery (LAD) or at the left
circumflex artery (LCx), which are usually not sufficient to
cause enough dysfunction that develops severe HF in clinical
situation. In patients with severe ischemic HF, who are the
candidates for the novel therapies, there usually exist a very
large MI or multiple moderate-sized MIs of different coronary
territories. Therefore, the ideal preclinical model should have
largest MI as possible to represent these populations. Our aims
were to establish a HF model with clinically relevant large MI
by occluding proximal LAD and to characterize the model by
comparing the structural and functional phenotype with that of
LCx MI in pigs. In addition to general left ventricular (LV)
function parameters, we used echocardiographic speckle-track-
ing strain analysis to evaluate the functional differences more
closely. Speckle-tracking derived strain and torsion have been
shown to provide additional mechanistic insights in evaluating
LV function (4, 32). Echocardiographic strain in coronary
artery disease improves detection of coronary ischemia, assess-
ment of myocardial viability, and prognosis prediction (11).
However, the role of strain and torsion in chronic HF after MI
is not fully established, and whether the MI location would
impact these parameters at chronic stages remains unknown.
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Accordingly, we investigated how these parameters are linked
to physiological and structural presentations in ischemic HF
after large anterior MI. Because we took advantage of large
animal models that have close physiological profiles to human,
our models enable the comparison of strain and torsion while
eliminating confounding factors such as comorbidities and
time from MI.
METHODS
Animal protocols. All animal protocols complied with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and standards of United States regulatory agencies. They
were approved by the Institutional Animal Care and Use Committee
of the Mount Sinai School of Medicine. Yorkshire pigs (18–22 kg)
were premedicated using intramuscular Telazol (8.0 mg/kg; Fort
Dodge, IA). After the placement of an intravenous line, animals were
intubated and ventilated with 100% oxygen. General anesthesia was
maintained with intravenous propofol (6–10 mg·kg1·h1) through-
out the procedure. Electrocardiograms and pulse oximeter measure-
ments were recorded at 5-min intervals. Continuous monitoring with
an intravenous saline infusion was maintained for a period of 30 min
to stabilize the hemodynamic status. Then, all animals underwent
echocardiographic assessment, followed by hemodynamic measure-
ment. Pigs received either proximal LAD MI (n  15, LAD group) or
proximal LCx MI (n  6, LCx group), and the cardiac performance
was evaluated at 1 and 3 mo after MI. Nine pigs with LAD MI overlap
with the pigs previously reported in another study (15). The sham-
operated group (Sham group) consisted of three animals that received
sham procedure without MI.
Pressure and volume measurements. The methods for pressure
measurement were previously described in detail (15). Briefly, per-
cutaneous punctures were performed to establish the vascular access
to the femoral artery and femoral vein. Heparin (100 IU/kg iv) was
then administered to maintain an activated coagulation time of 250–
300 s. Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA) was
proceeded to the main pulmonary artery, and pressure measurements
were collected. Approximately 0.25 BW(kg) ml of cold saline were
injected into the inferior vena cava to obtain cardiac output by the
thermodilution method. Next, through the femoral arterial sheath, a
Millar catheter (Millar Instruments, Houston, TX) was advanced to
the LV to obtain hemodynamic parameters. All measurements were
performed after the confirmation of hemodynamic stability for 3 min.
An MPVS Ultra System (Millar Instruments) was used to acquire
analog signal and convert it to digital data. Data analyses were
performed using an iox2 application (EmkaTechnologies, Falls
Church, VA).
MI creation. After cardiac performance evaluation was completed,
a bolus of atropine (0.05 mg/kg) and amiodarone (1–3 mg/kg) were
given intravenously or intramuscularly. A 1,000-ml saline solution
mixed with atropine (0.1 mg/kg), amiodarone (3 mg/kg), and potas-
sium acetate (20 meq) was continuously infused at the rate of 300
ml/h for the duration of the procedure. A 5-Fr hockey-stick catheter
(Cordis, Miami, FL) was advanced to the right coronary artery, and
the coronary angiography was performed. The catheter was then
exchanged for a 7-Fr hockey-stick catheter (Cordis) and advanced to
the left coronary artery. After the coronary angiogram, a 0.014-inch
guide wire (Abbott, Park, IL) was advanced into either the LAD or
LCx, depending on the animal group. An 8-mm-long, 4.0-mm
VOYAGER over-the-wire balloon (Abbott) was advanced to the prox-
imal part of the coronary artery. The balloon was then inflated to 3 to 4
atm for 90–120 min followed by reperfusion (Fig. 1). In two LCx MI
pigs, an embolic coil was implanted at the balloon occlusion site after
60 min of coronary occlusion. At the end of the study, these pigs
showed similar hemodynamic profiles to the pigs that received 90 min
occlusion/reperfusion of the LCx, thus grouped together as the LCx
MI group. In case of malignant arrhythmia, direct current shock was
applied immediately with continuous chest compression. After con-
firmation of hemodynamic stability, animals were allowed to recover.
Intramuscular injections of nitroglycerine and furosemide were ad-
ministered. Intravenous saline with amiodarone, atropine, and potas-
sium acetate infusion is decreased to 50 ml/h and was given overnight.
The animals were housed in their cages and examined daily for any
signs of pain or distress. The visual guidance of the procedure is
available in Ishikawa et al (17).
Echocardiographic analysis. Comprehensive trans-thoracic echo-
cardiographic studies including Doppler, two-dimensional (2-D), and
three-dimensional (3-D) echocardiography were performed at base-
line (before MI), 1 mo, and 3 mo. A Philips iE-33 ultrasound system
(Philips Medical Systems, Andover, MA) was used to acquire echo-
cardiographic data with a multi-frequency imaging transducer (S5
probe for 2-D images or X3 probe for 3-D images). A subxiphoid
approach provided an apical four-chamber view as well as 3-D images
of the LV. With the use of the parasternal approach, cross-sectional
images of the LV short axis were obtained at the levels of the base,
papillary muscle, and apex with a high frame rate (60–100 Hz). The
2-D images were loaded into the Q-lab application (version 7.0;
Philips Medical Systems) for strain analysis using a speckle-tracking
algorithm. LV volumes and ejection fraction (EF) were obtained from
3-D images. Body surface area (in m2) was calculated as previously
described (21), and volume parameters were divided by the body
surface area to calculate volume indexes. Longitudinal strain (LS) was
obtained from apical four-chamber views. Short axis images from the
papillary muscle level were used for the circumferential and radial
strain (CS and RS, respectively) analyses. The LV short axis was
divided into six segments and categorized into three zones as previ-
ously described: ischemic, border, and remote areas. A good inter- and
intra-observer agreement has been previously reported with this
method (16) and Cronbach’s  for inter- and intra-observer variation
in the present study were 0.93 and 0.98 for CS, 0.69 and 0.99 for RS,
0.94 and 0.96 for LS, and 0.76 and 0.88 for torsion, respectively. LV
short-axis planes of basal and apical levels provided rotation curves
Fig. 1. Representative images of balloon occlusion site. Balloon is inflated at
the proximal left anterior descending artery (LAD). Images at top show before
the occlusion, and images at bottom show during the occlusion. Arrows
indicate the position of the balloon. LCx, left circumflex artery.
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for each level. LV twist was calculated as the instantaneous net
difference in rotation between the apical and basal levels, and the peak
value was obtained. LV sphericity index was calculated at end diastole
using 3-D images as previously reported (22). Left atrium size was
measured as a diameter from right superior pulmonary vein to the root
of left appendage.
Survival. To investigate the survival rate of the pigs that underwent
our MI creation protocol, accumulated data of 100 LAD MI and 9
LCx MI pigs in our database were reviewed. Because many of our
pigs received some kind of treatment, which may affect the cardiac
function after 1 mo, the survival curves were limited to 28 days.
Postmortem histology. Hearts were explanted, weighed, and sec-
tioned into six slices. Heart slices were immersed in triphenyl tetra-
zolium chloride to demarcate the infarct area. Adobe Photoshop CS2
(Adobe Systems, San Jose, CA) was used to quantify the infarction
size by digital planimetry.
Coronary dominance and diagonal branch disparity. Coronary
angiograms of pigs included in survival study were reviewed. Seven
pigs were excluded due to ambiguous image of the angiogram. The
dominance was defined as previously described (3). In right domi-
nance, both the posterior descending artery and 1 posterolateral
branches originated from the right coronary artery; in left dominance,
posterior descending artery and all posterolateral branches originated
from LCx. Balanced, posterior descending artery originated from the
right coronary artery, but all posterolateral branches originated from
the LCx. To check the diagonal branch disparity, the numbers of large
diagonal branch were counted. They were considered large when they
had branching or circulated a significant area. When the branch was
significantly larger than other branches, it was counted as a major
diagonal branch.
Statistical analysis. Data are expressed as means  SD. The
Kaplan-Meier method with a log rank test was used to analyze the
survival curves. The unpaired t-test was used to compare the differ-
ences between two groups. For group comparisons, 1-way ANOVA
was performed. Levene’s test was used to determine whether ANOVA
was appropriate. Welch’s ANOVA was applied where heterogeneity
of variance was indicated. Post hoc analysis was performed using
either the Tukey test or the Games-Howell test, depending on the
heterogeneity. All P values 0.05 were considered statistically sig-
nificant. Relation between strain and torsion to functional and struc-
tural parameters was assessed by Pearson or Spearman correlation as
appropriate. Inter- and intra-observer variability was assessed in seven
randomly chosen animals from the MI pigs and all three pigs from the
sham-operated group.
RESULTS
A total of 24 pigs were included in the study (LAD, n  15;
LCx, n  6; Sham, n  3). One pig from the LCx MI group
died at day 80 without undergoing 3 mo follow up. Postmortem
studies indicated no signs of HF, thus malignant arrhythmia
was suspected as a cause of death. LVEF decreased signifi-
cantly 1 mo after MI in both groups, and the dysfunction
persisted to the 3-mo time point. There were significant differ-
ences in LVEF between LAD and LCx MI at 1 mo and 3 mo
(Fig. 2). In contrast, peak LV pressure rate of rise (dP/dtmax)
decreased only in LAD group, whereas LCx and Sham groups
had similar values during the study period (Fig. 2). ANOVA
revealed that there was a statistical difference only between the
Sham and LAD groups at 3 mo; however, direct comparison of
LAD versus LCx in MI revealed significantly higher dP/dtmax
in LCx group both at 1 mo (LCx, 2,204  619 vs. LAD, 1,642 
245; P  0.007) and at 3 mo (LCx, 2,142  84 vs. LAD,
1,752  309; P  0.02). Volume indexes showed larger LV
sizes in LAD MI pigs with a statistical difference relative to
both LCx and Sham group in end-systolic volume index (Fig.
2). Temporal changes of other related parameters are shown in
Table 1, indicating decreased systolic function and greater
heart remodeling in the LAD group. Interestingly, diastolic
function parameters were similarly impaired in the LAD and
LCx groups, although statistical significance was only reached
when comparing the LAD and Sham groups. Of note, LV
end-diastolic pressure was significantly higher in LAD MI
Fig. 2. Temporal changes of systolic param-
eters and volume indexes. LAD myocardial
infarction (MI) had significantly lower ejec-
tion fraction and larger end-systolic volume
index (ESVI) than both LCx MI and Sham at
1 and 3 mo after the MI. LAD MI showed
decreased peak LV pressure rate of rise (dP/
dtmax) after MI; however, LCx MI took sim-
ilar course to the Sham without significant
decrement. Ejection fraction and volume in-
dexes were assessed by 3-dimensional echo-
cardiography. *P  0.05 against Sham;
†P  0.01 against Sham; ¶P  0.05 against
LCx MI; ‡P  0.01 against LCx MI. EDVI,
end-diastolic volume index.
H1480 CHARACTERIZING LARGE ANIMAL MODEL OF MI
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00797.2013 • www.ajpheart.org
 by 10.220.32.246 on February 14, 2017
http://ajpheart.physiology.org/
D
ow
nloaded from
 
57
group than LCx MI group both at 1 mo and 3 mo time point,
indicating severe HF condition.
Scar size. Representative images of LV at 3 mo are shown in
Fig. 3. Although LAD MI involved apex in all the pigs, LCx
MI tended to have larger scar at the base and lesser extent
toward the apex. Scar size was larger in LAD pigs compared
with LCx (14.2  3.2% vs. 10.6  1.9%, P  0.03); however,
LV weight was not different between the groups (Fig. 4).
Mitral valve regurgitation. Eight pigs in the LAD MI group
(53%) and three pigs in the LCx MI group (60%) developed a
Seller’s grade of 1 to 2 mitral valve regurgitation, whereas
none of the pigs presented with more than a grade 3 mitral
valve regurgitation at 3 mo.
Survival. Four pigs were excluded from the survival analysis
because they reached humane endpoints and were euthanized
due to prolonged lameness (n  2) and deaths from intubation
problems (n  2). Out of 96 recent pigs, the survival rate of
LAD MI at 1 mo was 81% and that of LCx was 88% (P 
0.62) (Fig. 5). Whereas most of the nonsurviving pigs died
during or within 48 h post-MI creation, there were three deaths
in LAD MI group after that period. All three of them had
significant amount of pleural effusion, suggesting the involve-
ment of HF for the cause of the deaths.
LV strain, torsion, and sphericity. Both RS and CS of
ischemic area were significantly lower than those of remote
area in MI pigs. RS and CS in the remote area in MI groups
were lower compared with the average of all areas of Sham.
Similarly, global RS and global CS at the papillary muscle
level were reduced in MI pigs. However, there were no
significant differences in RS or CS between LAD and LCx
(Fig. 6). In contrast, LS was significantly lower in the LAD
group compared with the LCx group, while both showed lower
values compared with the Sham group (Fig. 6). LV torsion was
significantly lower than that of the Sham group, but there was
no difference found between LAD and LCx groups. Table 2
shows the relationship of strain and torsion to functional and
structural parameters in MI pigs. Whereas RS and CS did not show
any significant correlation to these parameters, torsion showed
modest correlation to EF, dP/dtmax, end-systolic volume, and
scar size. Moreover, LS showed stronger correlation to these
important parameters of physiological and morphological in-
dexes. Pigs with LCx MI had highest LV sphericity index
among the groups with significant difference to the Sham
group (Fig. 6).
Coronary dominance and diagonal branch disparity. Al-
though majority of pigs showed balanced coronary circulation
between the left coronary artery and the right coronary artery,
there were10% each of pigs with either left or right coronary
dominance. The dominance was mainly determined by the
different balance between the LCx and the right coronary
artery. Although the total of the LAD main and side branches
circulate similar size of the anterior area, the size and numbers
of diagonal branches showed modest variability. Out of 102
pigs with a good quality coronary angiogram, 22% had only
one large diagonal branch, whereas 44% had two large
branches and 34% had more than three large branches (see
METHODS for the definition of large branch). First diagonal
branch was the major branch in 27% of the pigs, which can
lead to smaller infarct size when the distal of first diagonal
branch was occluded during MI induction.
DISCUSSION
In this study, we have established the successful creation of
preclinical HF models with large anterior MIs while maintain-
ing reasonable mortality for at least 3 mo. Additionally, we
found that the proximal LAD MI resulted in more severely
impaired LV function, larger infarct size, and more remodeled
LV compared with LCx MI, but with similar mortality. Fur-
thermore, we compared, for the first time, the myocardial strain
and torsion between LAD and LCx MI in chronic stages after
MI. Although RS, CS, and torsion did not differ between the
different MI groups, LS was significantly lower in LAD MI
pigs.
Emerging novel therapies, newly discovered drugs, and
evolving technologies are offering promising options for treat-
ing patients with severe HF. To validate the efficacy and safety
of each treatment, careful evaluation is necessary before it can
be translated to the clinic. Large animal preclinical studies in
addition to small animal studies are essential because of sim-
Table 1. Temporal changes of cardiac parameters after myocardial infarction
Baseline 1 mo 3 mo
LAD LCx Sham LAD LCx Sham LAD LCx Sham
n 15 6 3 15 6 3 15 5 3
Body weight, kg 19.3  1.5 19.5  1.5 18.7  1.2 24.6  1.3 24.2  1.8 24.3  2.5 38.0  3.2 40.6  2.8* 34.3  2.1
Echocardiography
Three-dimensional, ml
EDV 36.4  3.5 39.0  4.4 38.7  1.5 78.3  17.1* 64.9  17.6 42.8  3.0 107.1  22.9* 91.0  22.8 51.2  1.5
ESV 10.1  2.0 12.5  3.4 9.9  1.4 48.8  15.1*¶ 31.6  11.3 11.2  0.4 65.6  20.0* 42.6  15.7 11.6  1.4
SV 26.2  2.3 26.5  1.4 28.8  1.3 29.5  4.0 33.3  6.5 31.6  2.7 41.5  6.7¶ 50.4  8.6* 39.6  2.6
E/A 1.27  0.24 1.31  0.16 1.29  0.24 1.16  0.27 1.28  0.86 1.37  0.17 1.03  0.25 1.19  0.40 1.34  0.35
Left atrium, mm 33  5 35  7 35  5 38  4 39  7 36  2 44  3* 44  8 38  1
Invasive hemodynamics
LVPmax, mmHg 109  18 102  14 100  8 115  12 110  5 111  13 122  9 122  18 129  27
End-diastolic pressure,
mmHg
14.4  4.3 11.8  1.5 11.1  0.6 25.9  9.5*¶ 15.8  4.5 15.9  3.3 19.2  6.3¶ 10.9  3.8 16.3  3.5
CI, l/m2 min 4.0  1.4 3.1  0.9 2.9  1.0 3.7  0.7 4.1  0.5 4.0  0.8 3.7  0.7 4.0  1.0 3.8  0.9
HR, beats/min 78  22 75  19 51  16 69  13 77  23 62  3 73  12 77  12 64  9
dP/dtmin, mmHg/s 1,715  614 1,491  456 1,313  89 1,417  367* 1,508  371 2,078  223 1,891  393* 2,018  431 2,842  769
	, ms 46.4  21.7 50.0  24.5 47.4  14.1 45.6  19.4 41.3  12.3 29.6  1.2 38.8  9.7* 36.7  3.9 25.4  3.5
Values are means  SD. LAD, left anterior descending artery; LCx, left circumflex artery; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke
volume; E/A, mitral valve early and late ventricular filling velocity ratio; LVPmax, maximum left ventricular pressure; CI, cardiac index measured by Swan-Ganz;
HR, heart rate; dP/dtmin, minimum peak LV pressure rate of decay. *P  0.05 against sham; ¶P  0.05 against LCx.
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ilarities in metabolic rates, anatomy, size, and cardiac func-
tional properties to humans (27). Ideally, the large animal HF
models should have significant cardiac dysfunction reflecting
the clinical candidates for the novel therapies. However, if the
myocardial injury is too severe, the mortality becomes too
high. Current ischemic HF models often balance survival rate
and cardiac dysfunction; thus the infarct size is somewhat
compromised. In most previous studies, the location of coro-
nary occlusion took place at the mid-LAD or LCx. Our prox-
imal LAD MI model results in larger anterior MIs, which
mimic the clinical ischemic HF phenotype while maintaining
the similar mortality in previous studies (19, 33, 35). It is clear
that proximal LAD occlusion induces larger infarct sizes than
mid-LAD occlusion, since the first diagonal branch is involved.
Although proximal LCx was occluded in our study, most of the
parameters indicated a less severe MI relative to the LAD MI
model. Moreover, dP/dtmax of the LCx MI group was not
significantly different than the Sham group. Furthermore, LV
volumes were more increased in LAD MI group, indicating
more severe post-MI LV remodeling than in the LCx MI
group. It has been shown that infarct expansion occurs pre-
dominantly in MI associated with the LAD (28). Therefore, the
remodeling process is more intensified after LAD MI and thus
recapitulates important characteristic of clinical HF develop-
ment. In accordance with the model of ischemic HF, interstitial
fibrosis of the remote myocardium was also observed in our
models (data not shown). The model with a larger MI may also
have an advantage in evaluating therapeutic efficacy. In fact,
Fig. 3. Representative images of the infarct in LAD and LCx MI. Although the
scar in LAD MI involves apex, the scar of LCx MI was shifted toward base
with less apical involvement to the left anterior.
Fig. 4. Scar size and the ventricular weight adjusted
by the body weight (BW). Size of the scar was
significantly larger in LAD MI than in LCx MI. In
LAD MI, despite the initial infarct area of 35–40%
assessed by MRI, infarct size becomes to around
15% at 3 mo because of scar thinning and hypertro-
phy of nonischemic remote area. Ventricular weight
increased in MI pigs without statistical difference
between the MI groups. NS, not significant.
Fig. 5. Survival curves of each group. Similar survival rate up to 1 mo was seen
in LAD (n  96) and LCx MI (n  9). Note that there are a few deaths after
48 h due to heart failure in LAD group.
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meta-analysis of stem cell therapy in preclinical studies re-
vealed that the LAD-related infarction, when compared with
the LCx infarction, benefits more from the treatment (37). This
is presumably attributed to the larger infarct size, lower cardiac
function, and increased cardiac remodeling (37).
There are several important characteristics of our protocol
required to achieve severe dysfunction without raising the
mortality. First, we use propofol as anesthetic agent instead of
isoflurane. Although isoflurane is an easily administered inhal-
ant anesthetic, it is cardio-protective and a vasodilator (36).
Because it acts similar to 
-blockers, isoflurane anesthesia may
result in smaller infarct sizes. Maintaining blood pressure over
80 mmHg during the coronary occlusion enhances recovery
from malignant arrhythmia. Propofol is also beneficial in
maintaining higher blood pressures, because the blood lower-
ing effect is much lower than in cases where isoflurane is used
(2). When the blood pressure falls below 80 mmHg, fluid load
and/or atropine should be administered to maintain the pres-
sure. In cases of malignant arrhythmia, continuous chest com-
pression and immediate cardioversion are critical to pig sur-
Fig. 6. Left ventricular (LV) strain, torsion, and sphericity by 2-dimensional echocardiography 3 mo after MI. The LV short axis was divided into 6 segments
and categorized into 3 zones: ischemic, border, and remote areas. Radial strain (RS) and circumferential strain (CS) were analyzed at the papillary muscle level.
Both MI groups presented impaired RS and CS at the remote area, as well as global RS and CS compared with Sham. Sham values are average of all the segments.
LAD MI presented significantly lower longitudinal strain (LS) than LCx MI. LV torsion was significantly less in MI groups than in Sham; however, no difference
was found between LAD and LCx MI. LV sphericity index was higher in MI pigs than in Sham.
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vival during this acute phase. Finally, continuous administra-
tion of amiodarone and maintaining the potassium level reduce
arrhythmic deaths during the peri-MI period.
Although ischemic MI models are the most frequently used,
the differences in LAD MI and LCx MI have not been well
documented. The present study investigated the differences in
various parameters including systolic and diastolic function
and volumetric parameters between different branch MIs. Our
results indicate that the LAD MI model induces more LV
remodeling and has decreased systolic function relative to the
LCx MI model. The infarction area of the LAD MI model was
shifted to the apical region, whereas the LCx MI model had
basal dominancy. Similar findings were documented in patients
with MI when the scar was analyzed with magnetic resonance
imaging (5). Although LV rotation is most prominent at the
apical LV (26), there was no difference between LAD and LCx
MI models in our study. This suggests that mid-ventricular
myocardial fibers play important role on generating LV twist
mechanics. Notwithstanding, torsion yet showed modest cor-
relation to functional and structural indexes, suggesting the
important role in cardiac contraction. Despite the functional
differences, myocardial strain analyses revealed no differences
in RS and CS at the papillary muscle level between the
different MI groups. Meanwhile, LS was significantly lower in
the LAD MI group. Hoit et al. investigated the different impact
of LAD and LCx ischemia on remote areas in the acute setting
and demonstrated that compensatory increases of ejection
phase shortening were only present after LCx ischemia (12).
However, similar RS and CS in the remote area in our study
suggests that this was not the case in chronic phase of MI. Our
results indicate diminished longitudinal contraction together
with larger infarct size is responsible for the lower cardiac
function in LAD MI. Correlation of strain to various functional
and structural parameters indicated that LS reflects important
features of HF the most, suggesting the usefulness of LS in
evaluating chronic ischemic HF. Utility of LS to estimate scar
size has been demonstrated in patients with chronic LV dys-
function (30), and our data are consistent with this finding.
Despite less remodeling with preserved systolic function in
LCx MI compared with LAD MI, sphericity index was higher
in LCx MI. Although spherical shape is an important feature of
LV remodeling in heart failure (9) and sphericity index is
applied as a parameter to assess LV remodeling (7), our data
suggest that the location of MI influences this index after MI.
In sheep, Llaneras et al. reported that the ligation of the
second and third LCx obtuse marginal branches resulted in a
reproducible mitral valve regurgitation over the 8 wk follow up
(25). Because mitral valve regurgitation is an important deter-
minant of HF progression in patients after MI, we investigated
the prevalence of this phenomenon in our models. However,
proximal occlusion of the LCx was unable to induce significant
mitral valve regurgitation in our pigs. We therefore conducted
a preliminary study to determine whether we can induce
ischemic mitral valve regurgitation in pigs. Concurrent occlu-
sion of the LCx and the diagonal branch successfully resulted
in reproducible mitral valve regurgitation in 3 pigs (supple-
mentary video). Notwithstanding, all three pigs developed such
severe HF that none of the pigs were able to undergo hemo-
dynamic evaluation at 3 mo after the MI induction. This model
may be useful for testing surgical or device therapy targeting
mitral valve insufficiency at the sub-acute stage of MI; how-
ever, more extensive investigation would be required to estab-
lish this model.
We observed more variability in the circulatory area of the
LCx compared with the LAD in our pigs. The main LAD
branch presented similar length, and the variability of the LAD
mostly depended on the sizes of the diagonal branches. How-
ever, the overall circulatory areas of diagonal branches were
relatively similar when taken together. In contrast, the LCx
shared the posterior wall with the right coronary artery to the
different degree. Although all the LCx MI pigs in our study had
balanced coronary arteries, 20% of the pigs have either right
coronary artery or LCx dominance. This is a major disadvan-
tage to the LCx MI model, since there is already 10–30%
inter-animal variability in various parameters even with similar
coronary circulation area. This also applies to the LAD MI
model when the distal of first diagonal branch is occluded
because the inter-individual size variability is high. By creating
an MI using the proximal LAD occlusion approach, we can
diminish the impact of differences in diagonal branch disparity.
In summary, our results suggest that proximal LAD MI model
is more suited to study chronic HF experiments considering
that it has larger infarct size, worse LV function, more LV
remodeling, and less variability compared with those of the
LCx MI model. It is important to note that LCx MI model is
still useful for many of the studies that are not targeting
advanced HF such as prevention of ischemic-reperfusion injury
studies (10).
Limitation
The major limitation in the present study is a small sample
size, especially in the LCx MI and sham-operated groups.
Although our study might be underpowered to detect small
differences between the groups, we found significant differ-
ences in LVEF, end-systolic volume, and scar size between
LAD and LCx MI pigs. Observing differences in these impor-
tant parameters clearly indicate that LAD MI has more severe
HF compared with LCx MI. Therefore, we believe our primary
motivation of establishing a porcine ischemic HF model with
clinically relevant large MI was achieved. Although LAD
proximal occlusion can minimize the effect of diagonal branch
Table 2. Correlation of strain and torsion to functional and structural parameters at 3 mo after myocardial infarction
Ejection Fraction EDV ESV SV LVPmax dP/dtmax HR CI Scar Size
Longitudinal strain 0.77** 0.42 0.61** 0.45 0.07 0.54* 0.26 0.66** 0.81**
Global circumferential strain 0.07 0.17 0.17 0.25 0.21 0.31 0.24 0.34 0.17
Global radial strain 0.30 0.27 0.34 0.04 0.2 0.13 0.03 0.41 0.42
Torsion 0.54* 0.37 0.45* 0.18 0.07 0.46* 0.04 0.37 0.52*
Values indicate Pearson or Spearman’s correlation coefficient, depending on the distribution. Sham-operated animals are not included. dP/dtmax, peak LV
pressure rate of rise. *P  0.05; **P  0.01.
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disparity, there still remains a significant degree of inter-animal
variability after MI induction. Uniform dysfunction may be
ideal for the preclinical data interpretation; however, the inter-
individual variability can be often found in clinical situations
as well. Therefore, we believe it reflects the clinical population,
and when conducting a translational study, we suggest a
comparison of parameters before and after the treatment rather
than comparing groups only after treatments. We did not
include a distal LAD occlusion model in the present study, and
this model may result in similar characteristics to LCx MI.
However, because LCx MI was also induced by occlusion of
the proximal LCx, we believe comparing proximal LAD MI
with proximal LCx MI model is more appropriate.
Conclusion
Occluding the proximal LAD in pigs induces larger infarct
size, depressed systolic function, and more extensive cardiac
remodeling than the LCx MI model. Location of MI signifi-
cantly impacts the severity of HF; thus careful consideration is
required when choosing an MI model for preclinical HF
studies. LAD MI model reflects important features of clinical
HF more and thus may be suited for preclinical studies involv-
ing HF. Greater impaired LS after LAD MI is one of the key
mechanisms for the decreased systolic function over the LCx
MI model.
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Increased Stiffness Is the Major Early Abnormality in a Pig Model of
Severe Aortic Stenosis and Predisposes to Congestive Heart Failure
in the Absence of Systolic Dysfunction
Kiyotake Ishikawa, MD; Jaume Aguero, MD; Jae Gyun Oh, PhD; Nadjib Hammoudi, MD; Lauren A. Fish; Lauren Leonardson, LVT;
Belen Picatoste, PhD; Carlos G. Santos-Gallego, MD; Kenneth M. Fish, PhD; Roger J. Hajjar, MD
Background-—It remains unclear whether abnormal systolic function and relaxation are essential for developing heart failure in
pathophysiology of severe aortic stenosis.
Methods and Results-—Yorkshire pigs underwent surgical banding of the ascending aorta. The animals were followed for up to
5 months after surgery, and cardiac function was assessed comprehensively by invasive pressure–volume measurements,
3-dimensional echocardiography, echocardiographic speckle-tracking strain, and postmortem molecular and histological analyses.
Pigs with aortic banding (n=6) exhibited signiﬁcant left ventricular hypertrophy with increased stiffness compared with the control
pigs (n=7) (end-diastolic pressure–volume relationship b: 0.0530.017 versus 0.0280.009 mm Hg/mL, P=0.007); however, all
other parameters corresponding to systolic function, including ejection fraction, end-systolic pressure–volume relationship, preload
recruitable stroke work, echocardiographic circumferential strain, and longitudinal strain, were not impaired in pigs with aortic
banding. Relaxation parameters were also similar between groups. Sarcoplasmic reticulum calcium (Ca2+) ATPase protein levels in
the left ventricle were similar. There were signiﬁcant increases in 3-dimensional echocardiographic left atrial volumes, suggesting
the usefulness of these indexes to detect increased stiffness. Right atrial pacing with a heart rate of 120 beats per minute induced
increased end-diastolic pressure in pigs with aortic banding in contrast to decreased end-diastolic pressure in the control pigs.
Histological evaluation revealed that increased stiffness was accompanied by cardiomyocyte hypertrophy and increased perimysial
and perivascular ﬁbrosis.
Conclusion-—Increased stiffness is the major early pathological process that predisposes to congestive heart failure without
abnormalities in systolic function and relaxation in a clinically relevant animal model of aortic stenosis. ( J Am Heart Assoc.
2015;4:e001925 doi: 10.1161/JAHA.115.001925)
Key Words: diastolic dysfunction • ﬁbrosis • hypertrophy • stiffness • systolic dysfunction
T ranscatheter aortic valve implantation has emerged as analternative therapeutic approach for patients with aortic
stenosis. Implementation of this approach in clinical practice
has expanded the population of candidates for aortic valve
replacement, including patients with severe aortic stenosis
who are considered high risk or ineligible for conventional
surgical aortic valve replacement. These patients are often
elderly with limited daily physical activity, and patients remain
asymptomatic despite vulnerability to developing heart failure
(HF); therefore, identifying the patient population with masked
HF symptoms has become of increasing importance. To this
end, it is essential to understand the underlying pathophys-
iology of HF development in severe aortic stenosis.
Newer techniques such as echocardiographic strain or
magnetic resonance strain imaging allow for more detailed
assessments of myocardial function than traditional modali-
ties. Several studies have suggested the association of
subnormal systolic function with HF in patients with severe
aortic stenosis.1–5 Meanwhile, others have reported impaired
relaxation as a major contributor to HF development in aortic
stenosis.6,7 These changes, however, can be the result of
disease progression and not the cause of HF. Consequently, it
is not clear whether these abnormalities in systolic function
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and relaxation are essential for HF development. We hypoth-
esized that increased left ventricular (LV) stiffness is the
major early abnormality in patients with severe aortic stenosis
and that it predisposes these patients to congestive HF in the
absence of systolic dysfunction or impaired relaxation. A large
animal model that mimics human aortic stenosis was
developed to test this hypothesis with comprehensive func-
tional and histological assessments.
Methods
Animal Protocols
All animal protocols complied with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and
standards of US regulatory agencies. Protocols were approved
by the institutional animal care and use committee of the Icahn
School of Medicine at Mount Sinai. A total of 14 female
Yorkshire pigs (Animal Biotech Industries (Danboro, PA)) were
included in the study. Seven pigs received aortic banding (AoB)
and were compared with control animals composed of 3 sham-
operated animals and 4 na€ıve pigs of similar age at the ﬁnal time
point. Sham-surgery animals were included to provide an
overview of changes in various parameters due to animal
growth. The long-term animals underwent echocardiographic
and hemodynamic assessments at 2 months after surgery,
followed by ﬁnal assessments at 3 to 5 months after surgery
(Figure 1).
Yorkshire pigs were premedicated using intramuscular
Telazol (8.0 mg/kg; Fort Dodge). After the placement of an
intravenous line, animals were intubated and ventilated with
40% oxygen. General anesthesia was maintained with intra-
venous propofol (8 to 10 mg/kg per hour) throughout the
procedure except for surgeries in which isoﬂurane (2% to 3%)
was used. Intravenous saline infusion (body weight910 mL)
was maintained for a period of 30 minutes under continuous
monitoring to correct dehydration from overnight fasting. All
animals then underwent echocardiographic assessment, fol-
lowed by an AoB surgery at day 0 and hemodynamic
measurements for other time points.
Aortic Banding
After an echocardiographic evaluation, pigs (10 to 13 kg)
were positioned in the right lateral decubitus position, and left
thoracotomy was performed in the third intercostal space. A
3-cm opening was created in the pericardium, and the
ascending aorta proximal to the brachiocephalic artery was
gently isolated. A 1-cm-thick customized rubber band with a
ﬁxed inner radius of 12 mm (approximate inner area of
4.5 cm2) was placed around the aorta and ﬁxed with umbilical
tape. The chest was closed, air was evacuated, and animals
recovered. Sham animals received pericardial opening without
AoB.
Pressure and Volume Measurements
The methods for pressure measurement were previously
described in detail.8 Brieﬂy, percutaneous punctures were
performed to establish vascular access to the femoral artery
Figure 1. Study design and the number of animals. Two groups of animals were included in the study.
Control group consists of 3 sham-surgery animals and 4 na€ıve pigs with similar age and weight to match the
numbers of animals in the AoB group. One pig was euthanized at 1 month because of infectious aortic
stenosis. AoB indicates aortic banding; cath., catheterization; Echo, echocardiography.
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and femoral vein. Heparin (100 IU/kg intravenously) was
administered to maintain an activated coagulation time of 150
to 250 seconds. A Swan-Ganz catheter (Edwards Lifesciences
LLC) was advanced to the main pulmonary artery, and
pressure measurements were collected. Next, through the
femoral arterial sheath, a Millar catheter (Millar Instruments)
was advanced to the left ventricle to obtain hemodynamic
parameters. Approximately 0.259body weight (in kilograms)
milliliter of cold saline was injected into the inferior vena cava
to obtain cardiac output by the thermodilution method. All
measurements were performed after the conﬁrmation of
hemodynamic stability for 3 minutes. Data analyses were
performed using an iox2 application (Emka Technologies). At
the ﬁnal time point, an inferior vena cava occlusion was
conducted to evaluate the pressure–volume relationship
during the preload reduction. The slope of the end-systolic
pressure–volume relationship was deﬁned as a measure of
contractility. The stiffness constant (b) was determined from a
set of relationships between end-diastolic pressure (EDP) and
volume, using the following calculation: EDP=aebEDV. EDV
indicated end-diastolic volume, and a indicated the curve-
ﬁtting constant. After the preload-reduction study, a pacing
catheter was advanced through the venous sheath. To
evaluate the response of a physiologically relevant increase
in heart rate, the right atrium was paced at 120 Hz, and
hemodynamic parameters were measured again.
Echocardiographic Analysis
Comprehensive transthoracic echocardiographic studies
including Doppler, 2-dimensional, and 3-dimensional (3D)
echocardiograms were performed at baseline (prior to AoB), at
2 months after AoB, and at the ﬁnal time point. A Philips iE-33
ultrasound system (Philips Medical Systems) was used to
acquire echocardiographic data with a multifrequency imaging
transducer (S5 probe for 2-dimensional images or X3 probe
for 3D images). A subxiphoid approach provided an apical 4-
chamber view and 3D images of the left ventricle. Using the
parasternal approach, 3D images of the left atrium (Figure S1)
and cross-sectional images of the LV short axis were obtained
at the levels of the base, papillary muscle, and apex with a
high frame rate (60 to 100 Hz). The 2-dimensional images
were loaded into the Q-lab application (version 7.0; Philips
Medical Systems) for strain analysis using a speckle-tracking
algorithm. LV volumes and ejection fraction were obtained
from 3D images. Body surface area (in square meters) was
calculated as described previously,9 and volume parameters
were divided by body surface area to calculate volume
indexes. Longitudinal strain was obtained from apical 4-
chamber views. Short-axis images from the papillary muscle
level were used for the circumferential strain analysis. Good
inter- and intraobserver agreement was reported previously
with this method.10 Tissue Doppler images were analyzed to
determine isovolumic relaxation time. Left atrium size was
measured as the diameter from the right superior pulmonary
vein to the root of the left appendage. The degree of stenosis
due to AoB was serially evaluated by maximum velocity and
the mean pressure gradient using the continuous-wave
Doppler signal at each echocardiographic study by aligning
the ultrasound beam with the aortic ﬂow at the level of the
banding in the apical view. In the absence of systolic
dysfunction, these parameters are used as an established
indicator of stenosis severity and allows classiﬁcation of
severe aortic stenosis when the mean gradient is
>40 mm Hg, calculated by the simpliﬁed Bernoulli equation.11
Postmortem Molecular Analysis and Histology
At the end of the study protocol, the animals were euthanized
by intravenous injection of potassium chloride under deep
isoﬂurane anesthesia. Hearts were explanted and weighed,
and the left ventricle was sectioned into 5 slices. One middle
slice was used for histological and molecular analyses.
Samples measuring 1 cm3 were obtained from the anterior
wall and preserved both by snap freezing and in formalin.
Frozen cardiac tissue was minced and subsequently homog-
enized in radioimmunoprecipitation assay buffer containing a
protease inhibitor cocktail (Sigma-Aldrich). Protein extracts
(10 lg) were separated on 10% SDS-PAGE, transferred to a
nitrocellulose membrane (Bio-Rad), and probed with antibod-
ies speciﬁc for sarcoplasmic reticulum Ca2+ ATPase (SER-
CA2a; Cell Signaling) and phospholamban (Cell Signaling).
Peroxidase-conjugated antibodies targeting both primary
antibodies (Sigma-Aldrich) and GAPDH (Sigma-Aldrich) were
also used. Blots were developed with SuperSignal West Pico
(Pierce). Protein band densities were quantiﬁed using ImageJ
software (National Institutes of Health). Formalin-ﬁxed tissues
were embedded in parafﬁn, sectioned (8 lm), and mounted
on positively charged microscope slides. The slides were
stained with ﬂuorescein isothiocyanate–labeled wheat-germ
agglutinin (Life Technologies) for assessing cell area as an
indicator of hypertrophy and with picrosirus red (Abcam) to
detect levels of collagen as an indicator of ﬁbrosis.
Statistical Analysis
Data are expressed as meanSD unless stated otherwise.
The Shapiro–Wilk normality test was conducted to test the
normality of the distribution. The unpaired t test was used to
compare the differences between 2 groups, and the Mann–
Whitney U test was used as appropriate. A paired t test was
used to compare changes within the same animal. SPSS
version 22.0 (IBM Corp) was used for all statistical analyses. A
P value <0.05 was considered statistically signiﬁcant.
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Results
One pig in the AoB group was euthanized at 1 month after
the surgery because of worsening general condition.
Postmortem evaluation in this pig revealed infectious vege-
tation at the stenosis site. This pig was excluded from the
analysis; therefore, the AoB group consisted of 6 pigs
(Figure 1). There was no signiﬁcant difference in the growth
of the pigs, and most functional parameters remained
nonsigniﬁcant at 2 months after the surgery, although this
was most likely due to the small number of pigs in the sham
group at this time point (Table 1). In the AoB group
compared with the control group, echocardiographic assess-
ments of pressure gradients (mean pressure gradient at
Table 1. Temporal Changes of Cardiac Parameters
Baseline 2 Months Final (3 to 5 Months)
AoB (n=6) Sham (n=3) AoB (n=6) Sham (n=3) P Value AoB (n=6) Control (n=7) P Value
BW, kg 11.51.2 10.70.6 24.21.9 22.72.1 0.32 41.37.1 37.14.4 0.22
Days after surgery 0 0 573 551 0.53 12120 1078† 0.37
Echocardiography
Ejection fraction (3DE), % 70.04.8 70.43.8 82.913.9 85.70.61 0.75 85.25.4 81.56.8 0.31
End-diastolic volume
index (3DE), mL/m2
72.116.9 78.315.7 69.420.3 81.77.1 0.35 81.911.7 87.110.3 0.41
End-systolic volume
index (3DE), mL/m2
21.66.1 22.92.9 11.27.7 11.71.3 0.92 11.83.7 15.64.7 0.14
Stroke volume index
(3DE), mL/m2
50.512.2 55.513.8 58.221.5 70.05.8 0.39 70.112.3 71.613.8 0.84
E wave, cm/s 62.511.6 72.319.1 65.813.5 61.13.7 0.58 61.414.1 71.17.0 0.14
E-wave deceleration time, ms 10940 8518 12448 8423 0.23 10222 8526 0.22
A wave, cm/s 52.68.1 60.712.9 66.68.4 56.512.6 0.19 74.413.5 70.014.5 0.58
E/A 1.200.27 1.180.07 1.020.36 1.120.30 0.68 0.820.07 1.050.22 0.03
E’, cm/s 8.41.6 11.31.9 7.91.6 9.93.7 0.27 7.31.9 10.31.5 0.01
E/E’ 7.51.0 6.30.6 8.51.6 6.92.9 0.31 8.72.3 7.01.1 0.10
IVRT, ms 71.826.3 71.18.3 76.814.9 70.36.0 0.39 95.125.8 80.48.2 0.23
LA diameter, mm 26.03.5 27.32.5 33.83.8 28.33.5 0.07 42.04.2 38.64.8 0.20
Left atrial ejection fraction
(3DE), %
64.38.7 62.54.9 61.17.4 64.49.3 0.58 58.36.8 63.65.4 0.14
LA maximum volume index
(3DE), mL/m2
26.42.3 26.15.1 39.210.0 28.42.5 0.12 51 (34, 66) 29 (27, 43) 0.04*
LA minimum volume index
(3DE), mL/m2
9.42.7 9.71.5 15.35.5 10.02.3 0.16 23.112.9 12.12.7 0.05
Invasive hemodynamics
LV maximum pressure, mm Hg N/A N/A 17134 12417 0.07 214 (186, 245) 132 (125, 141) 0.005*
End-diastolic pressure, mm Hg N/A N/A 20.14.0 13.84.4 0.07 16.74.8 14.43.4 0.34
Maximum dP/dt, mm Hg/s N/A N/A 2890380 2055350 0.02 2445387 2331528 0.67
dP/dt at pressure 40, mm Hg/s N/A N/A 1609342 1641226 0.89 1503410 1644310 0.5
Minimum dP/dt, mm Hg/s N/A N/A 2100592 2277445 0.67 28701051 2612461 0.6
Tau, ms N/A N/A 52.911.4 59.78.4 0.39 47.216.7 53.18.8 0.46
Relaxation time, ms N/A N/A 11914 14013 0.06 11812 13117 0.13
MeanSD. 3DE indicates 3-dimensional echocardiography; A, late diastolic transmitral ﬂow velocity; AoB, aortic banding; BW, body weight; dP/dt, peak left ventricular pressure rate; E,
early diastolic transmitral ﬂow velocity; E’, early diastolic mitral annular velocity; IVRT, isovolumic relaxation time; LA, left atrial; LV, left ventricular; N/A, not available.
*Mann–Whitney U test, median (interquartile range).
†Sham pigs.
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2 months: 45.422.5 versus 1.71.2 mm Hg, P=0.01;
ﬁnal: 78.127.4 versus 3.72.1 mm Hg, P=0.003) and
velocities (maximum velocity (Vmax) at 2 months:
43677 versus 9323 cm/s, P<0.001; ﬁnal: 510130 ver-
sus 1068 cm/s, P=0.001) at the banding sites increased
signiﬁcantly after surgery (Figure 2). There were nonsigniﬁ-
cant increases in these parameters from 2 months to the
ﬁnal time point (Vmax P=0.16, mean pressure gradient
P=0.10), suggesting stenosis progression due to animal
growth. At the ﬁnal time point, pigs with AoB presented with
signiﬁcantly higher maximum LV pressure than control pigs.
The hearts of the pigs with AoB exhibited signiﬁcant
hypertrophy, demonstrated by a higher ratio of heart weight
to body weight (Figure 3).
Figure 2. Echocardiographic assessment of stenosis at the aortic banding site using continuous Doppler.
Both Vmax and mean PG were signiﬁcantly increased at 2 months and at ﬁnal time points in AoB pigs.
*P<0.05. AoB indicates aortic banding; PG, pressure gradient; Vmax, maximum velocity.
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Importantly, major systolic and relaxation parameters
including LV ejection fraction by 3D echocardiography, peak
LV pressure rate of rise, peak LV pressure rate of decline, Tau,
and relaxation time were similar between the groups,
indicating no depression in contractility and lusitropy in pigs
with AoB (Table 1). These observations were supported by the
pressure–volume analysis during the preload reduction study,
in which higher end-systolic elastance and preload recruitable
stroke work were demonstrated without impaired arterial–
ventricular coupling (Figure 4, Table 2). Interestingly, LV EDP
was not different between the groups, suggesting a compen-
sating condition in pigs with AoB; however, pressure–volume
relationship analysis revealed stiffer left ventricles in pigs with
AoB, determined by signiﬁcantly higher b of the end-diastolic
pressure-volume relationship (Figure 4, Table 2).
Echocardiographic Strain and Left Atrial Volumes
Speckle-tracking strain analysis was performed at the ﬁnal
time point. All acquired images were adequate for strain
analysis. Although pigs with AoB presented signiﬁcant hyper-
trophy, there was no difference in longitudinal or circumferen-
tial strain between AoB and sham pigs (Figure 5). Left atrial 3D
echocardiographic imaging exhibited signiﬁcantly higher max-
imum and minimum left atrial volumes (Table 1).
Pacing Study
After baseline hemodynamic measurements were acquired, a
pacing study was performed to examine the impact of
increased heart rate within a physiological range. A pacing
rate of 120 beats per minute in the right atrium increased LV
EDP in pigs with AoB, whereas LV EDP decreased in the
control animals (Figure 6). On average, there was an increase
of 50% in EDP during pacing in pigs with AoB. These results
indicate a propensity for developing congestive HF in these
pigs. Changes in LV maximum pressure, LV pressure rate of
rise and decline, and Tau were lower in pigs with AoB but did
not reach statistical difference.
Postmortem Histology and SERCA2a Expression
Consistent with the macroscopic presentation, histological
evaluation of the left ventricle conﬁrmed cardiomyocyte
hypertrophy in pigs with AoB (Figure 7). In addition, myocar-
dium of pigs with AoB had signiﬁcantly increased collagen
volume fractions in both perimysial and perivascular areas
(Figure 7). To investigate whether there was molecular
evidence of systolic dysfunction, expression of SERCA2a
and phospholamban was studied. We found no difference in
these protein expression levels between the groups (Fig-
ure 8).
Discussion
In the present study, we demonstrated that increased LV
stiffness alone, but not impaired LV systolic function or
abnormal relaxation, is the major abnormality at the early
stages of severe aortic stenosis in a clinically relevant
experimental animal model; however, this increased LV
stiffness was associated with a propensity to develop
congestive HF in response to the physiological increase in
heart rate despite the absence of systolic dysfunction and
relaxation abnormalities. Normal systolic function was con-
ﬁrmed by comprehensive cardiac functional analyses includ-
ing 3D echocardiography, pressure–volume relationship, and
speckle-tracking echocardiographic strain. Consistent
with our ﬁndings that relaxation and systolic function were
normal, myocardial SERCA2a protein levels were similar
between the groups. In contrast, LV stiffness evaluated by
Figure 3. Cross-sections of the explanted heart. Macroscopic hypertrophy is apparent in pigs with aortic banding (AoB), with signiﬁcantly
heavier heart weight (P=0.001). *P<0.05.
DOI: 10.1161/JAHA.115.001925 Journal of the American Heart Association 6
Isolated Stiffness in Aortic Stenosis Ishikawa et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 14, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
70
pressure–volume loop analysis revealed stiffer left ventricle in
pigs after AoB. This ﬁnding is consistent with the severe
myocardial hypertrophy observed in the pigs with AoB.
Moreover, histopathological studies indicated that cardiomyo-
cyte hypertrophy and increased ﬁbrosis are major contribu-
tors to increased LV stiffness. To our knowledge, this study is
the ﬁrst to demonstrate isolated increased LV stiffness and its
association with HF in the absence of systolic dysfunction and
impaired relaxation in severe aortic stenosis, using compre-
hensive functional analyses.
Several large animal models of AoB have been developed
previously, with use of dogs, pigs, and sheep showing varying
results.6,12–20 Although some studies have reported subnor-
mal systolic function after AoB,13,15,16 our animals did not
develop systolic dysfunction up to 5 months after the surgery,
with ﬁnal LV maximum pressure >200 mm Hg. In contrast,
our animals showed supranormal systolic function, as
suggested by the increased slope of the end-systolic
pressure–volume relationship, the higher preload recruitable
stroke work, and the lower arterial–ventricular coupling. The
discrepancy may be due to the time point examined after AoB,
the age of the animals, and the degree of induced stenosis.
The absence of systolic dysfunction with increased stiffness is
an attractive feature of our model because it allows for
isolation of LV stiffness and systolic dysfunction. This model
also may be useful for evaluating various therapeutic
approaches targeting HF with preserved ejection fraction;
the presentation of this type of HF is similar, with increased
myocardial stiffness as a major contributor to development of
HF in both diseases.
Relaxation and stiffness are sometimes discussed together
as a form of diastolic dysfunction without clear distinction.
This is because in many cases, impaired relaxation and
increased stiffness coexist in diastolic dysfunction; however,
our pigs with AoB presented with increased stiffness without
delayed relaxation. Consistent with this ﬁnding, it was
reported that a mouse model of a-myosin heavy chain
missense mutation presented signiﬁcantly impaired relaxation
in the absence of HF or elevated EDP.21,22 These data suggest
that relaxation and stiffness abnormalities do not necessarily
parallel and that increased stiffness alone is the key factor for
Figure 4. Representative pressure–volume loops of AoB and control pigs. Steeper end-systolic pressure–
volume relationship was found in pigs with AoB compared with control pigs. Despite similar end-diastolic
pressure before occlusion, pigs with AoB presented steeper end-diastolic pressure–volume relationship,
indicating stiffer left ventricle. AoB indicates aortic banding; corr., corrected.
Table 2. Pressure–Volume Loop Relationships
AoB (N=6) Control (n=7) P Value
ESPVR
Slope,
mm Hg/mL
4.66 (2.83 to 5.74) 1.68 (1.13 to 1.90) 0.005*
V0, mL 29.822.0 62.923.1 0.02
Ea/Ees 0.970.61 1.680.51 0.04
PRSW
Slope,
mm Hg
176 (103 to 202) 55 (48 to 81) 0.008*
EDPVR
a 3.032.29 0.630.22 0.15
b 0.0530.017 0.0280.009 0.007
AoB indicates aortic banding; a, curve ﬁtting constant; b, stiffness constant; Ea/Ees,
arterial elastance/end-systolic elastance; EDPVR, end-diastolic pressure volume
relationship; ESPVR, end-systolic pressure volume relationship; PRSW, preload
recruitable stroke work; V0, volume axis intercept of end-systolic pressure-volume
relationship.
*Mann–Whitney U test, median (interquartile range).
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HF induction. They also highlight the importance of distin-
guishing relaxation and stiffness when evaluating HF with
diastolic abnormalities. We found that increased cardiomyo-
cyte hypertrophy and increased ﬁbrosis were potential
contributors to increased LV stiffness. A recent study in a
rat model of swimming-induced cardiac hypertrophy without
signiﬁcant myocardial ﬁbrosis reported improved LV relaxa-
tion without altered stiffness.23 Although it remains specula-
tive, ﬁbrosis seems to have a signiﬁcant impact on LV
stiffness, although the amount is minor in our model.
Our ﬁndings have important clinical implications. If
subnormal systolic function or impaired LV relaxation is the
key early indicator of HF development in patients with severe
aortic stenosis, clinicians can focus on detailed functional
imaging studies to identify these abnormalities. Unfortunately,
our study demonstrated that this is not the case, and thus
patients with severe aortic stenosis are at risk of developing
congestive HF without any evidence of systolic dysfunction or
impaired relaxation. Instead, increased LV stiffness seems to
be the critical early pathological process that predisposes to
congestive HF development in this model. Precise measure-
ment of LV stiffness requires pressure–volume loop analysis
using invasive catheterization and load-alteration studies.
Several formulas for estimating LV stiffness have been
proposed,24,25 but these formulas contain many assumptions,
and whether they are always applicable to different disease
conditions remains unclear. Consequently, identifying the
early manifestation of HF in asymptomatic severe aortic
Figure 5. Echocardiographic speckle-tracking strain analysis. AoB pigs exhibited thicker wall thickness at
both end-diastole and end-systole (top); however, both peak circumferential and longitudinal strains were
not different between the groups (P=0.63 and P=0.45, respectively) (bottom). AoB indicates aortic banding;
bpm, beats per minute; GC, global circumferential, HR, heart rate; NS, not signiﬁcant.
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stenosis patients remains challenging. Although most studies
of patients with severe aortic stenosis report the presence of
diastolic functional abnormalities,26,27 comprehensive evalu-
ation of speciﬁc diastolic parameters is not yet available using
standard noninvasive tools; therefore, in current guidelines,
diastolic functional parameters are not included in the
decision-making process for patients with severe aortic
stenosis.28 Our results demonstrated that 3D echocardiogra-
phy–derived left atrial volumes were signiﬁcantly increased in
pigs after AoB, and these indexes had superior sensitivity
relative to conventional 2-dimensional left atrial diameter to
detect the difference between groups. The left atrium is
constantly exposed to increased LV ﬁlling pressure in a stiff
heart, promoting left atrial remodeling. In fact, left atrial
remodeling has been proposed as a chronic marker for
diastolic dysfunction.29 Focused evaluation of the left atrium
using sophisticated techniques may provide better diagnostic
information in patients with severe aortic stenosis. Another
approach that may be useful in the detection of early signs of
HF in this patient population is ﬁbrosis evaluation, based on
our ﬁndings. Noninvasive quantiﬁcation of ﬁbrosis may be
performed with serum markers30 or with cardiac magnetic
resonance. In fact, several studies have shown correlation
between ﬁbrosis assessed by histology and cardiac magnetic
resonance imaging using late gadolinium enhancement31,32
and T1 mapping33 in patients with severe aortic stenosis.
Because these correlations were evaluated in patients with a
relatively large degree of ﬁbrosis, further study is necessary to
examine cardiac magnetic resonance sensitivity to small
increases in myocardial ﬁbrosis, as found in our study. From a
therapeutic point of view, our ﬁndings suggest that antihy-
pertrophic and antiﬁbrotic therapies may be beneﬁcial to
prevent the development of HF in patients with aortic
stenosis.
Limitations
Due to the nature of animal studies, whether the pigs had HF
symptoms remains uncertain, although we did not ﬁnd any
difference in the pig behaviors compared with the sham
animals. The propensity for development of congestive HF
was determined by increased EDP during the pacing study.
Ideally, this should be performed by exercise testing; however,
the difﬁculty of training the pigs for adequate exercise testing
and of performing stable placement of the pressure–volume
catheter during exercise precluded this option. The pacing
method to mimic exercise has been reported previously,14
and the clear difference in response to pacing in our study
suggests the utility of this method to uncover the propensity
for HF development in patients with limited exercise ability.
Figure 6. Hemodynamic changes induced by pacing study. Pigs received right atrial pacing (120 bpm) with continuous hemodynamic
monitoring. End-diastolic pressure decreased in the control group but increased in the AoB group (P<0.001), suggesting the propensity of the
latter to develop congestive heart failure. Although the parameters did not reach statistical signiﬁcance, changes in dP/dtmax, dP/dtmin, and Tau
were smaller in AoB pigs, suggesting limited functional reserve. *P<0.05. AoB indicates aortic banding; bpm, beats per minute; dP/dtmax, peak
left ventricular pressure rate of rise; dP/dtmin, peak left ventricular pressure rate of decline; LV, left ventricular; NS, not signiﬁcant.
DOI: 10.1161/JAHA.115.001925 Journal of the American Heart Association 9
Isolated Stiffness in Aortic Stenosis Ishikawa et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 14, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
73
The supracoronary stenosis in the AoB pig model may differ in
the coronary ﬂow pattern from valvular stenosis in humans;
however, impaired coronary ﬂow similar to human aortic
stenosis has been shown in a dog model of AoB with a
banding location similar to ours.14 Not all animals in the
control group underwent sham surgery, and this may have
caused unrecognized heterogeneity in this group related to
the surgical procedures.
Figure 7. Histological characterization of the left ventricular myocardium. AoB pigs presented a signiﬁcantly larger cardiomyocyte area
(P<0.001), increased perimysial ﬁbrosis (P=0.01), and increased perivascular ﬁbrosis (P=0.045). Scale bars indicate 50 lm for WGA ﬁgures,
200 lm for perimysial ﬁbrosis ﬁgures, and 100 lm for perivascular ﬁbrosis ﬁgures. Error bars indicate standard error. *P<0.05. AoB indicates
aortic banding; WGA, wheat-germ agglutinin.
Figure 8. SERCA2a and PLN expression in the left ventricle. Both SERCA2a and PLN levels were not different between the AoB and control
groups. AoB indicates aortic banding; NS, not signiﬁcant; PLN, phospholamban; SERCA2a, sarcoplasmic reticulum calcium (Ca2+) ATPase.
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Conclusion
Early abnormality in severe aortic stenosis is characterized by
increased LV stiffness, whereas systolic dysfunction or
impaired relaxation is not necessarily present in this early
pathological process. Increased LV stiffness due to cardio-
myocyte hypertrophy and increased tissue ﬁbrosis contrib-
utes to the propensity to develop congestive HF. Our animal
model offers a unique opportunity to study the role of LV
stiffness independent of systolic dysfunction and impaired
relaxation.
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SUPPLEMENTAL MATERIAL 
 
Figure S1. Cited in Methods: echocardiographic analysis 
 
 
An example of three‐dimensional left atrial volume analysis. 
Bottom right figure shows the mesh (maximum volume) and color (minimum volume) of the left atrium. 
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ABSTRACT.  
BACKGROUND. Left atrial (LA) remodeling after acute myocardial infarction (AMI) is poorly characterized and 
little is known about its determinants and potential impact on ischemic mitral regurgitation and cardiac 
hemodynamics. 
OBJECTIVES. 1) To compare LA remodeling in a pig model of AMI caused either by left anterior descending 
(LAD) coronary artery occlusion or by left circumflex (LCx) coronary artery occlusion with and without occlusion of 
the LA branch. 2) To analyze the interplay of LA and LV remodeling and the development of ischemic mitral 
regurgitation (MR). 
METHODS. Three pig models of MI were created: 1) occlusion of the proximal LCx coronary artery with 
concomitant occlusion of the LA coronary artery (LA infarction, LAI group); 2) occlusion of the proximal LCx coronary 
artery without involvement of the LA branch (LCx group); and 3) occlusion of the LAD (LAD group). The 3 models 
were evaluated for structural and functional remodeling of the LA and for LV remodeling and the occurrence of 
ischemic MR. Animals underwent serial cardiac magnetic resonance (CMR) at 1 and 8 weeks post-AMI to monitor 
cardiac remodeling parameters. Pulmonary hemodynamics were assessed at 8 weeks post-AMI by right heart 
catheterization. Animals were sacrificed thereafter, and structural remodeling of the LA was characterized by 
histological examination. 
RESULTS. Compared with the other groups, occlusion of the LCx and LA arteries (LAI) was associated with a 
greater degree of LA dilation on CMR at 1- and 8-week follow-up. LA coronary occlusion induced severe impairment 
of LA reservoir function, evident at 1 week post-AMI and persistent at 8-week follow-up; in contrast, in the other 
groups this dysfunction was less pronounced and not consistent. In the LAI group, atrial infarction was confirmed by 
extensive fibrotic replacement of the atrial myocardium at 1 and 8 weeks, whereas LCx alone was associated with 
milder, interstitial fibrosis. All groups showed progressive LV remodeling. Development of ischemic MR was more 
pronounced in the LAI group than in the LCx group and was evident as early as 1 week post-AMI. The combination of 
atrial remodeling, LV remodeling, and ischemic MR was associated with pulmonary hypertension measured 
invasively at 8-week follow-up. In the LAD group, LA remodeling was not observed by CMR or histology, despite a 
similar degree of LV dysfunction to the other groups. 
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CONCLUSIONS. We provide the first experimental evidence of the deleterious impact of acute LA infarction 
during LCx AMI on LA and LV remodeling, with consequent development of ischemic MR. Atrial coronary occlusion 
induced early and severe LA enlargement, followed by persistent LA functional impairment and extensive fibrosis. 
The combination of ischemic LA remodeling and MR led to early onset pulmonary hypertension, reflecting post-
infarction heart failure.  
 
KEYWORDS. Myocardial infarction, atrial infarction, mitral regurgitation, experimental model, atrial fibrosis. 
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Introduction  
Chronic heart failure (HF) is a major cause of death and hospital admission. Despite advances in patient care, 
incident HF in myocardial infarction (MI) survivors remains a major cost burden on health care systems.1 In the 
aftermath of an acute MI (AMI), left ventricular ejection fraction (LVEF) is currently the main recommended 
predictor of future events, including sudden cardiac death and HF.2 More recently, left atrial (LA) enlargement has 
been proposed as novel predictor of HF, providing independent prognostic value in addition to LVEF.3-5 
Excessive dilation of the LA is described in ~15-45% of patients in the early post-MI period.3-5 However, the 
main determinants of this finding are not well characterized. The main driver of LA dilation is thought to be 
increased atrial pressure due to LV dysfunction .6 However, 2 potentially major contributors to post-MI LA 
remodeling have scarcely been characterized: ischemic mitral regurgitation (MR) and atrial infarction. Ischemic MR is 
caused by LV remodeling and distorted valve geometry, resulting in altered leaflet coaptation8. Previous studies 
suggest a close association between ischemic MR and LA remodeling after AMI9, but the time course of LA 
remodeling in patients developing ischemic MR has not been described. The incidence and consequences of atrial 
infarction remain unknown, mainly due to a lack of reliable diagnostic biomarkers10. Recently, LA coronary branch 
occlusion was reported as a complication of percutaneous coronary angioplasty in up to 15% of patients, leading to a 
higher prevalence of atrial arrhythmias, peri-procedural MI, and mortality.13 However, the impact of LA infarction on 
LA structure and physiology has not been explored before, and current knowledge is based mostly on autopsy 
reports.14  
The aim of this study was to provide insight into the causes, mechanisms, and consequences of LA 
remodeling as a complication of AMI. The specific aims were twofold: 1) to evaluate the incidence and progression of 
post-MI LA remodeling and the interplay among potential contributing factors (ventricular necrosis/remodeling, 
ischemic MR, and atrial infarction); and 2) to examine the impact of LA remodeling and ischemic MR on the 
development of post-MI HF. To address these questions, we performed time course studies in porcine AMI models 
recapitulating LV remodeling, ischemic MR, and LA infarction and evaluated LA remodeling by noninvasive imaging 
and histology. 
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Methods. 
The study was approved by the local institutional animal research committee and conducted in accordance 
with the National Research Council Guide for the Care and Use of Laboratory Animals. An expanded description of 
experimental procedures is provided in the Supplementary Methods. 
Study design. Male large-white pigs (30-35Kg) underwent closed-chest MI by occluding the LAD or LCx 
coronary arteries. LCx infarctions were conducted with or without associated atrial coronary occlusion (see detailed 
description below) and were used as a model of ischemic MR. Anterior infarctions were generated by LAD 
ischemia/reperfusion to provide a post-MI model of LV dysfunction with no or mild ischemic MR. Three experimental 
groups were created: 1) LCx occlusion (LCx group, n=7), 2) LCx occlusion involving the LA branch and therefore 
inducing LA infarction(LAI group, n=8), and 3) anterior MI (LAD group, n=18) (Figure 1). An additional 4 healthy pigs 
served as controls during serial imaging studies. Hearts were examined by cardiac magnetic resonance (CMR) before 
MI and at 1 and 8 weeks post-MI to evaluate LA and LV remodeling and MR development. Pulmonary hemodynamics 
were measured invasively by right heart catheterization (RHC) at 8-week follow-up. Animals were sacrificed at 8 
weeks post-MI and hearts were excised for histological analysis. 
Model of chronic post-MI ischemic MR and LA infarction. Pilot experiments (Supplementary Methods and 
Supplementary Figure 1) enabled us to establish the optimal technique for creating an ischemic MR model in pigs by 
placing a coronary coil in the proximal segment of moderate-to-large LCx arteries. A 5-French AL-2 guide catheter 
was used to engage the left coronary artery. The LCx coronary anatomy pattern (including size and distribution of 
marginal branches) was examined in 2 angiographic projections to select those vessels likely to develop large 
posterolateral infarcts based on pilot studies. The catheter tip was then was positioned in the proximal LCx artery 
using a 0.014-inch guide wire. A CMR-compatible steel-alloy embolization coil (MREye, Cook Medical, 3-cm long, 3-
mm embolus diameter) was deployed using a 0.035-inch vascular wire. In all animals, total occlusion of the LCx 
artery was confirmed by angiography within 5 minutes of coil deployment.  
To evaluate the effect of acute LA injury during MI, animals undergoing LCx coiling were further classified 
based on angiographically-determined occlusion of the LA coronary artery (LCx vs. LAI groups), which branches off 
from the proximal LCx segments or less frequently from the mid LCx segment.  
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Model of anterior acute MI. To evaluate the presence and severity of post-MI LA remodeling due to LV 
necrosis and remodeling in the absence of other potential contributors, anterior infarction was induced with the LAD 
ischemia/reperfusion protocol previously reported by our group (LAD group).15 In this model, AMI is achieved by 45-
minutes mid-LAD occlusion (distal to the first diagonal branch) followed by reperfusion.16 This procedure generates 
consistent transmural infarcts characterized by chamber dilation and systolic dysfunction, consistent with clinical 
presentation.16 
CMR acquisition protocol. All studies were performed in a Philips 3-T Achieva Tx whole-body scanner (Philips 
Healthcare, Best, the Netherlands) equipped with a 32-element phased-array cardiac coil. The imaging protocol 
included a standard segmented cine steady-state free-precession (SSFP) sequence to provide high-quality anatomical 
references. The imaging parameters for the SSFP sequence were field of view (FOV) 280x280 mm, slice thickness 6 
mm with no gap, repetition time (TR) 2.8 ms, echo time (TE) 1.4 ms, flip angle 45, cardiac phases 30, voxel size 
1.8x1.8 mm, and number of excitations (NEX) =3.  
Delayed enhancement imaging was performed 10 to 15 min after intravenous administration of 0.20 mmol 
of gadopentetate dimeglumine contrast agent per kg of body weight using an inversion-recovery spoiled turbo field 
echo (IR-T1TFE) sequence with the following parameters: FOV 280x280 mm, voxel size 1.6x1.6 mm, end-diastolic 
acquisition, thickness 6 mm with no gap, TR 5.6 ms, TE 2.8 ms, inversion delay time optimized to null normal 
myocardium. 
Forward stroke volume was determined by 2D flow imaging (phase-contrast) performed on cross-sectional 
views of the ascending aorta, with a velocity-encoded gradient echo sequence using the minimum upper velocity 
limit without signal aliasing. The following imaging parameters were applied: repetition time/ echo time 5.4/3.4 ms, 
number of averages 2, slice thickness 8 mm, voxel size 2.5 x 2.5 mm, reconstructed heart phases 40.  
CMR data analysis. CMR images were analyzed with dedicated software (MR Extended Work Space 2.6, 
Philips Healthcare, and QMass MR 7.5, Medis, Leiden, the Netherlands) by 2 observers experienced in CMR analysis. 
Short-axis epicardial and endocardial contours were manually traced to obtain LV volumes at end-diastole (EDV) and 
end-systole (ESV) and LV mass. Delayed gadolinium-enhanced regions were defined as >50% of maximum 
myocardial signal intensity (full width at half maximum), and infarct size was defined as a percentage of LV mass. 
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Given that no volumetric estimation methods have been validated in swine, we quantified LA dimensions based on 
the mean area in 4- and 2-chamber views. From these views, 3 phasic parameters were derived as follows: 
- Reservoir function (%): 100*(Maximal LA area – minimum LA area)/ Maximal LA area 
- Conduit function (%): 100*(Maximal LA area – pre-atrial contraction area)/ Maximal LA area 
- Booster function (%): 100*(Pre-atrial contraction area – minimum LA area)/ Maximal LA area. 
Post-MI MR severity in the ischemic MR groups (LCx and LAI) was quantified using LV forward stroke volume 
(SV) obtained from a phase-contrast sequence in the ascending aorta. Regurgitant volume (RegVol) and regurgitant 
fraction (RF) were calculated as follows: 
- CineSV = LV end-diastolic volume – LV end-systolic volume 
- RegVol= Forward SV – (CineSV) 
- RF= RegVol/CineSV 
Histology. After excision of the heart, tissue samples from the LA anterior wall and mitral leaflets were fixed 
in 10% neutral buffered formalin, embedded in paraffin wax, and cut into 4 µm sections. Sections stained with 
Picrosirius red, hematoxylin-eosin, and Masson’s trichrome were digitized with a Nanozoomer-RS C110730® scanner 
(Hamamatsu). The level of collagen organization was evaluated qualitatively by polarized light microscopy of 
Picrosirius-red-stained sections (Nikon ECLIPSE 90i). 
Invasive measurement of pulmonary pressure. RHC was performed in the LCx, LAI, and control groups at 8-
week follow-up, using a 7.5-Fr Swan-Ganz catheter (Edwards Lifesciences). Hemodynamic measurements were 
obtained under mechanical ventilation (oxygen inspiratory fraction 30%, tidal volume 7 ml/kg). Cardiac output was 
measured by the thermodilution method.  
Statistical analysis. Continuous variables are expressed as medians and interquartile ranges. Between-group 
comparisons at different time points were performed using one-way ANOVA or the non-parametric Kruskal-Wallis 
test, followed by post-hoc analyses corrected for multiple comparisons (Holm method). Linear or ordinal 
associations between different parameters were evaluated using the Pearson or Spearman’s correlation coefficient, 
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as appropriate. Statistical analyses were performed using R version 3.1.1 (http://cran.r-project.org/). Differences 
were considered significant at p-value < 0.05. 
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Results. 
Data related to the generation of the 3 porcine MI models are provided in the Supplementary Data. The final 
analyses were performed in all animals that completed the study protocol (Control group, n=4; LCx group, n=7; LAI 
group, n=8; and LAD group, n=18). Experimental procedures, study timeline, and experimental groups are 
summarized in Figure 1. 
Time course of LA dilation after MI. While LA dilation (at 1 week post-MI) was present in both pig groups 
undergoing LCx coil occlusion (LCx and LAI groups), it was larger in pigs in the LAI group (Table 1 and Figure 2). In 
addition, between 1 and 8 weeks post-MI, LA dilation progressed faster in the LAI group. Interestingly, pigs in the 
LAD group showed no LA enlargement (compared with control pigs) despite the presence of LVEF depression and 
ventricular chamber remodeling. At 1 week, we found a modest but significant linear association of LA dilation with 
infarct size (R=0.38, p=0.015) and LVESV (R=0.34, p=0.025). 
LA dysfunction after MI: association with LA dilatation 
Impaired LA reservoir function was observed 1 week after MI in all 3 groups (Table 1 and Figure 3). Early 
reduction in reservoir function was most prominent in the LAI group (13.8% vs. 38.2% in the control group, 
compared with 24.1% and 27.1% for the LCx and LAD groups, respectively). Between 1 and 8 weeks, markedly 
impaired LA reservoir function indicated persistent dysfunction in LAI animals (16.5% vs. 38.3% in controls), whereas 
impairment was milder in the LCx (24.1%) and LAD (27.1%) groups, with some animals even showing functional 
recovery (Figure 3). Atrial contractility, measured from the booster function, followed a similar time course to 
reservoir function, with the most notable changes occurring in the LAI group (Table 1). Individual animals showed a 
strong correlation between reservoir and contractile properties (R=0.89, p<0.001). Acute MI impaired atrial conduit 
function to a similar extent in all groups, but there were no significant differences between 1-week and 8-week 
follow-up (Table 1). 
LV remodelling post-MI and development of ischemic MR 
Time courses of CMR-derived LV remodeling and ischemic MR parameters across all experimental models 
are summarized in Table 2. In all experimental groups, post-MI remodeling was characterized by enlarged LV 
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dimensions and decreased LVEF. Infarct size (quantified by late gadolinium enhancement CMR sequence at 1 week 
post-MI) was significantly larger in the LCx and LAI occlusion groups than in the LAD group (median infarct size = 
37.8%, 37.2%, and 28.1% in the LCx, LAI, and LAD groups, respectively), with LV volume showing a similar pattern 
(Table 2). 
Ischemic MR was estimated from CMR-derived regurgitant volumes and fractions (Table 1). Ischemic MR was 
mild in the LCx group at 1 week post-MI (RF 4.3%) but markedly increased by 8 weeks (RF 15.6%). In the LAI group, 
ischemic MR was even more pronounced at 1 week (RF 17.2%) with further progression by 8 weeks (RF 25.1%). 
Impact of LA remodeling and ischemic MR on pulmonary pressure  
Eight weeks after MI, LAI animals had a worse pulmonary hemodynamic profile than controls, with a trend 
toward high PA pressures and resistances (Table 3). Within the LAI group, 6 of 8 animals had a mean pulmonary 
artery pressure equal to or greater than 25 mmHg, indicating pulmonary hypertension. In 2 of these pigs, mean 
pulmonary artery pressure was severe (> 40 mmHg), and these animals had hepatic congestion secondary to heart 
failure (Supplementary Figure 4). Pulmonary artery pressure was normal in the LCx group (Table 3). 
Within the LCx and LAI groups, pulmonary artery pressure correlated better with ischemic MR severity 
(R=0.84, p<0.001) and LA enlargement (R=0.83, p<0.001) than with LV parameters such as LVEF (R=-0.58, p=0.009) 
and LVESV (R=0.47, p=0.04) (Supplementary Figure 5). 
Histology findings: post-infarction left atrial structural remodeling 
The impact of permanent LA coronary occlusion on chamber histology was evaluated in 2 additional animals 
undergoing the LAI procedure and sacrificed after CMR exam on day-7 post-MI. Compared with healthy tissue, atrial 
tissue of these animals showed extensive myocardial injury, with cardiomyocyte loss and areas of fibrosis (Figure 4, 
panels C-H), confirming the effects of atrial infarction in this model. Qualitative assessment by polarized light 
microscopy revealed immature collagen-fiber organization in these areas, indicating an early post-infarction 
reparative process in the LA myocardium. 
Histological changes at 8 weeks post-MI were evaluated in the atria of animals completing the protocol. Atria 
were harvested after the final CMR exam. The LAI group showed extensive LA enlargement (Supplementary Figure 2) 
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associated with pronounced patchy and diffuse interstitial collagen deposition (Figure 4, and Supplementary Figure 
3). Conversely, LA tissue from the LCx group was characterized by mild interstitial fibrosis with focal or no fibrotic 
areas. No pathological changes were observed in atria of LAD animals. The absence of LA remodeling was consistent 
with the absence of LA disease in the CMR studies in this group. 
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Discussion 
The present study provides insight into the determinants and consequences of LA remodeling after acute MI 
in translational large-animal (pig) models evaluated by CMR. Our main findings are as follows: 1) LA infarction as a 
complication of LCx-dependent infarction results in massive LA remodeling with extensive fibrosis during the first 
week post-MI. These anatomical LA changes are associated with markedly altered contractile and reservoir function 
and progression of ischemic MR.; 2) Ischemic MR without concomitant LA infarction is associated with early and 
progressive LA remodeling, although to a less extent than cases with associated LA infarction; 3) Post-MI LV 
dysfunction without ischemic MR or LA infarction is associated with mild and transient LA remodeling; 4) The 
combination of post-MI ischemic MR and LA infarction is associated with early onset pulmonary hypertension and 
liver congestion, hallmarks of post-MI HF. 
Atrial infarction complicating acute MI induces severe remodeling and persistent LA dysfunction 
The most prominent finding of this study is the dramatic impact of LA infarction (secondary to LA coronary 
artery occlusion) on LA chamber remodeling and the persistent impairment of LA contractile and reservoir 
physiology. These functional abnormalities reflect extensive fibrotic replacement of the atrial myocardium. The 
progressive LA chamber dilation and persistent functional impairment seen from the subacute (1 week) to chronic (8 
week) phases identifies a specific time course of atrial myopathy. To our knowledge, this is the first experimental 
evidence of the structural and functional impact of LA infarction, in both the early and late post-MI periods. In this 
regard, although diagnosis of atrial infarction remains elusive,13 autopsy reports suggest that its impact is 
significant.14 The atrial coronary circulation system is complex17 and the response of the atrial chamber to ischemia is 
not well characterized. Prior studies showed that LA coronary ischemia blunted the compensatory booster function 
during acute occlusion.18 Left atrial infarction secondary to permanent occlusion of the LA coronary artery 
(associated with proximal LCx occlusion) resulted in severe atrial fibrosis due to the replacement of extensive areas 
of cardiomyocyte loss. Collagen staining revealed an immature structure at 7 days post-MI. Conversely, at 8 weeks a 
well-organized network was observed, with both patchy and interstitial distributions. At this chronic stage, the 
remodeling of the atrial extracellular matrix was characterized by excessive collagen deposition. The net increase in 
collagen content likely contributes to this change in LA physiology. In this regard, most previous reports have 
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focused on fibrotic area or collagen content as markers of extracellular matrix changes in atrial remodeling models, 
such as chronic atrial pacing, HF,19 or volume overload.20  
Contribution of MR and LV dysfunction to post-MI atrial remodeling 
Our experimental approach did not confirm an independent contribution of isolated LV dysfunction to LA 
enlargement because LAD occlusion alone, in the absence of ischemic MR or LA infarction, produced no CMR or 
histological LA abnormalities 8 weeks after MI. However, in the absence of induced LA ischemia, mild degrees of 
ischemic MR were related to significant atrial enlargement at 7 days. Severe LV dysfunction, and not volume 
overload (mild at this stage), contributed to the larger infarct size in the LCx group (~38%, vs. 25% in the LAD group). 
In clinical studies, the severity of LV injury (measured from the degree of enlargement, infarct size, or the presence 
of diastolic function abnormalities) has been regarded as a key determinant of early post-LA dilation. While the LV is 
typically larger in patients with LA dilation, restrictive LV filling is found in less than 30% of these patients.3-5 In 
addition, moderate or severe MR is described in ~16-45% of patients with early LA dilation,3-5 suggesting that LA 
disease after MI is a complex phenomenon, with prior conditions and early acute changes both contributing to the 
remodeling process. In previous experimental models, LA remodeling was not characterized comprehensively. 
Chamber dilation was described in very large, proximal LAD infarctions after 3 months of follow up25 and in the rat 
model of post-MI HF,26 whereas most reports on ischemic MR models have focused on valve geometry rather than 
LA remodeling.8, 27-29 A limitation of our study in this regard is the absence of MR quantification in the LAD group. 
However, in our experience, MR after acute anterior MI is infrequent and usually very mild even after induction of 
proximal LAD occlusions.22  
Determinants of LA function after MI and clinical relevance 
In our study, only LCx infarctions with ischemic MR (with or without associated LA infarction) were 
associated with LA enlargement. Conversely, all 3 groups, including the LAD infarction group, showed a deterioration 
in LA phasic function after acute MI. However, these changes were severe and permanent only in LCx MI 
complicated with LA infarction. In the LCx group (with ischemic MR but without LA infarction) and the LAD group, 
these functional changes were milder and even reversible in some cases. Some clinical studies reported that 
abnormal LA function post-MI is an independent prognostic marker7, 21-22; however, a recent report suggests that LA 
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reservoir (peak atrial longitudinal strain) is dependent on LA size and LV longitudinal strain.23 In this regard, our atrial 
infarction model presents a specific situation, severe fibrosis, in which reservoir function is mostly dependent on the 
contractile performance of the atria but not the LV. 
Translational impact  
The present study provides evidence of the effects of atrial infarction complicating an acute MI on the LA 
remodeling process. This direct injury mechanism joins the list of other mechanisms known to contribute to atrial 
remodeling: volume or pressure overload (mitral valve disease), neurohormonal activation (chronic HF), electrical 
disturbances (atrial fibrillation-induced remodeling), and inflammation30. An important finding of the present study is 
the impact of mild-to-moderate ischemic MR on the development of pulmonary hypertension. This effect is related 
to the presence of severe LA remodeling, highlighting the need to evaluate both parameters in the clinical setting. 
In addition to impairing LA function and cardiac performance, the infarct-related structural remodeling is 
likely to deleteriously affect LA electrical activity. In this regard, recent data suggest that atrial coronary occlusion is a 
relatively frequent complication of percutaneous stenting (~15%), and entails a markedly elevated risk of atrial 
arrhythmias.13 This confirms previous experimental observations that link acute LA ischemia to a greater arrhythmia 
vulnerability than seen with other stimuli occurring during acute MI, such as atrial stretch or neurhormonal 
activation.11-12, 31 Patient atrial tissue is infrequently available after acute MI, underscoring the value of experimental 
studies; however, advances in cardiac imaging provide new bedside tools for evaluating patients after MI. 
Remodeling of the LA is now considered an important feature and a potential therapeutic target. The present study 
provides important information for understanding LA remodeling, revealing the consequences of atrial ischemia and 
ischemic MR on cardiac performance and fibrotic substrate. Early identification and close monitoring of these 
features may provide new therapeutic opportunities in patients at high risk of developing HF and atrial arrhythmias 
after MI. In addition, a potential advantage of atrial ischemia modeling is the ability to detect rapid development of 
extensive fibrotic atrial cardiomyopathy (in the absence of chronic atrial fibrillation), not possible with atrial pacing 
models,32 providing a new preclinical tool for understanding LA remodeling.33 
Limitations 
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Our results are limited to the specific modeling conditions presented, and by the small sample size. As 
discussed above, ischemic MR and atrial ischemia are clinically relevant scenarios but do not represent the whole 
clinical spectrum; our findings should thus be interpreted accordingly. The LCx occlusion induced to model atrial 
ischemia also entailed severe LV remodeling and ischemic MR, limiting our ability to isolate the contribution of each 
component. The comparison of different animal models provided a more comprehensive description of the LA 
remodelling process, but at the cost of a loss of statistical power after post-hoc adjustments in some comparisons.  
Conclusions 
The current study provides the first experimental evidence of the impact of LA ischemia after acute MI. In 
addition to acute chamber enlargement, other hallmarks are severe and persistent atrial function impairment, with a 
slight recovery after 1 week. Furthermore, this study reveals an interplay between ischemic MR and LA remodeling 
that should be taken into account during clinical assessment. These models may provide new tools for exploring 
structural remodeling of the LA. 
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Figure Legends. 
Figure 1. Study design and experimental procedures. (A) Two porcine models of ischemic MR were created 
by chronic occlusion of the left circumflex artery: 1, No additional vessel occlusion (LCx); 2, Additional occlusion of 
the main left atrial branch to induce LA Infarction (LAI). 3, A third model of MI was generated with no ischemic MR 
by LAD occlusion. (B, C) Typical segmental scar distributions. (D) Timeline of imaging and histology evaluation. 
Figure 2. Left atrial remodeling after MI. (A) Maximum LA size at 1 and 8 weeks post MI for each group (see 
Figure 1), indicating progressive LA dilation in the LAI and LCx groups, most pronounced in the former. Controls are 
non-infarcted pigs. (B-G) Representative end-systolic frames from 3-chamber views; MI group and time point are 
indicated in each image.  
Figure 3. Changes in left atrial reservoir function after MI. (A) LA reservoir at 1 and 8 weeks post MI, 
indicating early (1 week) impairment in all AMI groups, the most severe and persistent (at 8 weeks) corresponding to 
the LAI group (B) Representative -chamber planimetry images at 8 weeks post MI. Maximum area is delineated by 
solid contours, and minimum area by red-shading and dashed contours. 
Figure 4. Histology of LA remodeling. (A) Representative atrial tissue of an LAI pig at 1 week post MI. (B) 
Endocardium (top) and endocardium in atrial tissue of an LAI pig at 1 week post MI. (C-H) Histological sections of 
atria from Control and LAI pigs at 1 week post-MI, showing evidence of marked cardiomyocyte loss (E) with extensive 
fibrosis (F-H). (I-L) Histological sections of atria from the 3 MI at 8 weeks, showing evidence of interstitial fibrosis in 
the LCx group (J) and severely fibrotic replacement in the LAI group (K), contrasting with the Control and LAD groups 
(I,L). Scale bars, 1 mm (top row); 200 µm (bottom row). Stainings: Picrosirius Red in brightfield (B, D, F-G) and 
polarized light microscopy (H); Hematoxylin-eosin (C and E); Masson’s trichrome (I-L).  
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Table 1. Left atrial remodeling CMR parameters: time course by group 
 
Control (n=4) LCx (n=7) LAI (n=8) LAD (n=18) 
 
Baseline 8 weeks 1 week 8 weeks 1 week 8 weeks 1 week 8 weeks 
Maximal area, cm2 
13.1 
(12.7-
13.3) 
18.8 
(18.2-
19.6) 
19.5 (18.6-
20.9)* ‡ 
25. (22-
27) ‡ 
22.6 (20.3-
23.8)* ‡ 
32.6 (27.2-
38.9)* † ‡ 
13.2 
(12.4-
14.5) 
16.2 
(14.8-
18.2) 
Maximal indexed 
area, cm2/m2 
15.7 
(15.2-
16.3) 
15.3 
(14.8-
15.9) 
19.9 (19.0-
22.3) * ‡ 
17.0 
(16.6-
19.1) ‡ 
22.5 (21.4-
23.2)* ‡ 
25.1 (19.3-
30.0)* † ‡ 
15.4 
(13.4-
16.4) 
14.3 
(12.8-
15.0) 
Minimum area, 
cm2 
8.0 (7.7-
8.4) 
11.4 
(11.1-
11.9) 
15.0 (14.3-
15.9) * ‡ 
17.0 
(16.2-
20.4) 
18.9 (17.5-
20.7) *† ‡ 
27.3 (22.2-
32.8) * † ‡ 
9.7 (8.9-
10.7) 
11.6 (9.7-
13.4) 
Minimum indexed 
area, cm2/m2 
9.6 (9.1-
10.2) 
9.2 (9.0-
9.7) 
15.5 (14.5-
17.2) * ‡ 
13.4 
(10.9-
14.4) 
19.2 (17.8-
20.6) *† ‡ 
19.8 (15.2-
27.7) * † ‡ 
10.9 
(10.3-
11.5) 
9.6 (8.7-
10.8) 
Reservoir function, 
% 
38.2 
(36.4-
39.2) 
38.3 
(37.4-
38.8) 
24.1 (19.9-
28.7)* ‡ 
26.4 
(21.7-
29.9) 
13.8 (11.2-
17.7)* † 
16.5 (9.7-
22.5) * ‡ 
27.1 
(24.2-
30.8)* 
28.6 
(25.1-
31.6) 
Conduit function, % 
15.0 
(14.9-
15.2) 
19.8 
(17.7-
22.8) 
10.2 (7.1-
14.4) 
11.7 (8.1-
14.9)* 
7.7 (6.2-9.7) 
8.7 (6.5-
10.7)* 
8.1 (5.6-
12.3)* 
9.6 (6.9-
13.7)* 
Booster function, % 
27.2 
(25.2-
28.6) 
22.7 
(20.3-
24.1) 
15.9 (13.9-
18.6)* 
18.5 
(15.8-
19.6) 
4.4 (2.4-
9.9)*†‡ 
8.1 (5.6-
15.4)* ‡ 
21.4 
(16.3-
22.9) 
21.2 
(19.7-
24.6) 
Data expressed in median (interquartile range). Pairwise comparisons at each timepoint: *p<0.05 
vs Control; †p<0.05 vs LCx; ‡ p<0.05 vs LAD.  
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Table 2. Time course of LV remodeling and MR parameters by study group 
 
Control (n=4) LCx (n=7) LAI (n=8) LAD (n=18) 
 
Baseline 8 weeks 1 week 8 weeks 1 week 8 weeks 1 week 8 weeks 
Body weight, kg 
29 (29-
29.4) 
55.3 
(53.5-
57.1) 
37 (35-
40)* 
70 (67.3-
73.5)* 
39 (34.8-
43)* ‡ 
62 (59.8-
71) 
34.3 (30.4-
37.4) 
54 (45.8-
55.8) 
Left ventricle 
        
Infarct size, % of 
LV mass 
0 0 
37.8 (27.2-
39.9)* 
18.0 (14.1-
18.9)* ‡ 
37.2 (33.2-
40.5)* 
23.0 (16.7-
27.9)* 
27.0 (23.9-
36.4)* 
23.8 (22.1-
31.3)* 
EDV, ml 
 
92.7 
(86.9-
98.8) 
118.1 
(112.5-
125.5) 
132.1 
(121.9-
142.1)* 
242.5 
(180.6-
246)* 
135.2 
(121.1-
141.8)* 
202.9 
(190.5-
220.4)* 
121.8 
(112.0-
133.9)* 
173.1 
(151.7-
201.1)* 
Indexed EDV, 
ml/m2 
111.7 
(103.8-
120.9) 
96.6 (94-
100) 
137.3 
(130.1-
147.8) 
161.5 
(138.3-
172.5)* 
139.9 
(129.8-
143.2) 
149.5 
(145.4-
154.4)* 
134.6 
(130.6-
142.1)* 
151.4 
(129.6-
165.3)* 
ESV, ml 
 
47.2 
(43.3-
50.4) 
40.9 
(38.3-
43.5) 
84.5 (69.3-
91.5)* 
121.4 
(101.2-
147.5)* 
87.1 (75.4-
90.6)* 
128.0 
(116.1-
144.1)* 
77.1 (66.3-
85.4)* 
119.0 
(95.9-
138.8)* 
Indexed ESV, 
ml/m2 
56.9 
(51.7-
61.6) 
33.1 (32-
34.5) 
90.1 (78.1-
95.2)* 
86.2 (76.7-
101.7)* 
88.2 (80.2-
93.1)* 
92.6 (87.9-
101.3)* 
86.1 (78.7-
94.2)* 
103.4 
(85.9-
116.6)* 
LVEF, % 
50.1 
(49.4-
50.8) 
66.4 
(64.0-
68.1) 
35.0 (34.6-
38.1)* 
47.3 (36.0-
49.0)* ‡ 
36.7 (35.7-
37.3)* 
36.6 (33.0-
40.1)* 
36.4 (35.1-
39.1)* 
30.3 (28.1-
33.7)* 
Mitral 
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regurgitation 
Regurgitant 
volume, ml 
0.74 ([-
1.4]-2.6) 
1.2 ([-
0.4]-2.1) 
2.1 (1.9-
4.0) 
13.2 (8.7-
16.6) 
7.4 (5.8-
11.1) 
17.8 (15.5-
27.2) 
NA NA 
Indexed 
regurgitant 
volume, ml/m2 
0.9 ([-
1.7]-3.4) 
0.9([-0.3]-
1.6) 
2.2 (2-3.9) 
9.6 (6.4-
11.3) 
7.5 (5.8-
10.7) 
13.8 (12.0-
18.9) 
NA NA 
Regurgitant 
fraction, % 
1.4 ([-
3.3]-5.5) 
1.4([-0.8]-
2.4) 
4.3 (3.5-
7.9) 
15.6 (11.5-
16.8) 
17.2 (11.4-
21.1) 
25.1 (23.0-
36.3) 
NA NA 
Abbreviations: LV, left ventricle; EDV, end-diastolic volume; ESV, end-systolic volume; LVEF, LV 
ejection fraction; NA, not applicable. 
Data expressed in median (interquartile range). Pairwise comparisons at each timepoint*p<0.05 
vs Control; †p<0.05 vs LCx; ‡ p<0.05 vs LAD.   
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Table 3. Hemodynamic data 8 weeks after MI 
 
Control (n=4) LCx (n=7) LAI (n=8) 
Heart rate, bpm 51 (46-57) 58 (48-71) 75 (57-85) 
PA wedge pressure, mmHg 4 (4-5) 9 (8-10) 14 (10-17)*† 
Mean PA pressure, mmHg 16 (15-16) 18 (16-20) 27 (24-34)*† 
Mean RA pressure, mmHg 4 (3-4) 4 (3-4) 5 (3-6) 
Cardiac output, l/min 4.1 (3.6-4.6) 5.4 (3.9-5.4) 4 (2.9-4.3) 
Cardiac index, l/min*m2 3.1 (2.7-3.4) 3.6 (2.8-3.9) 3.1 (2.2-3.3) 
Pulmonary vascular resistance, WU 2.6 (2.3-3.1) 2.2 (2-2.2) 3.8 (2.8-5.5)† 
Pulmonary vascular resistance, WU*m2 3.6 (3.2-4.1) 3.1 (2.9-3.3) 5.2 (3.6-7.3)† 
Abbreviations: PA, pulmonary artery; WU, Wood units.  
Data expressed in median (interquartile range). Pairwise comparisons: *p<0.05 vs Control; 
†p<0.05 vs LCx 
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Supplementary Methods. 
Experimental procedures 
The study was approved by the local institutional animal research committee and conducted in accordance 
with the National Research Council Guide for the Care and Use of Laboratory Animals. Anesthesia was induced with 
intramuscular ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam (0.5 mg/kg) and maintained by continuous 
intravenous infusion of ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), and midazolam (0.2 mg/kg/h). Mechanical 
ventilation was adjusted to 30% oxygen, 8-10 ml/kg tidal volume at 15 respirations per minute. Arterial and venous 
femoral access was achieved by the Seldinger technique. During acute MI induction, an unfractioned heparin iv bolus 
was administered (300 mg/kg) at the beginning of the procedure, and amiodarone was continuously infused (300 
mg/h). After the procedure, femoral sheaths were removed and the animals were allowed to recover. At the final 
time point of each study, animals were sacrificed with pentobarbital sodium and hearts were removed and 
processed for histological analysis. 
Ischemic MR model  
To establish a porcine model of ischemic MR, we evaluated the main factors contributing to the structural LV 
substrate that underlies changes in mitral-valve geometry. Most animal models have focused on LCx coronary artery 
infarction induced by surgical or percutaneous approaches, the most common being ligation of 2 oblique marginal 
branches in the sheep.29 To select the most effective model of ischemic MR, we first compared angioplasty-balloon-
induced ischemia/reperfusion with permanent occlusion induced by deployment of a percutaneous coronary coil. 
Both approaches produced similar-sized infarcts, but only permanent coronary occlusion produced the typical local 
remodeling causing ischemic MR during the observation period (Supplementary Figure 1). Second, given the variable 
LCx artery anatomy in the pig, we evaluated the influence of LCx size on the development of ischemic MR 
(Supplementary Figure 1). Only moderate-to-large LCx proximal occlusions consistently produced the typical features 
of ischemic MR and were included in the final analyses. In ~10% of animals, the LCx was too small to create the 
ischemic MR model with a high probability of success. In all animals included in the study, baseline echocardiograms 
showed no more than a trace degree of MR before model creation. 
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The data for the LAD ischemic/reperfusion group were obtained from 18 animals included in a previous, 
unpublished study in our laboratory. For the descriptive purposes of the present study, we minimized the number of 
animals needed to evaluate our hypothesis. For this reason, while the main remodeling endpoints were available for 
all animals in the LAD group (n=18), histological data were available only from a smaller but representative subset 
(n=5). 
The coiling procedure in the proximal LCx was feasible in most animals. Mortality was 28.6% (6/21 animals), 
and most deaths occurred during the first 2 weeks. In total, 2 animals died due to intraprocedural refractory 
ventricular fibrillation. 
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Supplementary Figures. 
Supplementary Figure 1. Comparison of left circumflex artery infarction by proximal LCx 
ischemia/reperfusion (B) and LCx coil occlusion (C). Images show end-systolic frames of the 3 chamber view. LCx coil 
occlusion was a superior model of chronic ischemic MR than proximal LCx ischemia/reperfusion, which evidenced 
minimal or no MR in pilot experiments. In addition, if the LCx was small (C), development of MR was mild in the 
dominant marginal branch, mid LCx, or even proximal LCx.  
Supplementary Figure 2. Post-MI LA remodelling at 8 weeks post MI. (A) Control heart. (B) LAI heart 
(characterized by ischemic MR), showing LA enlargement. (C) LAD heart, showing no LA enlargement. (D,E) Excised 
LA from a control animal (D) and an LAI animal (E), showing marked dilation and fibrosis after LA infarction and 
ischemic MR.  
Supplementary Figure 3. Representative histological sections showing the LA fibrosis pattern in animals 
developing ischemic MR in the absence of LA infarction (LCx group, left panel) and and in its presence (LAI group, 
center and right panels). Picrosirius red staining (left and center panels) and Masson’s trichrome staining illustrate 
the extent of fibrosis in different animals from each group, supporting the consistency of the models. Scale bars, 1 
mm. Picrosirius red and Masson’s trichrome staining are shown for the same samples in F and J and in H and L. 
Supplementary Figure 4. Representative Masson’s-trichrome-stained liver sections from a control animal (A) 
and from an animal from the LAI group exhibiting pulmonary hypertension 8 weeks after LCx occlusion (B). Scale 
bars, 1 mm.  
Supplementary Figure 5. Linear correlations between mean pulmonary artery pressure measured by right 
heart catheterization and cardiac imaging parameters at 8 weeks post-MI, including only the LCx and LAI groups. (A) 
Regurgitant fraction. (B) LA maximum area. (C) LA reservoir function. (D) LV ejection fraction. (E) LV end-systolic 
volume. (F) Table summarizing Pearson correlation coefficients and statistical significance for two-sided test.  These 
results indicate a greater linear association between LA remodelling parameters and ischemic MR severity (by 
regurgitant fraction) with pulmonary artery pressures. 
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Parte 3. Desarrollo de nuevas terapias experimentales en hipertensión 
pulmonar. 
Introducción a los artículos 5 y 6. 
Se trata de un trabajo de investigación aplicada en el ámbito preclínico. Tomando 
como modelo el descrito y caracterizado en el artículo 1 (Parte 1 de la presente Tesis 
Doctoral), se puso a prueba una nueva estrategia terapéutica basada en resultados previos 
del grupo de investigación en un modelo de roedor. La terapia a estudio es un virus adeno-
asociado recombinante como vector de expresión de SERCA2a, un enzima implicado en la 
homeostasis del calcio en el retículo sarcoplasmico.  
En este estudio, así como en la revisión metodológica posterior, fui responsable 
principal del proyecto y mi aportación personal fue necesaria en cada una de las etapas del 
mismo: diseño, generación de modelos animales, todos los procedimientos experimentales, 
así como la recogida y análisis de los datos y escritura de manuscritos. En este estudio, 
también tuve una participación parcial en la generación de vectores virales y realización de 
protocolos para detección de inmunidad humoral (anticuerpos neutralizantes) antes de la 
administración de la terapia. Como se indica en el artículo 6, uno de los principales aspectos 
técnicos previos al desarrollo del estudio de intervención terapéutica fue la puesta a punto 
del método de administración de vectores virales por vía aérea en el modelo de animal 
grande, para lo cual nos basamos en la metodología en el modelo de roedor.  
La Figura 4 (incluida en el propio artículo 5 como Ilustración central y síntesis del 
trabajo) resume el diseño y conclusiones de esta parte. 
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Figura 4 (Resumen Parte 3, Desarrollo de nuevas terapias experimentales en 
hipertensión pulmonar). En el modelo de HTP crónica se observan cambios en el 
remodelado vascular pulmonar. La terapia génica es capaz de enlentecer la progresión de 
la enfermedad y el desarrollo de disfunción ventricular derecha. 
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Intratracheal Gene Delivery of SERCA2a
Ameliorates Chronic Post-Capillary
Pulmonary Hypertension
A Large Animal Model
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ABSTRACT
BACKGROUND Pulmonary hypertension (PH) is characterized by pulmonary arterial remodeling that results in
increased pulmonary vascular resistance, right ventricular (RV) failure, and premature death. Down-regulation of
sarcoplasmic reticulum Ca2þ-ATPase 2a (SERCA2a) in the pulmonary vasculature leads to perturbations in calcium ion
(Ca2þ) homeostasis and transition of pulmonary artery smooth muscle cells to a proliferative phenotype.
OBJECTIVES We assessed the feasibility of sustained pulmonary vascular SERCA2a gene expression using aerosolized
delivery of adeno-associated virus type 1 (AAV1) in a large animal model of chronic PH and evaluated the efﬁcacy of gene
transfer regarding progression of pulmonary vascular and RV remodeling.
METHODS A model of chronic post-capillary PH was created in Yorkshire swine by partial pulmonary vein banding.
Development of chronic PH was conﬁrmed hemodynamically, and animals were randomized to intratracheal adminis-
tration of aerosolized AAV1 carrying the human SERCA2a gene (n ¼ 10, AAV1.SERCA2a group) or saline (n ¼ 10). Ther-
apeutic efﬁcacy was evaluated 2 months after gene delivery.
RESULTS Transduction efﬁcacy after intratracheal delivery of AAV1 was conﬁrmed by b-galactosidase detection in the
distal pulmonary vasculature. Treatment with aerosolized AAV1.SERCA2a prevented disease progression as evaluated by
mean pulmonary artery pressure, vascular resistance, and limited vascular remodeling quantiﬁed by histology. Thera-
peutic efﬁcacy was supported further by the preservation of RV ejection fraction (p ¼ 0.014) and improvement of the RV
end-diastolic pressure–volume relationship in PH pigs treated with aerosolized AAV1.SERCA2a.
CONCLUSIONS Airway-based delivery of AAV vectors to the pulmonary arteries was feasible, efﬁcient, and safe in
a clinically relevant chronic PH model. Vascular SERCA2a overexpression resulted in beneﬁcial effects on pulmonary
arterial remodeling, with attendant improvements in pulmonary hemodynamics and RV performance, and might
offer therapeutic beneﬁt by modifying fundamental pathophysiology in pulmonary vascular diseases.
(J Am Coll Cardiol 2016;67:2032–46) © 2016 by the American College of Cardiology Foundation.
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P ulmonary hypertension (PH) is a group of pul-monary endovascular diseases with hemody-namic consequences for right ventricular (RV)
function that portends a poor clinical prognosis.
Although the current classiﬁcation system for PH
segregates patients on the basis of clinical and patho-
logical features, all forms of PH are associated
with some degree of aberrant pulmonary vascular
remodeling (1). Current pharmacotherapies for PH do
not target pulmonary vascular remodeling directly
but rather aim to promote pulmonary artery vasodila-
tion and reduce RV afterload as adverse outcomes
are driven mainly by the onset of RV failure (2,3).
Epidemiological studies indicate that PH associ-
ated with increased pulmonary venous pressure and
left heart failure (HF) is the most common cause of
chronic PH (4). Furthermore, more than one-half of
all patients with HF may develop chronic PH, leading
to even more adverse cardiac events (5). Similar to
pulmonary arterial hypertension (PAH) (Group 1 PH),
left heart disease–related PH (Group 2 PH) has been
associated with impaired pulmonary vascular reac-
tivity, endothelial dysfunction, and excessive arteri-
olar muscularization, indicating that pre-capillary
pulmonary vascular remodeling is present concomi-
tant with post-capillary disease (6). Despite this,
therapeutics that are effective in PAH are either not
effective, have not been tested, or may be contra-
indicated in patients with left HF and PH (1).
Currently available pharmacotherapies were devel-
oped to ameliorate disease symptomatology by tar-
geting 1 of 3 main signaling pathways found to be
deﬁcient or activated in PH (7). Although several
available compounds have shown beneﬁt in Group 1
PH in randomized clinical trials, unresolved issues
remain. These include: 1) few studies in patients with
Group 2 PH; 2) a lack of evidence of long-term clinical
efﬁcacy; 3) uncertainty regarding the effects of drugs
on limiting or reversing vascular remodeling in the
presence of established disease; 4) the risk of serious
adverse effects that limit dose escalation within or
between class combination therapy; and 5) the high
cost of long-term treatments. Thus, novel approaches
are needed.
Gene therapy has evolved over the past several de-
cades due to advances in vector technology and
delivery methodologies. In a wide range of
chronic disorders, including cardiovascular
disease (8,9), efﬁcient gene transfer has been
achieved by newly designed recombinant
adeno-associated virus (AAV) vectors. Several
experimental studies have reported success-
ful modulation of PH signaling pathways in a
speciﬁc and efﬁcient manner using gene ther-
apy (10). Proof-of-concept studies in rodent
PH models have demonstrated the feasibility
of gene transfer of molecules related to cu-
rrently available pharmacotherapies, such as
the endothelial isoform of nitric oxide syn-
thase (eNOS) (11) or prostacyclin synthase (12),
that hold promise for treating PH in humans.
Abnormal calcium homeostasis in smooth muscle
cells (SMCs) contributes to PH pathobiology (13).
Chronically increased intracellular calcium levels in
pulmonary artery SMCs trigger signaling pathways
that are permissive for cellular proliferation, migra-
tion, and dedifferentiation, all of which contribute
to hypertrophic vascular remodeling (13). Our group
has reported previously that sarcoplasmic reticulum
Ca2þ-ATPase pump 2a (SERCA2a) is a key modulator
of calcium cycling in both cardiomyocytes and
vascular SMCs (14). We recently demonstrated that
pulmonary arterial SERCA2a expression is down-
regulated in the rat monocrotaline model of PH as
well as in humans with PAH. Furthermore, we
demonstrated in the rat model that selective pul-
monary vascular gene transfer of SERCA2a using
AAV1 was feasible, ameliorated arterial remodeling,
and improved hemodynamic abnormalities and RV
function (15).
Despite the evidence that gene therapy targeting
SERCA2a has merit, a major hurdle in the translation
of novel therapeutics to the clinic is the limited
availability of large animal models of PH that reca-
pitulate human disease. Most pre-clinical drug
development studies evaluate interventions in ro-
dent models of PH (16), yet there are marked differ-
ences between rodent models and human anatomy
and physiology (17). Accessible large animal models
of chronic PH allow for a more relevant approach
to evaluate novel interventions prior to human clin-
ical trials, as they offer similar dosing therapeutic
schemes, human-sized delivery tools, and state-
of-the-art diagnostic protocols to assess critical
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endpoints such as pulmonary hemodynamics and RV
structure and function (18,19). Validating the results
of rodent studies in large animal models of chronic
PH therefore increases the likelihood of success in
drug development at the pre-clinical stage (17).
The objectives of this study were to assess the
feasibility of sustained pulmonary vascular SERCA2a
gene transfer in a large animal model of chronic post-
capillary PH and to evaluate the efﬁcacy of gene
transfer on the progression of pulmonary vascular
and RV remodeling. On the basis of the encouraging
results in a number of studies (12,20,21), including our
own proof-of-concept study in a rodent model of
PH (15), we tested a novel aerosol inhalation gene
delivery strategy to minimize off-target transgene
expression and increase safety.
METHODS
The study was performed in accordance with the
Guidelines for the Care and Use of Laboratory Ani-
mals, with approval granted by the Icahn School of
Medicine at Mount Sinai Institutional Animal Care
and Use Committee. Results are reported following
the ARRIVE (Animal Research: Reporting of In Vivo
Experiments) guidelines. Detailed methodology is
available in the Online Appendix.
STUDY DESIGN. The study was designed to evaluate
the therapeutic effects of SERCA2a gene transfer to
the pulmonary vasculature using a novel aerosolized
inhalation gene delivery strategy in a large animal
model of chronic PH. Speciﬁcally, a swine model of
chronic post-capillary PH was created surgically by
partial banding of the pulmonary venous drainage, as
reported previously by our group (18). The model
produced a predictable and sustained rise in pulmo-
nary artery (PA) pressures and RV dysfunction. Two
months after the banding procedure, animals with
established PH were randomized to airway-based
AAV1.SERCA2a gene transfer (n ¼ 10) or saline
administration (n ¼ 10) and followed for an additional
2 months until the end of the study. A sham-operated
group (n ¼ 4) was included as a control for the PH
model. The main efﬁcacy endpoints for the study
were invasive cardiopulmonary hemodynamic pa-
rameters and RV performance indexes (Figure 1).
Human recombinant AAV1.SERCA2a and AAV1.LacZ
for transduction efﬁciency studies were produced as
described previously (22). The high prevalence of pre-
existing or post-exposure neutralizing antibodies is
a major hurdle for AAV-based gene therapies in both
animal (23) and human studies (24). We therefore
quantiﬁed neutralizing antibody titers against the
AAV1 serotype before and after airway delivery of the
FIGURE 1 Study Design and Timeline
Experimental procedure
Surgical PH model creation or Sham
Baseline PH and RV measurements
Randomization
Sham (n=4)
Final PH and RV measurements
Necropsy, tissue harvest
Chronic PH functional
assessment:
Day 0
2 months
4 months
AAV1.SERCA2a group (n=10)
Saline group (n=10) Right heart catheterization
Cardiac MRI
RV Pressure-volume loops
Timepoint
The chronic pulmonary hypertension (PH) model was created surgically by selective banding of pulmonary veins in 10- to 15-kg piglets. Two
months later, animalswere randomized to aerosolized airway delivery of either recombinant adeno-associated virus serotype 1 carrying the human
SERCA2a transgene (AAV1.SERCA2a) or saline. Changes in cardiopulmonary hemodynamics, right ventricular (RV) structure, and RV function were
evaluated 2 months after randomization to treatment. Sham-operated animals (n ¼ 4) served as controls. MRI ¼magnetic resonance imaging.
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AAV1 vector using a standardized protocol available in
our laboratory (25).
Animals were anesthetized with isoﬂurane 1% to
2%. AAV1.SERCA2a (1  1013 vg) or saline aerosol de-
livery was performed using the MicroSprayer Aero-
solizer (Model IA-1B, Penn-Century, Inc., Wyndmoor,
Pennsylvania). This aerosolizer produces particles of
w20 mm; airway delivery of AAVs using this system
has been shown to be effective in other large animal
models (26). Using ﬂuoroscopic guidance, the aerosol
needle was inserted in the airway through the endo-
tracheal tube using a 7-F multipurpose coronary
diagnostic catheter with the tip of the catheter posi-
tioned near the carina (Online Figures 1A and 1B). The
total dose of AAV1.SERCA2a was diluted into 6 ml of
sterile saline and aerosolized in 2 ml doses with the
animal in the dorsal, right, and left lateral recumbent
positions. After virus delivery was completed, the
animal was mechanically ventilated for an additional
20 to 30 min with continuous monitoring of the
electrocardiogram, hemodynamics, and respiratory
parameters. After this time, the animal was recovered
fully from the procedure.
Before randomization to the treatment groups, all
animals underwent right heart catheterization to
measure cardiopulmonary pressures for RV pressure-
volume analysis.
At 2 months (baseline) and 4 months (ﬁnal), cardiac
magnetic resonance (CMR) imaging studies were
performed with a 3.0-T magnet to examine changes in
RV and left ventricular (LV) structure and function.
HISTOLOGY. After the animals were euthanized, the
RV and LV were sectioned and weighed, and RV hy-
pertrophy was assessed by the following ratio:
RV/(LV þ septum). Heart and lung tissue samples
were placed in 10% neutral buffered formalin solution
and were subsequently ﬁxed, processed, embedded
in parafﬁn, and sectioned into 5-mm–thick sections for
histology and morphometry analyses.
Protein quantiﬁcation of SERCA2a was performed
in lung and RV tissue homogenates and standardized
using b-actin as described previously (15). Immuno-
staining was performed on acetone-ﬁxed lung sec-
tions as reported previously (15), using primary
antibodies as described in the Online Appendix.
STATISTICAL ANALYSIS. Continuous variables are
expressed as median with interquartile range (IQR)
unless otherwise speciﬁed. The invasive cardiopul-
monary hemodynamic parameters and invasive RV
performance indexes are reported as the mean
change estimate with 95% conﬁdence intervals (CIs)
for each group. The study groups were compared at
the time of randomization (baseline) using 1-way
analysis of variance (with post hoc comparisons be-
tween groups performed using the Holm-Bonferroni
method or Dunnett’s multiple comparisons method),
and change over time was evaluated by the group 
time interaction of the repeated measures analysis of
variance model. A p value <0.05 was considered
statistically signiﬁcant for all comparisons.
RESULTS
Two months after the model was created, PH was
conﬁrmed hemodynamically by invasive right heart
catheterization prior to the delivery of aerosolized
AAV1.SERCA2a or saline; this time point was consid-
ered the baseline for future studies that evaluated the
effectiveness of gene transfer. After an additional
2 months following aerosol inhalation delivery of the
randomized treatment, a ﬁnal assessment of cardio-
pulmonary hemodynamics, vascular remodeling, and
RV structure and function was performed (Figure 1).
In a pre-dosing study that established the time
course of hemodynamic compromise in the swine
chronic PH model, we found that the onset of RV fail-
ure was associated with rapid disease progression and
early death. Thus, to ensure that we would have suf-
ﬁcient power to examine the effects of AAV1.SERCA2a
gene transfer on pulmonary vascular and RV end-
points, we excluded from randomization those ani-
mals found to have amean PA pressure>45mmHg or a
low cardiac index (<2.5 l/m2) at right heart catheteri-
zation, as these measures were associated with RV
failure and early death (Online Table 1). At baseline
(once the PH was conﬁrmed), compared with sham
control subjects (n ¼ 4), we documented a signiﬁcant
increase inmean PA pressure in PH pigs randomized to
saline (n ¼ 10) and AAV1.SERCA2a (n ¼ 10) (median
17 mm Hg [IQR: 15 to 18 mm Hg] vs. 26 mm Hg [IQR: 23
to 30 mm Hg] vs. 23 mm Hg [19 to 28 mm Hg], respec-
tively; p ¼ 0.004). There were no signiﬁcant between-
group differences with respect to body weight,
pulmonary arterywedge pressure (PAWP),mean aortic
pressure, or heart rate. Cardiac index was increased
in PH pigs compared with sham control subjects
(p¼0.004), which is a recognized feature of thismodel
that has been described previously (18,27) (Table 1).
After randomization, 3 animals died during the
2-month treatment follow-up period (2 in the saline
group and 1 in the AAV1.SERCA2a group). In all 3
deaths, there were no complications that occurred
during or after the airway inhalation gene therapy
delivery procedure. The deaths occurred more than
1 month after randomization and were not attribut-
able to the intervention. At necropsy, there was no
evidence of lung inﬁltrates or infection; however, all
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3 animals had evidence of severe right HF, including
hepatomegaly and ascites, implicating this as the
primary cause of death. From these nonsurvivors, the
only available outcome measurement was RV weight
obtained at the time of heart explantation and is re-
ported in Online Table 1. One animal (AAV1.SERCA2a
group) that survived to the ﬁnal time point had clear
evidence of pneumonia with respiratory insufﬁciency
and failure to thrive; this animal was excluded from
the analyses (Online Table 1). Of the remaining ani-
mals that completed the study, no signs of pulmo-
nary infection or congestion were identiﬁed at
necropsy. In all cases, aerosol inhalation delivery of
either AAV1.SERCA2a or saline was well tolerated
and did not result in respiratory or hemodynamic
instability.
SERCA2a GENE TRANSFER AND CARDIOPULMONARY
HEMODYNAMICS. First, transduction efﬁciency of the
AAV1 vector was examined using airway delivery of
AAV1.LacZ. Examination of lung tissue sections
stained for b-galactosidase demonstrated abundant
transduction of the distal pulmonary airways and
vessels (Online Figure 2). Further evaluation of the
main PAs and vessels in the RV and LV revealed that
these vessels were not transduced, indicating that
aerosolized inhalation of AAV1.SERCA2a delivered
the transgene to the target vasculature effectively
and that there was no unanticipated gene transfer to
cardiac vessels or other nontarget organs (Online
Figures 3 and 4). Thus, the observed cardiopulmo-
nary hemodynamic effects of treatment with aero-
solized AAV1.SERCA2a are due to transduction of the
distal pulmonary vessels and effects on pulmonary
vascular remodeling as opposed to targeting the RV.
At the end of the study, 8 animals from the
AAV1.SERCA2a-treated group and 8 animals from the
saline-treated group were available for analysis.
Although mean PA pressures in the sham control
subjects did not change during the study, the increase
in mean PA pressure was signiﬁcantly larger in PH pigs
randomized to saline compared with AAV1.SERCA2a
(median 54mmHg [IQR: 43 to 63 mmHg] vs. 29mmHg
[IQR: 26 to 31 mm Hg]; p < 0.05) (Figures 2A and 2B).
Compared with baseline, mean PA pressure continued
to increase in PH pigs randomized to saline (median
26 mmHg [IQR: 23 to 30 mmHg] vs. 54 mmHg [IQR: 43
to 63 mm Hg]; paired Student t test p ¼ 0.005); how-
ever, compared with baseline, disease progression
was limited in the AAV1.SERCA2a PH pigs (median
23 mm Hg [IQR: 19 to 28 mm Hg] vs. 29 mm Hg [IQR: 26
to 31 mm Hg]; paired Student t test p ¼ 0.064) (Table 1,
Figures 2A and 2B). Corresponding to the observed
changes in PA pressure, indexed pulmonary vascular
resistance (PVR) was increased signiﬁcantly in the
saline-treated group but not in animals receiving
AAV1.SERCA2a (median 10.3 Wood U/m2 [IQR: 5.1 to
12.2 Wood U/m2] vs. 3.17 Wood U/m2 [IQR: 1.8 to 4.0
Wood U/m2]; p < 0.05) (Figures 2C and 2D), suggesting
that treatment with AAV1.SERCA2a had a beneﬁcial
effect on pulmonary vascular remodeling. There was a
parallel increase in the diastolic pulmonary gradient in
the saline group (median 5mmHg [IQR:1 to 8mmHg]
to 22 mm Hg [IQR: 10 to 26 mm Hg]; p < 0.05) that
was not present in AAV1.SERCA2a-treated animals
TABLE 1 Cardiopulmonary Hemodynamics*
Sham Saline AAV1.SERCA2a p Value (ANOVA)
Baseline
(n ¼ 4)
Final
(n ¼ 4)
Baseline
(n ¼ 10)
Final
(n ¼ 8)
Baseline
(n ¼ 10)
Final
(n ¼ 8)
Baseline
(Between
Groups)
Group/Time
Interaction
Body weight, kg 21.5 (21–22.8) 34 (31.5–36.3) 20.5 (19–23) 30.5 (28.5–32.5) 22.5 (20.5–24.8) 36 (34–37.3) 0.547 0.237
Heart rate, beats/min 61 (55–66) 75 (74–76) 73 (71–84) 73 (64–99) 68 (57–82) 78 (71–86) 0.071 0.684
Mean aortic pressure, mm Hg 92 (89–99) 121 (116–125) 85 (80–93) 103 (90–127) 84 (81–90) 112 (104–127) 0.242 0.695
Systolic PA pressure, mm Hg 22 (21–22) 23 (22–24) 34 (30–44) 70 (59–87) 34 (28–38) 40 (33–44) <0.001† 0.003†§
Diastolic PA pressure, mm Hg 10 (9–10) 10 (9–10) 15 (12–20) 35 (29–46) 14 (11–17) 18 (15–20) 0.014 0.004†§
Mean PA pressure, mm Hg 17 (15–18) 16 (15–17) 26 (23–30) 54 (43–63) 23 (19–28) 29 (26–31) 0.004†‡ 0.003†§
PA wedge pressure, mm Hg 10 (8–10) 9 (7–9) 12 (10–14) 15 (11–18) 9 (5–11) 12 (10–14) 0.244 0.482
Diastolic pulmonary gradient, mm Hg 0 (0–2) 0 (0–2) 5 ([–1]–8) 22 (10–26) 4 (2–6) 6 (1–9) 0.281 0.01†§
RA pressure, mm Hg 4 (3–5) 2 (1–2) 2 (2–3) 4 (3–5) 4 (3–5) 2 (1–3) 0.044§ 0.001†§
Cardiac index, l/min/m2 3.38 (3.29–3.51) 4.52 (4.3–4.86) 4.33 (4.13–5.13) 3.70 (3.14–4.68) 4.06 (3.53–5.04) 5.43 (4.71–5.76) 0.004† 0.052
Stroke volume index, ml/m2 58 (54–61) 60 (57–65) 57 (51–70) 51 (43–74) 59 (50–71) 65 (59–78) 0.870 0.269
PVR index, WU/m2 1.93 (1.29–3.03) 1.56 (1.49–1.85) 2.83 (2.55–4.38) 10.3 (5.14–12.21) 3.17 (2.3–4.8) 3.17 (1.8–4) 0.459 0.002†§
SVR index, WU/m2 26 (24.6–28.7) 27 (25.3–27.1) 17.5 (17–22.4) 27.4 (21.2–31.7) 19.4 (18–22) 21.9 (20.5–24.5) 0.052 0.055
Values are median (interquartile range [IQR]). *Baseline was at 2 months after model creation and ﬁnal was at 4 months after model creation (and 2 months after gene transfer). †Pairwise post hoc p < 0.05
sham versus saline. ‡Pairwise post hoc p < 0.05 for sham versus AAV1.SERCA2a. §Pairwise post hoc p < 0.05 for saline versus AAV1.SERCA2a.
AAV1.SERCA2a ¼ recombinant adeno-associated virus serotype 1 carrying the human SERCA2a transgene; ANOVA ¼ analysis of variance; PA ¼ pulmonary artery; PVR ¼ pulmonary vascular resistance;
RA ¼ right atrium; SVR ¼ systemic vascular resistance; WU ¼ Wood units.
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(median 4 mm Hg [2 to 6 mm Hg] vs. 6 mm Hg [1 to
9 mm Hg]; p ¼ NS). We also found that the cardiac in-
dex, which was increased at baseline in PH pigs, was
decreased in the saline group by the end of the study,
but improved in animals treated with AAV1.SERCA2a,
although there was no signiﬁcant difference between
these groups (p ¼ 0.112) (Table 1).
To conﬁrm that the observed effects of
AAV1.SERCA2a on cardiopulmonary hemodynamics
were attributable to gene transfer to the pulmonary
vasculature and not an effect of the degree of partial
venous banding, we also examined the degree of
constriction imposed by the banding procedure
over time using Doppler echocardiography (Online
Figure 5). Compared with sham control subjects,
Doppler velocities in the pulmonary veins in animals
with PH at the time of randomization to treatment
with AAV1.SERCA2a or saline were increased 3- to
4-fold with no between-group differences. Two
months after administration of AAV1.SERCA2a or
saline, Doppler velocities remained elevated, with
no difference observed between the groups or
compared with baseline. Thus, the effect of
AAV1.SERCA2a on cardiopulmonary hemodynamics
resulted from transduction of the pulmonary vessels
(Online Table 2).
SERCA2a GENE TRANSFER AND HYPERTROPHIC PA
REMODELING. Increased medial thickness and
hypertrophic PA remodeling are the main indexes of
vascular remodeling observed in this porcine model
of chronic PH (18,27). In the present study, compared
with sham control subjects, PH pigs randomized to
saline had signiﬁcantly increased medial thickness
of vessels <100 mm (p < 0.01) and vessels >100 mm
(p < 0.01). Although there was some evidence of
pulmonary arteriole remodeling in PH pigs treated
with AAV1.SERCA2a, there was signiﬁcantly less
medial thickness of vessels <100 mm (p < 0.05) and
>100 mm (p < 0.05) compared with that observed in
FIGURE 2 Pulmonary Hemodynamics
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Individual changes from baseline (2 months [m]) to study’s end (4 months) are reported for each animal following right heart catheterization to
evaluate the effect of adeno-associated virus serotype 1 carrying the human SERCA2a transgene (AAV1.SERCA2a) therapy on cardiopulmonary
hemodynamics. (A) The mean pulmonary artery pressure (mPAP) and (C) pulmonary vascular resistance index (PVRi) reported as well as
the corresponding mean changes for each study parameter (B and D) demonstrate improvement with AAV1.SERCA2a. Sham (n ¼ 4), saline
(n ¼ 8), AAV1.SERCA2a (n ¼ 8). *p < 0.05. PVR ¼ pulmonary vascular resistance.
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saline-treated PH pigs (Figure 3). These ﬁndings
agreed with the hemodynamic data described earlier.
Next, to determine if the observed ﬁndings in the
pulmonary vessels could be attributed to SERCA2a
gene transfer, we analyzed the association of vascular
remodeling with SERCA2a protein expression.
Consistent with our observations in patients with
PAH (15), SERCA2a protein was decreased in lung
homogenates in the saline group compared with sham
subjects; however, signiﬁcantly higher SERCA2a
levels were detected in the AAV1.SERCA2a-treated
animals (Figure 4A). Immunoﬂuorescence imaging of
pulmonary vessels with dual labeling of SERCA2a
and a-smooth muscle actin or SERCA2a and eNOS
revealed that SERCA2a was detected primarily in the
medial layers of the distal pulmonary arteries with
some expression in the endothelium as well as the
distal airway epithelium (Figure 4B, Online Figure 6).
The abundance of SERCA2a detected in vessels of
animals treated with AAV1.SERCA2a was greater than
that observed in the saline-treated group (Figure 4B).
In a prior study performed in a rodent model of PH,
we found that SERCA2a expression was inversely
related to STAT3, which has been shown to regulate PA
remodeling. To determine if this mechanism was
operative in our porcine model, we ﬁrst examined
STAT3 phosphorylation in lung tissue homogenates.
Comparedwith saline-treated PH pigs, animals treated
with AAV1.SERCA2a had a lower level of STAT3 phos-
phorylation (p < 0.01) (Online Figure 7). As STAT3 has
been identiﬁed as a mechanism that regulates bone
morphogenetic protein receptor, type II (BMPR2)
expression, we next examined this relationship in PA
SMCs infected with an adenovirus encoding SERCA2a.
Compared with cells infected with an adenovirus
encoding b-galactosidase as a control, SERCA2a-
infected cells had decreased STAT3 phosphorylation
(p< 0.005) and a trend toward increased expression of
FIGURE 3 Pulmonary Vascular Remodeling
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Distal vascular remodeling is ameliorated in adeno-associated virus serotype 1 carrying the human SERCA2a transgene (AAV1.SERCA2a)–treated
animals compared with the saline group. Representative hematoxylin-eosin staining is shown for (A) sham (n ¼ 4), (B) saline-treated (n ¼ 8),
and (C) AAV1.SERCA2a-treated (n ¼ 8) animals. (D) Medial thickness was quantiﬁed for pulmonary arteries of <100 and >100 mm diameter.
Data are mean  SEM. *p < 0.05; **p < 0.01.
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BMPR2 (p ¼ 0.07), suggesting that this may be a
mechanism by which SERCA2a gene transfer improves
pulmonary vascular remodeling (Online Figure 8).
EFFECT ON RV STRUCTURE AND PERFORMANCE. To
evaluate the effect of pulmonary vascular gene
transfer of SERCA2a on changes in RV remodeling and
global function, serial CMRs were performed before
randomization and at the ﬁnal time point. Animals
subsequently randomized to saline or AAV1.SERCA2a
were found to have similar RV volume, RV ejection
fraction (EF), and indexed RV mass at baseline.
Similarly, there were no between-group differences
with respect to LV volume or LVEF (Table 2).
In the saline group, RV function worsened by the
study’s end, with a decrease in RVEF that was associ-
ated with an increase in RV end-diastolic and end-
systolic volume indexes as well as an increase in RV
mass (paired Student t test p ¼ 0.130) (Table 2,
Figures 5A and 5B). In PH pigs randomized to AAV1.
SERCA2a, however, RVEF remained relatively stable
over the 2-month follow-up period post-gene transfer.
FIGURE 4 Lung and Pulmonary Artery SERCA2a Protein Expression
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(A) Sarcoplasmic reticulum Ca2þ-ATPase 2a (SERCA2a) protein expression was quantiﬁed in lung homogenates by Western blotting. Representative blots
are shown with densitometry data provided below comparing sham (n ¼ 3), adeno-associated virus serotype 1 carrying the human SERCA2a transgene
(AAV1.SERCA2a)-treated (n ¼ 6), and saline-treated (n ¼ 6) animals. *p < 0.05 vs. saline. (B) Representative immunoﬂuorescence images from confocal
microscopy showing speciﬁc localization of SERCA2a protein (red) in pulmonary vessels and distal airway epithelium in AAV1.SERCA-treated (top) and
saline-treated (bottom) animals. Green and blue staining localize to a-smooth muscle actin (SMA) and 4’,6-diamidino-2-phenylindole (DAPI), respectively.
Bar ¼ 50 mm.
TABLE 2 CMR Analysis of Ventricular Structure and Function*
Saline AAV1.SERCA2a p Value†
Baseline
(n ¼ 9)
Final
(n ¼ 5)
Baseline
(n ¼ 10)
Final
(n ¼ 8) Baseline
Group/Time
Interaction
RV EDV, ml/m2 108 (99–129) 161 (110–165) 111 (104–138) 132 (124–156) 0.710 0.878
RV ESV, ml/m2 45 (40–57) 82 (54–91) 48 (41–55) 51 (45–66) 0.971 0.101
RVEF, % 58 (56–64) 50 (44–51) 59 (58–63) 61 (56–63) 0.754 0.008
RV mass, g/m2 56 (49–69) 62 (57–63) 64 (55–71) 59 (55–62) 0.489 0.014
Stroke volume, ml/m2 58 (55–64) 55 (37–64) 69 (52–71) 71 (57–81) 0.200 0.084
LV EDV, ml/m2 87 (78–93) 89 (66–108) 97 (92–105) 109 (105–112) 0.090 0.022
LV ESV, ml/m2 31 (29–33) 33 (28–42) 38 (35–40) 38 (33–43) 0.157 0.571
LVEF, % 64 (63–67) 61 (61–62) 62 (58–63) 65 (63–66) 0.620 0.085
Values are median (IQR). *Baseline was at 2 months after model creation and ﬁnal was at 4 months after model creation (and 2 months after gene transfer). †Independent
samples Student t test.
CMR ¼ cardiac magnetic resonance imaging; RV ¼ right ventricular; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic volume; LV ¼ left ventricular;
other abbreviations as in Table 1.
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Indeed, compared with saline-treated animals, the
change in RVEF in AAV1.SERCA2a-treated PH pigs was
signiﬁcantly less (p ¼ 0.008), and there was a decrease
in RV mass (p ¼ 0.014) (Figures 5C and 5D). At the end
of the study, explanted hearts were weighed as a more
solid measure of RV mass. There was a signiﬁcant
increase in RV/LV þ septum in the saline group
compared with sham control subjects (p ¼ 0.006),
with a nonsigniﬁcant decrease in relative RV weight in
AAV1.SERCA2a animals.
To assess RV function further at the end of the
treatment period, RV pressure-volume relationships
were examined (Figure 6). At baseline, all measures
were similar between animals randomized to saline
and AAV1.SERCA2a (Table 3). At the end of the study,
RV end-systolic pressure-volume relationship or ela-
stance, a measure of RV contractility, was improved in
AAV1.SERCA2a-treated animals compared with the
saline group (p ¼ 0.043). The change in arterial ela-
stance (Ea), or RV afterload, was signiﬁcantly higher in
saline-treated animals compared with AAV1.SERCA2a-
treated pigs (p ¼ 0.005). Moreover, the increase in
pulmonary Ea was not compensated by an increase
in end-systolic pressure-volume relationship in the
saline group, whereas an improved Ea was observed
in the AAV1.SERCA2a-treated animals, suggesting
better RV-PA coupling. Among diastolic parameters,
a marked improvement in end-diastolic pressure-
volume relationship (i.e., RV compliance) was
observed in the AAV1.SERCA2a group compared with
the saline group (p ¼ 0.006) (Table 3, Figure 6). In
both PH groups, a signiﬁcant degree of pathological
ﬁbrosis was found in the RV myocardium compared
with the sham control subjects, with no quantitative
FIGURE 5 RV Remodeling
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Serial cardiac magnetic resonance imaging (CMR) was performed to examine the effect of aerosolized adeno-associated virus carrying SERCA2a
(AAV1.SERCA2a) on RV structural remodeling. At the end of the 2-month treatment period, CMR-derived measures of (A) right ventricular
ejection fraction (RVEF) and (B) indexed RV mass were preserved in the AAV1.SERCA2a-treated pigs (n¼ 8) but decreased in saline-treated pigs
(n ¼ 5). Mean change estimates with 95% conﬁdence intervals are shown for (C) RVEF and (D) RV mass. *p < 0.05. Abbreviations as in Figure 1.
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TABLE 3 RV Invasive Pressure-Volume Loop Measurements*
Saline AAV1.SERCA2a p Value†
Baseline
(n ¼ 10)
Final
(n ¼ 6)
Baseline
(n ¼ 10)
Final
(n ¼ 8) Baseline
Group/Time
Interaction
PA Ea, mm Hg/ml 1.25 (0.96 to 1.54) 1.88 (1.09 to 2.09) 1.02 (0.81 to 1.32) 0.81 (0.61 to 0.96) 0.653 0.005
ESPVR slope, mm Hg/ml 1.13 (0.64 to 1.40) 0.92 (0.74 to 1.40) 0.77 (0.63 to 1.15) 0.63 (0.53 to 0.76) 0.216 0.043
Vo, ml 4.9 (18.3 to 2.1) 14 (30.3 to 5.2) 10.5 (18.2 to 2.3) 24.8 (37.1 to 3.8) 0.856 0.6
ESPVR/Ea 0.84 (0.69 to 1.18) 0.72 (0.57 to 0.84) 0.74 (0.62 to 0.97) 0.97 (0.72 to 1.08) 0.434 0.167
dP/dt max, mm Hg/s 624 (591 to 800) 764 (690 to 875) 662 (493 to 731) 690 (671 to 861) 0.551 0.84
EDPVR slope, mm Hg/ml 0.21 (0.17 to 0.32) 0.28 (0.23 to 0.30) 0.27 (0.20 to 0.37) 0.12 (0.10 to 0.18) 0.391 0.006
dP/dt min, mm Hg/s 623 (732 to 468) 907 (1,039 to 629) 486 (628 to 406) 560 (626 to 474) 0.372 0.097
Tau, ms 33 (26 to 41) 37 (34 to 40) 33 (31 to 37) 34 (32 to 36) 0.301 0.423
Values are median (IQR). *Baseline was at 2 months after model creation and ﬁnal was at 4 months after model creation (and 2 months after gene transfer). †Independent samples Student t
test.
dP/dt ¼ peak RV pressure rate of rise (max) or decline (min); Ea ¼ arterial elastance; EDPVR ¼ end-diastolic pressure–volume relationship; ESPVR ¼ end-systolic pressure–volume rela-
tionship; PA ¼ pulmonary artery; Tau ¼ time constant of isovolumic relaxation; Vo ¼ volume intercept of the ESPVR slope; other abbreviations as in Tables 1 and 2.
FIGURE 6 Indexes of RV Performance
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At randomization and after the 2-month treatment period, RV pressure–volume relationships were assessed invasively and reported for animals randomized
to saline (n ¼ 6) or AAV1.SERCA2a (n ¼ 8). End-systolic pressure–volume relationship (ESPVR) (A) and end-diastolic pressure–volume relationship (EDPVR)
(B) slopes are shown, together with mean change estimate for EDPVR (C). (D) Representative pressure-volume loop volume reduction series from saline-
treated (blue) and AAV1.SERCA2a-treated (gray) animals show steeper slopes for the saline group. (E) Relative RV weight from explanted hearts expressed
as RV/left ventricle þ septum (LVþS). (F) Myocardial interstitial ﬁbrosis was assessed as collagen fractional area, which was quantiﬁed in RV free wall tissue
by picrosirius red staining. *p < 0.05. Ea ¼ arterial elastance; other abbreviations as Figure 1.
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differences detected between the treatment groups.
Compared with control subjects, SERCA2a expression
in the RV was decreased in saline-treated and
AAV1.SERCA2a-treated (both p < 0.05) PH animals
with no between-group difference in SERCA2a
expression (Online Figure 9). This suggests that
any observed improvements in RV function in
AAV1.SERCA2a-treated animals are more likely to be
attributed to reduced afterload than a higher RV
SERCA2a expression.
ALDOSTERONE LEVELS AND NEUTRALIZING ANTIBODIES.
Aldosterone levels were measured at study’s end as
an additional indication of right HF status. Aldoste-
rone levels were elevated in saline-treated pigs
compared with control subjects, with lower levels
detected in AAV1.SERCA2a-treated animals (mean 
SD: 30.6  5.2 vs. 76.6  7.3 vs. 51.4  7.1 mg/dl;
p < 0.02). In almost all animals receiving airway
delivery of aerosolized AAV1.SERCA2a or AAV1.LacZ
vectors, neutralizing antibody titers increased by the
end of the study, whereas no change in titers was
found in animals from the saline group that were not
exposed to any AAV1 viral vectors (Online Figure 10).
DISCUSSION
In this study, we report for the ﬁrst time a suc-
cessful AAV-based gene therapy intervention that
modulated progression of chronic PH in a large ani-
mal model. We provide data that support feasi-
bility, efﬁciency, and safety of airway distribution
and transduction of small pulmonary vessels using an
aerosolized AAV1 vector as a novel delivery method
for gene therapy in PH. We also describe the bene-
ﬁcial effects of selective vascular SERCA2a gene
transfer using this approach. In this study, PA trans-
duction with aerosolized AAV1.SERCA2a improved
cardiopulmonary hemodynamics and RV functional
parameters in a chronic PH model that recapitulates
the clinical features of the disease seen in patients
with chronic post-capillary PH (Central Illustration).
These data indicate that AAV1.SERCA2a therapy
slowed the progression of PH in a clinically
relevant large animal model and conﬁrm the
potential therapeutic role of SERCA2a as a novel
target in PH patients. Our data also extends
the “proof-of-concept” strategy of aerosolized gene
transfer of SERCA2a (15) by demonstrating efﬁcacy in
a truly pre-clinical animal model of PH. As there are
no established therapies that target prevention of
pulmonary vascular remodeling, a fundamental
pathophysiology of PH, our ﬁndings offer an innova-
tive option to treat patients with PH.
The time course of PH and pulmonary arteriolar
remodeling in the swine model of chronic PH has
been established. In this model, increases in PA
pressure occur prior to a rise in pulmonary vascular
resistance. This, in turn, precedes RV remodeling,
dysfunction, and, ultimately, failure (19). In the cur-
rent study, we found that the progression of disease
through these stages was ameliorated by intratracheal
administration of aerosolized AAV1.SERCA2a. This
was demonstrated by stabilization of the mean PA
pressure and PVR at the end of the 2-month follow-up
period. These observations also agreed with pulmo-
nary vascular remodeling assessed by medial thick-
ness scores of small (<100 mm) and medium (>100 mm)
vessels. We further conﬁrmed that SERCA2a was
down-regulated in the PAs in the swine model of
chronic PH compared with sham control subjects,
similar to what was observed in human PAH pul-
monary arterioles and in the rat monocrotaline-
induced PH model (15). Of note, pulmonary vascu-
lar SERCA2a abundance was markedly higher in
AAV1.SERCA2a-treated animals compared with the
saline group, indicating that there was efﬁcient vessel
transduction and that restoring PA SERCA2a levels
prevented disease progression.
These observations support previous reports from
our group regarding the association of SERCA2a
down-regulation with adverse vascular remodeling in
both the pulmonary (15) and coronary circulations
(28). In the hypertensive pulmonary vasculature,
gene transfer of SERCA2a exerted antiproliferative
effects by blocking the STAT3-NFAT pathway in SMCs
(15). Additionally, in vitro studies revealed that
SERCA2a overexpression restored eNOS to basal
levels (15). These mechanistic studies provide the
molecular basis for the observed beneﬁcial effects of
SERCA2a in pulmonary vascular remodeling in the
present model.
RV failure is the main determinant of clinical
outcome in patients with PH (29). In our chronic PH
model treated with AAV1.SERCA2a, hemodynamic
improvements were paralleled by the preservation of
RV performance as evaluated by systolic, diastolic, and
remodeling parameters quantiﬁed by serial CMR and
pressure-volume relationships. In a previous report,
we comprehensively analyzed the onset of RV failure
in this model of chronic PH and found that the pro-
gression of vascular disease was responsible for
nonadaptive RV remodeling and uncoupling from the
pulmonary circulation leading to RV failure (18). In the
present study, the most relevant differences between
treatment groups were found in diastolic function as
assessed by end-diastolic pressure-volume relation-
ship. The fact that beneﬁcial effects observed in RV
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performance were not paralleled by differences in
interstitial ﬁbrosis between treatment groups suggests
that RV performance improvement likely reﬂected
hemodynamic changes and could not be attributed to
the prevention or reversal of RV ﬁbrosis. Interestingly,
reports using CMR have shown that RV failure may
occur even in the presence of a favorable hemody-
namic response to vasodilator drugs in PAH patients
(3). This also underscores the need for a better un-
derstanding of the intrinsic mechanisms of RV
structural and functional remodeling to affect the
clinical outcome of this patient population (3).
CENTRAL ILLUSTRATION Inhaled AAV1.SERCA2a in PH
Aguero, J. et al. J Am Coll Cardiol. 2016;67(17):2032–46.
Chronic pulmonary hypertension (PH) is associated with increased right ventricular (RV) afterload and vascular remodeling, leading to right ventricular hypertrophy
(RVH) that results from distal pulmonary artery hypertrophic remodeling. Airway gene delivery of recombinant adeno-associated virus serotype 1 carrying the human
SERCA2a transgene (AAV1.SERCA2a) limits RV hypertrophy and failure by attenuating the progression of pulmonary artery hypertrophic remodeling in a swine model.
EC ¼ endothelial cell; SMC ¼ smooth muscle cell.
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In the past 2 decades, several groups have
explored gene therapy as a strategy to improve or
correct PH in rodent models (10), under the premise
that speciﬁc vascular targeting of therapeutics would
increase efﬁcacy and decrease systemic side effects.
Successful experiences have been reported in the
selective modulation of eNOS (30) and prostacyclin
synthase (12,31,32), aiming to enhance sustained
availability of short-lived endothelial factors, such as
NO or prostacyclin, which are known to be deﬁcient
in PH. Other targets of interest that have been stud-
ied in small animal models of PAH include vascular
growth factors (33), BMPR2 (34,35), apoptosis
(mutant survivin) (20), calcitonin-gene related pep-
tide (36), and voltage-gated potassium channels (21).
However, only a hybrid strategy based on the
administration of bone marrow–derived endothelial-
like progenitor cells overexpressing eNOS is
currently in the clinical study (37). This reﬂects the
complexity of advancing pre-clinical research in the
area of gene or cell therapy in PH as well as the need
for testing new interventions in relevant animal
models of disease (17).
A major aspect in the pre-clinical development of
gene therapy as a treatment modality is an optimal
delivery method. Due to potential off-target expres-
sion of the transgene, organ speciﬁcity is a major goal
to prevent adverse effects, and to this extent, large
animal models have provided an invaluable frame-
work in the ﬁeld of cardiovascular gene therapy (38).
We chose airway delivery of viral vectors on the basis
of a number of previous rodent studies that demon-
strated feasibility and selectivity to target the distal
pulmonary vasculature (12,15,20,21,30,32–34,36,39).
The present study is the ﬁrst to report feasibility of
AAV1 gene delivery to the distal pulmonary vessels in
a large animal model using an intratracheal sprayer
device. A previous report showed the advantages of
such a device to deliver AAV vectors to the distal
airway compared to oral nebulization or direct cath-
eter instillation. This study also reported that the
particle dimensions generated by the microsprayer
(w20 mm) did not affect the viability of AAV particles
due to their small size (w20 nm) (40). Thus, optimi-
zation and future advances in delivery device tech-
nology should further improve the ability to
transduce the distal pulmonary vessels and minimize
the invasiveness of the procedure.
Safety represents a signiﬁcant concern in the eval-
uation of nonconventional treatments such as gene or
cell therapy. In recent years, gene therapy studies
focusing on chronic disorders have shifted to using
recombinant AAV as vectors due to their ability to
achieve sustained transgene expression, the fact that
no human disease is currently attributed to AAV
infection, and the very low integration rate of AAV into
the host genome (8). Conversely, frequent AAV expo-
sure in humans has led to a high prevalence of
neutralizing antibodies that limit the proportion of
patients who are candidates for this therapy and make
repeated administrations of the AAV vector inefﬁcient
(25,41). In the present study, as seen in clinical trials in
patients with cystic ﬁbrosis (42), airway administra-
tion of AAV led to a high rate of seroconversion.
The inability to perform repeated administrations was
considered a major hurdle in the development of gene
therapies in cystic ﬁbrosis programs and must be
addressed to increase the broad applicability of gene
therapies using AAV vectors for PH.
Overall, AAV vectors have shown a good safety
proﬁle in several clinical trials (43), leading to the
regulatory approval of the ﬁrst AAV1-based gene
therapy to treat a human disease (44). Furthermore,
compared with other viral vectors (i.e., adenovirus)
used in gene therapy studies, AAVs elicit almost no
inﬂammatory response and are nonpathogenic in
humans, although they have a smaller packaging ca-
pacity, limiting the size of the transgene. With respect
to AAV1.SERCA2a, the ﬁrst clinical trial of this vector
and transgene in patients with advanced HF has been
reported (45), including long-term follow-up (w3
years) (46), indicating that this therapy was safe
when delivered by intracoronary administration.
STUDY LIMITATIONS. In our model of chronic
post-capillary PH, the partial venous banding proce-
dure may lead to remodeling of the banded pulmonary
veins with potential implications for cardiopul-
monary pressures. Although we investigated pulmo-
nary venous inﬂow and the PA diastolic pressure at
several time points to ensure that there were no dif-
ferences between animals, we did not assess inferior
lung lobe vein remodeling histologically (47). Thus,
we cannot exclude an effect of AAV1.SERCA2a on
pulmonary vein remodeling. We also believe that
PAWP accurately reﬂects left atrial pressure in our
model; however, it is possible that PAWP was elevated
artiﬁcially due to damping or other measure-related
issues. The study was also performed with a small
sample size that may have limited power and limited
follow-up (8 weeks after gene delivery). Therefore,
future studies focusing on long-term efﬁcacy and
safety endpoints are warranted prior to advancing
airway gene delivery to the clinic.
CONCLUSIONS
Our ﬁndings indicate that AAV1-based gene therapy
was efﬁcacious in PH and position pulmonary
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vascular SERCA2a gene transfer via aerosol inhalation
delivery as a therapeutic modality in PH and other
related pulmonary vascular diseases.
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 Chapter 24 
 Inhaled Gene Transfer for Pulmonary Circulation 
 Jaume  Aguero ,  Lahouaria  Hadri ,  Nadjib  Hammoudi , 
 Lauren  Leonardson ,  Roger  J.  Hajjar , and  Kiyotake  Ishikawa 
 Abstract 
 Chronic pulmonary hypertension (PH) is associated with right ventricular failure and high mortality regardless 
of the underlying disease. Currently, therapies can improve clinical outcomes in specifi c subsets of patients, but 
have little impact on the progression of pulmonary vascular remodeling. Upon new advances in vector devel-
opment and delivery techniques, gene therapy is a novel strategy in this fi eld with the potential of overcoming 
the main limitations of approved drug therapies: modulation of novel anti- remodeling targets and selective 
pulmonary vasculature targeting with minimal systemic effects. In the recent years, several reports have shown 
that gene transfer to the pulmonary vascular system is feasible in rodent models of PH. Our group has focused 
on the translation of airway delivery of viral vectors in small and large animals. Here, we describe a procedure 
to achieve vector transduction at the distal vasculature in animal models of PH and the methods to evaluate 
the outcomes of this intervention as a promising new approach in pulmonary vascular diseases. 
 Key words  Airway delivery ,  Gene therapy ,  Pulmonary hypertension ,  Large animal model ,  Adeno-
associated virus ,  Right ventricular failure ,  Vascular remodeling ,  Pulmonary vascular disease 
1  Introduction 
 Pulmonary vascular disease (PVD) is defi ned by the development of 
vessel wall remodeling changes in the distal pulmonary vasculature, 
and is a consequence of a heterogeneous group of clinical conditions 
[ 1 ]. In the clinical setting, PVD is characterized by progressive dys-
pnea and exercise intolerance, and diagnosis relies on the detection of 
pulmonary hypertension (PH) upon right heart catheterization. PH 
is  defi ned by a mean pulmonary artery (PA) pressure above 25 mmHg 
[ 1 ], and based on available clinical studies, underlying PVD is sus-
pected by additional hemodynamic abnormalities in the pulmonary 
circulation, such as increased pulmonary vascular resistance (PVR), 
transpulmonary gradient or diastolic to PA wedge pressure differ-
ences [ 1 – 3 ]. The main determinant of prognosis in patients suffering 
PH is the impact of sustained high afterload on right ventricular func-
tion, leading to premature heart failure and death [ 4 ]. 
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 Current  therapeutic options for chronic PH are largely depen-
dent on the clinical classifi cation for each patient undergoing the 
diagnostic process [ 1 ]. Advances in the cellular and molecular 
mechanisms involved in  Group 1 PH (also designated as pulmonary 
arterial hypertension, PAH) have led to novel drug developments 
targeting the main pathways including endothelin receptor antago-
nists, prostacyclin analogs and activators of the soluble guanylate 
cyclase (sGC)/cGMP axis (phosphodiesterase fi ve inhibitors, and 
more recently, sGC activators) [ 1 ]. Clinical trials for these drugs 
have focused on Group 1 PH, while some benefi t may be present in 
other groups with novel agents [ 5 ,  6 ], in particular groups 2 (PH 
due to left heart disease) and 4 (chronic thromboembolic PH). 
 Limitations for the widespread use of current vasodilator  drugs 
include the frequency of systemic, undesired side effects, lack of 
long-term sustained clinical benefi ts, as well as a high economic 
cost of these treatments [ 1 ]. In addition, during the past few years, 
the unraveling of novel molecular mechanisms involved in PH 
have set growing interest in developing more specifi c, target-driven 
therapeutic strategies. In this regard, gene therapy may overcome 
some of the limitations of current treatments, by selectively modu-
lating novel pathways that are not targeted by any drug at present 
[ 7 ]. Recently, several studies by independent groups have shown 
the potential therapeutic benefi t of modulating a variety of molec-
ular targets using gene therapy [ 7 ,  8 ]. For instance, endothelial 
NOS, prostacyclin synthase or BMPR2 have been successfully 
modulated in the pulmonary vasculature leading to improved 
hemodynamics in animal models of PH [ 9 – 11 ]. 
 In order to develop gene therapy strategies for PH, vectors that 
effi ciently target the pulmonary vasculature and provide sustained 
expression of the gene of interest are needed. In this regard, 
advances in  viral vector technology have made available the  recom-
binant adeno-associated viruses (AAV) s that allow different tissue 
tropisms based on the capsid proteins composition, while eliciting 
minimal immune response. In addition, delivery methods that pref-
erentially transduce the lung vasculature with minimal exposure of 
the vector to off-target tissues are essential to guarantee the feasibil-
ity, safety, and translatability of this strategy for PH patients [ 12 ]. 
 The purpose of this protocol is to describe a novel airway 
delivery method of vectors in large animal models of PH that effi -
ciently transduces the distal pulmonary circulation and elicits 
improvements in  vascular remodeling and  hemodynamics . 
2  Materials 
 For  Anesthesia Induction and Maintenance 
  1.  Telazol ( tiletamine /zolazepam). 
  2.  Isofl urane. 
2.1  Animal 
Preparation and PH 
 Model Creation 
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  3.  Propofol. 
  4.  Fentanyl patch. 
  5.  Prophylactic antibiotics. 
  6.  Respirator suitable for swine with adjustable inspiratory oxy-
gen concentration. 
  7.  ECG and pulse oxymetry monitor. 
 For Surgical PH Model Creation in Swine 
  8.  Surgical suite and sterile drapes. 
  9.  Standard surgical tools: Scissors, forceps, scalpel. Bioabsorbable 
and Nylon sutures, Silicone Thoracic Drain 20Fr., Gauzes. 
  10.  Cotton Umbilical Tape 1/8″ × 18″. 
  11.  A 3.5-mm diameter plastic cylinder. 
  12.  Furosemide. 
  1.  Procedure room equipped with a fl uoroscopy system (C-arm). 
  2.  Standard cath pack for sterile percutaneous angiographies 
(syringes, towels, bowls, gauze). 
  3.  Sheath introducer 8 French. 
  4.  Swan-Ganz Catheter 7 French. 
  5.  Capnograph. 
  6.  Blood gas analyzer. 
  7.  Pressure transducers. 
  1.  Procedure room equipped with a fl uoroscopy system (C-arm). 
  2.  MicroSprayer ® Aerosolizer and accompanying syringes (Model 
IA-1B, Penn-Century, Inc.) customized for large animal exper-
iments (in 20–40 kg Yorkshire swine, a 50 cm-length tip is 
optimal, but needs to be designed according to the animal spe-
cies and the proximal airway to carina distance). 
  3.  Multipurpose coronary diagnostic catheter shortened to fi t the 
Sprayer (7 Fr). 
  4.  Viral vector encoding reporter gene (lacZ or GFP) or the ther-
apeutic gene of interest. 
  5.  Ambu bag. 
  6.  Airway fi lter with high fi ltration effi ciency. 
  7.  Personal protective equipment (PPE) including gloves, masks, 
gown, and eye protection. 
  1.  O.C.T. Compound. 
  2.  Glass slides. 
  3.  Cryotome. 
  4.  X-Gal staining kit. 
2.2  Functional 
Evaluation of PH 
in Large Animals: 
Hemodynamic 
and Echocardiography 
Assessments
2.3  Airway Gene 
Delivery 
2.4  Evaluation of the 
Transduction 
 Effi ciency Using 
 β-Galactosidase  
Expression 
Intra-Airway Delivery
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  5.  Neutral buffered 10 % formalin solution. 
  6.  Primary antibodies against reporter gene or gene of interest. 
  7.  Brightfi eld and confocal microscope. 
3  Methods 
  1.  Fast the animals overnight. Administer prophylactic antibiotics 
prior to surgery. 
  2.  Anesthesia is induced with intramuscular administration of 
6.0 mg/kg Telazol (tiletamine/zolazepam). Orotracheal intuba-
tion is performed fi rst by trained personnel, and peripheral oxy-
gen saturation and heart rate are continuously monitored ( see 
 Note  1 ). A peripheral ear vein access is subsequently obtained. 
  3.  For surgical procedures (surgical PH model creation), inhaled 
isofl urane (1–3 %) is adjusted according to animal sedation sta-
tus. Analgesia after the procedure is provided using postopera-
tive 25–50 μg/h fentanyl patch. During the procedure, oxygen 
saturation, heart rate, and systemic blood pressure are continu-
ously monitored. Animals are given prophylactic antibiotics 
twice daily for 5 days after the thoracotomy. 
  4.  Surgical creation of the PH model in swine. A left lateral tho-
racotomy at the fi fth intercostal space is performed under ster-
ile conditions ( see  Note  2 ). Remove the lung from surgical site 
by applying a wet gauze and squeeze ( see  Note  3 ). Obtain a 
good view of the left atrial posterior wall where pulmonary 
veins enter. Widen the incision if necessary. 
  5.  The superior left pulmonary vein and the common inferior 
pulmonary vein are carefully dissected in the extrapericardial 
space close to the left atrium. Consistent degree of venous ste-
noses are achieved by placing a cotton umbilical tape around a 
3.5-mm diameter plastic cylinder that is subsequently removed 
once the tape is tightly secured ( see  Note  4 ). 
  6.  Close the chest in layers, making sure that all air is evacuated 
using a drainage chest tube. Furosemide 4 mg/kg is given after 
the procedure to prevent acute pulmonary edema [ 13 ,  14 ]. 
  1.  Follow the same anesthesia induction as in Subheading  2.2 . 
Use intravenous propofol 8–10 mg/kg/h for hemodynamic 
evaluation ( see  Note  5 ). 
  2.  Transthoracic echocardiography can be used for right ventricle 
(RV) noninvasive imaging and is convenient to perform within 
the animal facility. Apical views of the RV can be obtained with 
the animal on right lateral recumbency by placing the probe in 
the sub-xiphoid position. Modifi ed apical views of the RV and 
3.1  Animal 
Preparation and PH 
 Model Creation 
3.2  Functional 
Evaluation of PH in 
Large Animals: 
Hemodynamic and 
Echocardiography 
Assessments
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3D datasets can be acquired with ECG gating (Fig.  1 ). Offl ine 
analyses provides quantitative information of RV dimensions 
and performance [ 13 ].
  3.  Under sterile conditions, a femoral vascular access is obtained 
using the Seldinger technique. For right heart catheterization 
with a 7 French Swan-Ganz catheter, an 8-Fr sheath is placed 
in the femoral vein ( see  Note  6 ). As an alternative, the jugular 
veins can also be accessed in swine but care must be taken to 
avoid undesired carotid artery punctures. 
  4.  Positioning of the Swan-Ganz catheter to obtain right side 
hemodynamics is achieved using fl uoroscopic guidance 
(C-arm). Calibrate pressure sensor carefully. This is particularly 
important when measuring right side pressures as they are 
often much lower than left side pressures. Before measure-
ments are obtained, hemodynamic stability must be obtained 
and the catheter locations should be confi rmed for every mea-
surement ( see  Note  7 ). 
  1.  Therapies should be preceded by hemodynamic measurements 
to obtain baseline values. Gene delivery can be performed sub-
sequently. Connect an airway fi lter to the tracheal tube. 
  2.  Research personell in the operating room should take appro-
priate precautions for vectors ( see  Notes  8 and  9 ). 
3.3  Airway Gene 
 Delivery 
 Fig. 1  Right ventricular noninvasive characterization using echocardiography allows evaluation of the PH 
model and the changes induced by therapeutic gene transfer. Two- ( a ) and three ( b ) dimensional datasets can 
be obtained from modifi ed apical views in swine models, as well as the Doppler spectral signal ( c ) for time 
intervals and Tei index 
 
Intra-Airway Delivery
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  3.  The vector is prepared in the injection syringes ( see  Note  10 ). 
  4.  The aerosolizer device is inserted carefully through the endo-
tracheal tube and the position of the tip determined using fl uo-
roscopic guidance ( see  Note  11 ). By inserting the aerosolizer 
tip in a 7 Fr multipurpose coronary diagnostic catheter, cut to 
fi t the Sprayer inside, the device can be advanced in the trachea 
while avoiding undesired damage in the tracheal mucosa. Once 
the tip of the aerosolizer is 2–3 cm proximal to the tracheal 
bifurcation, the multipurpose coronary diagnostic catheter is 
gently pulled back a few cm (Fig.  2 ).
  5.  The total vector dose is split into three equal aliquots that will be 
injected in the dorsal, right, and left lateral recumbent positions, 
allowing at least 5 min between each injection ( see  Note  12 ). 
  6.  Injection of the vector solution should be coordinated to the 
inspiration phase. Also, pre-injection alveolar recruitment 
maneuvers using the Ambu will facilitate a more even and dis-
tal distribution of the vector. 
  7.  After vector delivery is completed, mechanically ventilate for 
an additional 20–30 min with continuous monitoring of the 
EKG, hemodynamics, and respiratory parameters. 
  8.  Once the observation period is fi nished without complications, 
the animal is recovered. The vector leak from the airway is 
minimal; however, keep the precaution materials on through-
out the procedure. 
  1.  Humanly euthanize the animals after an appropriate time post- 
gene delivery to allow transgene expression. Through a median 
sternotomy, lung tissue from both side of the lungs at different 
lobes are collected. Remove blood from the tissue specimens 
by perfusing the vessels with PBS ( see  Note  13 ). 
3.4  Evaluation 
of the Transduction 
 Effi ciency 
 Fig. 2  Intratracheal gene delivery requires a MicroSprayer device ( a ) that is placed near the carina guided by 
fl uoroscopy ( b ) 
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  2.  For lung tissue fixation, gently insufflate the airway with 
50 % OCT in PBS, embed in labeled OCT molds and freeze 
the blocks. Using a cryotome, sections (8–10 μm) are pre-
pared on glass slides for subsequent staining ( see  Note  14 ) 
(Fig.  3 ).
  3.  The staining technique to detect transgene expression depends 
on the reporter or protein of interest. For vectors with the 
lacZ reporter, the product of β-galactosidase activity can be 
detected in brightfi eld microscopy using the X-Gal staining 
kit. However, detection of β-galactosidase using specifi c pri-
mary antibodies is more sensitive and can be more precisely 
localized using confocal microscopy. For specifi c proteins of 
interest, primary antibodies that are well validated in swine 
tissue are needed. Colocalization with specifi c cell type mark-
ers such as alpha-smooth muscle actin (for smooth muscle 
cells) or endothelial NOS (endothelial cells) allows a more 
clear identifi cation of preferential cell type of gene expression 
( see  Note  15 ) (Fig.  4 ).
 Fig. 3  Lung tissue is infl ated with OCT for easier handling and ulterior staining techniques 
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4  Notes 
  1.  In animals with moderate to severe PH, hypoxia can signifi -
cantly worsen the hemodynamics and animals can easily die 
from brief hypoxia. Oxygen should be supplied continuously 
during the preparation, and rapid intubation and immediate 
ventilation is necessary to prevent prolonged hypoxemia that 
may infl uence the stability of the hemodynamic evaluation. 
  2.  When entering the pleural cavity, use caution not to injure the 
lung. Cutting the pleural membrane during the expiration will 
reduce the risk of accidental injury. 
  3.  Lungs can be infl ated using an Ambu bag after banding the 
pulmonary veins. 
  4.  The optimal degree of vein stenosis depends of the animal 
growth rate. Applying too tight of a stenosis can cause sub-
acute lung edema that develops 2–3 h after surgery. The data 
provided applies to female Yorkshire swine with BW 10–13 kg. 
  5.  Some anesthesia drugs such as isofl urane have a strong vasodi-
latory effect and can mask mild PH. 
  6.  Guidance of the percutaneous puncture using vascular echog-
raphy minimizes the number of attempts and vascular injury, 
and is advisable if repeated right heart catheterization proce-
dures to monitor hemodynamics overtime are planned. 
 Fig. 4  Assessment of transgene expression can be performed using immunofl uorescent staining. Four weeks 
after the delivery procedure, β-galactosidase protein is found in the pulmonary vasculature ( pink ,  a ). Upon 
delivery of the AAV1.CMV.SERCA2a vector, overexpression of SERCA2a protein ( red ,  b ) colocalizes with smooth 
muscle cells ( green ,  b ) 
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  7.  Appropriate ventilation parameters are set depending on the 
investigators needs. The following parameters provide stable 
and reproducible conditions under general anesthesia in our 
experience: oxygen inspiratory fraction 40 %, 10 ml/kg tidal 
volume at 15 respirations per minute to maintain an end-tidal 
CO 2 between 35 and 45 mmHg as determined by capnogra-
phy. A portable blood gas analyzer provides a detailed blood 
gas profi le that can be particularly informative in diseased ani-
mals. Cardiac output is determined by thermodilution. 
  8.  When testing vectors that can affect research personnel, per-
sonal protective equipment including gloves, gowns, shoe cov-
ers, respirators, face shields and safety glasses must be worn 
during the viral vector delivery procedures and animal necrop-
sies. The risk of infection by exposure to an infectious aerosol 
must be minimized by primary containment and multiple sec-
ondary barriers such as specialized ventilation systems, air 
treatment systems to decontaminate or remove agents from 
exhaust air, and controlled access zones. 
  9.  We have previously used AAV vectors using this delivery 
method [ 12 ]. According to the NIH Guidelines, recombinant 
AAVs in which the transgene does not encode either a poten-
tially oncogenic gene product or toxins, and are produced in 
the absence of a helper virus can in most cases be handled at 
Biosafety Level 1. Decontamination of working areas is recom-
mended. Experiments must be performed in accordance with 
the Guidelines for the Care and Use of Laboratory Animals 
and approved by the Institutional Animal Care and Use 
Committee for the use of AAV in these animals. 
  10.  If the vector should be kept cold to maintain its activity, vector 
preparation should be done by a second operator after placing 
the Sprayer in the appropriate position. 
  11.  An L-shape connector with a hole for inserting the sprayer will 
facilitate the procedure and reduce vector leak from the animal. 
  12.  Raising the head by 20 cm will facilitate a more distal deposi-
tion of the injected solution. 
  13.  Lung adhesions at the site of surgical manipulation is frequent 
in these animal models. This may limit the integrity of certain 
regions of the lung parenchyma. 
  14.  Cryosectioning of the lung OCT block may be challenging 
especially when incomplete airway insuffl ation is present. As an 
alternative, prior fi xation in 10 % formalin can be used. In for-
malin-fi xed paraffi n blocks, deparaffi nation and the antigen 
retrieval step with sodium citrate pH 6.0 may yield good 
immunostaining results for many of the antibodies. 
  15.  Due to cellular turnover, the gene expression signal detected 
using different techniques may fade overtime. 
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6. Discusión. 
La caracterización de modelos animales preclínicos en el ámbito de las 
enfermedades cardiovasculares tiene dos objetivos generales: 
1) Descriptivo-analítico: consiste en generar modelos e identificar si las principales 
características propias de la enfermedad de interés están presentes. Para ello las técnicas 
de imagen cardiovascular desempeñan un papel clave. En modelos de animal grande o 
preclínicos, es posible emplear los mismos biomarcadores de imagen que en los estudios 
en humanos, favoreciendo la traslación de nuevos hallazgos al ámbito clínico. En esta fase 
es importante definir si la gravedad de las alteraciones es similar a la patología en humanos, 
y describir el curso temporal de dichas alteraciones (cambios predominantemente agudos 
frente a crónicos, progresión temporal de las alteraciones, y posibilidad de mejoría 
espontánea que pueda confundir el efecto de una intervención). El objetivo final es 
determinar la relevancia o validez del modelo clínico respecto a la enfermedad de interés. 
2) Modelo de intervención para probar nuevas terapias. Una vez definida la 
relevancia clínica del modelo, e identificados los biomarcadores en los que se basará la 
efectividad de un nuevo tratamiento, se pasa a ensayar la nueva estrategia frente a un 
grupo control. 
En la presente Tesis Doctoral se han desarrollado y caracterizado modelos animales 
preclínicos enfocados en aspectos muy concretos de la enfermedad cardíaca crónica: 1) la 
hipertensión pulmonar crónica y disfunción ventricular derecha, y 2) la disfunción ventricular 
izquierda, así como el uso aplicado de uno de estos modelos con fines terapéuticos. 
Aunque los artículos presentados como parte de esta Tesis incluyen una Discusión 
pormenorizada de sus contenidos, es importante proporcionar una perspectiva más amplia 
e integral del ámbito de aplicación de este tipo de investigación en cada uno de los 
apartados previamente desarrollados. 
Modelos de HTP y desarrollo de nuevas terapias. En la literatura hay escasas 
referencias sobre la creación de modelos animales preclínicos en hipertensión pulmonar 
crónica. Esto se debe en gran medida a la heterogeneidad de esta patología por lo que 
respecta a las causas, mecanismos y fenotipos clínicos. De los dos modelos que hemos 
caracterizado7-8, uno de ellos presentaba un fenotipo cercano a la patología que se deseaba 
modelizar y se consideró clínicamente relevante, lo que permitió continuar la línea de 
investigación sobre terapias experimentales en el ámbito de la transferencia génica. Este 
estudio11 ha sido la primera experiencia sobre terapia génica en hipertensión pulmonar 
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crónica en un modelo preclínico, y supuso la continuación de una línea de investigación 
iniciada unos años antes por nuestro propio grupo en modelos in vitro y en roedores12. La 
terapia que se puso a prueba fue, a su vez, la primera terapia génica empleada en 
pacientes con insuficiencia cardíaca crónica en el ensayo CUPID13. Pese a todo, los 
modelos animales de hipertensión pulmonar siguen siendo un campo en desarrollo con 
aspectos no resueltos y deben interpretarse con cautela los resultados de las nuevas 
intervenciones15. Respecto a la aplicación de los modelos descritos, nuestro grupo ha 
publicado nuevos estudios sobre nuevos conceptos en el diagnóstico y tratamiento de esta 
enfermedad que necesitan ser validados en humanos16-17. 
Si bien existen descripciones previas de modelos de hipertensión pulmonar, el 
enfoque en el remodelado del VD es novedoso en ambas publicaciones, gracias a la 
definición del patrón oro mediante curvas de presión-volumen, y su combinación con 
técnicas de imagen multimodalidad. Recientemente, diversos documentos y revisiones de 
expertos han destacado la relevancia de caracterizar los cambios en el VD en modelos 
preclínicos para entender mejor el efecto de las nuevas terapias18.  
Modelos de disfunción del VI. La disfunción del VI ha sido la característica central 
de la IC en estudios preclínicos y en ensayos clínicos. Si bien hoy sabemos que la IC es un 
síndrome más complejo y que requiere una visión más amplia para diagnosticar y tratar 
adecuadamente a los pacientes, la mayoría de terapias se han orientado a mejorar la 
función del VI. En este sentido, los modelos de infarto han sido descritos ampliamente en la 
literatura, fundamentalmente para estudios sobre regeneración miocárdica. En uno de los 
trabajos de la presente Tesis Doctoral evaluamos las ventajas e inconvenientes de estos 
modelos de cardiopatía isquémica. Un aspecto controvertido en la literatura es la idoneidad 
de estos modelos post-infarto para probar terapias “no regenerativas” de tipo farmacológico 
o terapia génica. Esto supone describir no sólo cambios globales en el remodelado 
ventricular, si no también cambios regionales en miocardio remoto (no infartado) que sean 
susceptibles de tratamientos dirigidos. En relación a estos resultados descritos en la 
presente Tesis Doctoral, recientes estudios en pacientes han sugerido que los cambios en 
el miocardio remoto detectables por técnicas de imagen son importantes en el remodelado 
global a largo plazo19, y podrían indicar que tratamientos específicos podrían ser efectivos. 
Respecto a la caracterización de modelos de cardiopatía isquémica, nuestro grupo ha 
estudiado recientemente los cambios regionales dinámicos en el territorio infartado 
mediante técnicas de imagen avanzada, que han contribuido a una mejor comprensión del 
daño por isquemia y reperfusión del miocárdio20-22 y potencial desarrollo de nuevas terapias. 
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La caracterización del modelo de cardiopatía isquémica ha facilitado el desarrollo de 
estudios sobre nuevas terapias en este contexto. Nuestros grupos de investigación han 
publicado gracias a estas descripciones y a la experiencia adquirida en estos modelos, 
diversos trabajos basados en nuevas dianas terapéuticas en terapia génica mediante 
vectores virales23-25, nuevas aplicaciones de tratamientos farmacológicos y nuevas 
modalidades de reperfusión miocárdica para prevenir el remodelado ventricular26-27. 
En modelos de cardiopatía isquémica hemos caracterizado la insuficiencia mitral 
funcional debida a remodelado del VI. Así mismo, hemos descrito por primera vez en un 
modelo experimental las consecuencias de la isquemia auricular prolongada en el sustrato 
fibrótico, y el deterioro funcional auricular asociado a este daño. Con el reciente desarrollo 
de terapias percutáneas para el tratamiento de valvulopatías en el ámbito del 
intervencionismo estructural, consideramos que este modelo ofrece características únicas 
para probar nuevos dispositivos en fenotipos específicos de insuficiencia mitral isquémica. 
La caracterización del modelo de sobrecarga de presión no permitió, sin embargo, su 
desarrollo hacia estudios terapéuticos. Tras comprobar que el fenotipo observado pese a un 
largo seguimiento no era óptimo para ser objeto de intervención terapéutica, fue descartado 
para este propósito. A diferencia de lo que hemos podido observar en el modelo porcino, en 
modelos de roedor se ha descrito que la sobrecarga de presión da lugar a un remodelado 
inicialmente adaptativo, que posteriormente progresa a disfunción del VI, lo que ha 
favorecido de este modelo in vivo de IC. La ausencia de esta transición en el modelo 
preclínico de animal grande supone una limitación importante de su relevancia para evaluar 
nuevas terapias. A este respecto cabe destacar que, si bien un modelo similar se había 
empleado para la evaluación preclínica de un tratamiento en IC28, los resultados positivos 
no fueron posteriormente confirmados en la fase clínica29, lo cual podría deberse entre otras 
cosas a los problemas de relevancia clínica de este modelo. Sin embargo, un modelo similar 
ha permitido a nuestro grupo desentrañar aspectos mecanísticos novedosos en el 
remodelado eléctrico y propensión a arritmias cardíacas en el contexto de la hipertrofia 
ventricular (en revisión). 
Papel de los modelos preclínicos en investigación traslacional. Los modelos de 
animal grande son un eslabón importante en la investigación traslacional de nuevos 
descubrimientos desde el laboratorio a la clínica. Su papel principal es el de confirmar los 
beneficios de terapias seleccionadas en modelos más sencillos (in vitro, roedor, 
simulaciones in silico) en un modelo más complejo, y a su vez más cercano a la enfermedad 
en humanos, así como evaluar aspectos relacionados con la bioseguridad. La presente 
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Tesis Doctoral se enmarca en este contexto englobando investigación traslacional en 
terapia génica cardiovascular, y modulación del sistema adrenérgico. Así pues, los modelos 
de cardiopatía isquémica se emplearon en la validación preclínica de nuevas dianas 
terapéuticas mediante transferencia génica12, 23-25, 30-32 y modulación farmacológica de la 
señalización adrenérgica33. En algunos casos, se ha podido avanzar hasta fases clínicas 
que han confirmado los resultados observados en el modelo animal34.  
Los modelos preclínicos presentan pese a todo lo expuesto anteriormente, 
limitaciones importantes que deben ser tenidas en cuenta. La principal es la dificultad para 
capturar aspectos complejos de la enfermedad cardiovascular, en particular la gran 
heterogeneidad de los fenotipos, y que a menudo está relacionada con el envejecimiento de 
los pacientes y las comorbilidades. Esta complejidad puede explicar que un tratamiento 
exitoso en fases preclínicas no produzca ningún beneficio en ensayos clínicos. Estas 
diferencias entre la enfermedad en el modelo animal y los pacientes pueden ser más 
profundas respecto al potencial efecto de terapias avanzadas como la regeneración celular 
y la transferencia génica. En estos casos, intervienen además las diferencias interespecies 
en la respuesta inmune al producto administrado, lo cual influye de manera decisiva en la 
efectividad del mismo. Esta es una de las explicaciones que se ha postulado en diversas 
líneas de investigación traslacional en regeneración celular miocárdica, y más reciente en 
terapia génica, que mostraron ausencia de beneficio clínico en pacientes pese a haber 
demostrado eficacia en modelos preclínicos13, 35. 
Limitaciones. 
Los comentarios anteriores sobre estos modelos animales ponen de manifiesto 
potenciales aplicaciones, pero a su vez importantes limitaciones: 
- Necesidades de infraestructura, coste económico y personal experto. La 
investigación preclínica en modelos de animal grande requiere una gran inversión en 
infraestructura que permita asumir los cuidados necesarios de estas especies animales, así 
como equipamientos costosos para crear y evaluar mediante técnicas de imagen. Así 
mismo hace falta personal experimentado en técnicas de investigación preclínica, y en 
imagen clínica. 
- La puesta a punto de un modelo requiere una gran inversión de recursos y tiempo, 
que a menudo obliga a descartar esta opción. Con frecuencia, hallazgos publicados en la 
literatura respecto a determinados modelos pueden no ser reproducibles de forma fiable, lo 
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que obliga a cambios de protocolo o en el modelo seleccionado. Una vez caracterizado el 
modelo, puede que este no reúna los aspectos deseados por lo que obliga a descartarlo. 
- Con todo ello, la investigación preclínica puede resultar poco rentable y es 
necesario definir claramente a qué se va a aplicar el modelo y justificar el tiempo y elevado 
coste que requerirá su puesta a punto. 
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7. Conclusiones. 
1. Los modelos preclínicos son un paso necesario para demostrar la eficacia de 
nuevas dianas terapéuticas antes de iniciar los primeros ensayos en humanos. Permiten a 
su vez llevar a cabo estudios de bioseguridad. 
2. Las técnicas de imagen cardiovascular son una herramienta clave en la 
caracterización de modelos preclínicos, y permiten definir los criterios de beneficio clínico en 
estudios de validación de nuevas terapias. 
3. Los modelos preclínicos en el ámbito de la HTP crónica presentan características 
clínicamente relevantes respecto a las alteraciones de la circulación pulmonar y el 
remodelado ventricular derecho. La selección del modelo animal, métodos de evaluación y 
duración del seguimiento son críticos para evaluar nuevas terapias experimentales en 
estudios preclínicos. 
4. Los modelos de IC secundaria cardiopatía isquémica presentan características 
clínicamente relevantes y pueden ser evaluados de forma precisa mediante técnicas de 
imagen avanzada. 
5. Los modelos de sobrecarga de presión presentan cambios típicos de fases 
precoces de la enfermedad, y eso limita su aplicación en estudios de IC establecida. 
6. Los modelos de HTP crónica han permitido evaluar el potencial de nuevas 
estrategias de terapia génica dirigida de forma selectiva a dianas terapéuticas específicas, y 
abren un nuevo campo en este grupo de enfermedades.   
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